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1.1  The virus  
 
The identification of hepatitis A and hepatitis B virus in the sixties and seventies of 
the last century (1, 2) led to the recognition that one or more other viruses were 
capable of causing acute liver inflammation or hepatitis after blood transfusion (3). 
The then not yet identified virus was subsequently named post-transfusion non-A, 
non-B hepatitis. In 1989 a RNA virus could be identified by molecular cloning 
techniques, consequently named hepatitis C virus (HCV) (4). This virus proved to be 
responsible for most cases of post-transfusion non-A, non-B hepatitis. 
 
The hepatitis C virus is an enveloped virus, approximately 50 nm in diameter that 
belongs to the family of flaviviruses. Its genome is a positive sense, single-stranded 
RNA with an average length of 9.6 kb, including 2 untranslated regions at the 5’ and 
3’ ends, and an open-reading frame encoding a large polyprotein that is processed 
into structural and nonstructural proteins (5). HCV has high rates of replication (1012 
virions per day) and mutation that promote chronicity and the development of 
resistance to antiviral therapy. Within an individual, viral mutations produce closely 
related strains called quasi-species. Genetic heterogeneity within the population is 
categorized in 6 major genotypes that show geographic and patient communities 
dependant variation. In Western Europe genotypes 1a and 1b are most common, 
followed by genotype 2 and 3. Genotype 3 is mainly found in (former) drug addict 
communities; genotype 1 in people having received blood transfusion. 
 
HCV is spread almost exclusively by direct blood contact. Transmission through 
blood (product) transfusions that are not screened for HCV infection, through the 
reuse of unsterilized injection equipment (needles, syringes) or other medical 
equipment, or through needle sharing among drug-users, is well documented. In 
addition, people who undergo traditional scarification, body piercing, tattoo and 
circumcision are at risk if they use or reuse unsterilized tools. Sexual and vertical 
transmission does occur, but is unusual. 
 
Humans and chimpanzees are the only known species susceptible to infection, with 
both species developing similar disease. HCV preferentially infects hepatocytes but 
evidence of extrahepatic replication sites has accumulated during the past decade. 
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Worldwide, it is estimated that 3% of the world population, about 170 million people, 
have been infected with HCV and 3 to 4 million persons are newly infected each 
year. The prevalence varies throughout the world (fig. 1), with the highest number of 
infections reported in Egypt and the lowest in Europe and North America. In Europe, 
HCV prevalence is not clearly established. It could be at least 1.03% of the general 
population, which represents 8.9 million infected people (6). Prevalence in Northern 
Europe is lower than in Southern Europe. For the Netherlands the estimated 
prevalence is 0,1% (7). However, this figure is based on a limited survey in only 7373 
persons in whom 6 had antibodies against HCV. In patient communities like 
hemophiliacs, drug addicts or people transfused with blood before 1990 the 
prevalence can be as high as 25 to 60 %. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Global prevalence of hepatitis C virus (6).  
It is estimated that 3% of the world population have been infected with the hepatitis C virus. The 
prevalence of HCV in the Netherlands is among the lowest in the world. 
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1.2  The disease 
 
Hepatitis C is a dichotomous disease in which only a subset of patients will die from 
liver-related causes (fig. 2). Acute infection can be severe but is rarely fulminant (8); 
in fact the majority of persons who develop acute HCV is unaware of it, so that 
disease onset is rarely identified other than through assumption based on potential 
circumstances of exposure. In ±85% the initial acute infection leads to a chronic 
phase; defined as persistence of HCV RNA in the blood for 6 months of more. ±15% 
of the infected persons is able to clear the virus after an acute infection. Factors 
associated with spontaneous clearance of HCV infection appear to include female 
gender, younger age and some major histocompatibility complex genes (9). 
Chronic viral hepatitis leads to slow but progressive increasing degrees of fibrosis but 
is often asymptomatic or associated with non-specific symptoms such as fatigue. 
Most patients are diagnosed in a presymptomatic stage, because of an identifiable 
risk factor or because of abnormal liver biochemistry. Of those infected, ± 20% will 
eventually develop cirrhosis and its related complications within a period of 10-20 
years; about 1 to 5% will eventually develop liver decompensation or liver cancer 
over a period of 20 to 30 years. Fibrosis progression is not necessarily linear and 
seems to be highly variable among persons. The rate of fibrosis progression is 
affected by some host-related characteristics such as the age of infection and alcohol 
abuse and factors like co-infection with other hepatitis viruses or HIV. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Natural history. 
Data from the EASL consensus 1999; adapted from Orlent et al.(10) 
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1.3  The problem in the treatment of chronic hepatitis C  
 
In 1986, three years before the identification of the hepatitis C virus Hoofnagle et al. 
introduced “long-term, low-dose” interferon-α (IFN) for the treatment of chronic non-A 
non-B hepatitis (11). Since then, the treatment of chronic HCV has made remarkable 
progress. Originally, the response to antiviral therapy in patients with HCV was 
expressed in terms of biochemical response (normalization of serum alanine 
aminotransferase (ALT) levels). However, since the introduction of sensitive PCR 
assays for the detection of viral RNA, expression in terms of virological response is 
preferred. Consequently, the success of an antiviral treatment modality is expressed 
in terms of sustained virological response, defined as a negative result of a sensitive 
PCR assay for HCV-RNA after a 24-week treatment-free follow-up period. A 
sustained virological response should be regarded as a surrogate marker for cure of 
HCV; it does not completely exclude late virological relapse (1-3% after 4 years for 
patients treated with interferon alfa-2b and ribavirin for 24-48 week (12)). 
For interferon-α monotherapy, sustained virological response rates were between 2-
9% in genotype 1 and between 16-23% in genotype 2 and 3 (13, 14). By adjusting 
treatment duration up to 48 weeks for genotype 1 and combining regular interferon-α 
with ribavirin, sustained response rates could be improved to 28-31% in genotype 1 
and 65% in genotype 2 and 3 (13, 15). With the introduction of long acting pegylated 
interferon-α (PEG-IFN-α) in combination with ribavirin sustained virological response 
rates of 80% can be obtained in genotype 2 and 3 (16, 17).  
Genotype 1 is the predominant genotype and patients infected with it are still cured in 
less then 50%. Another group in need for better treatment options are patients with 
cirrhosis in whom sustained response rates are also considerably lower. Moreover, 
as increasing numbers of patients are treated, the number of patients failing to 
respond will also increase. 
 
1.4 The hypothesis 
A strong decline and early clearance of serum HCV RNA within the first weeks of 
treatment, is a strong predictor for SVR (18, 19). The rate of decline appeared to be 
dose dependent for interferon (20). With 4 weeks of daily high dosed interferon-α an 
early virological response could be obtained in 80% of difficult-to-treat patients 
eventually leading to a high rate of SVR (67%)(21). However, whether high-dosed 
Chapter 1 
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Peginterferon-α has comparable or even improved efficacy remains to be 
established. Moreover, whether the individual Peginterferon pharmacokinetics affect 
the rate HCV RNA decline in that individual and its chance to achieve SVR has not 
yet been revealed. 
Major pre-treatment factors influencing the response rates to therapy are HCV 
genotype and the degree of fibrosis (14-16, 22, 23). These characteristics are 
however, not useful for the prediction of the chance to respond to therapy in the 
individual patient. Immune markers at the site of disease, i.e. in the liver might have a 
more causal relation to response.  
 
Aims of the study 
A) To evaluate the effects of high-dose (Peg)interferon therapy in non-responders 
and “difficult to treat” patients. 
B) To identify immunological factors in peripheral blood and the liver associated with 
(non-)response.  
C) To describe (peg)interferon pharmacokinetics and its relation to (non-)response. 
General Introduction 
 15
1.5 REFERENCES 
 
1. Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune 
electron microscopy of a viruslike antigen associated with acute illness. Science 
1973;182(116):1026-8. 
2. Blumberg BS, Alter HJ, Visnich S. A "New" Antigen in Leukemia Sera. Jama 
1965;191:541-6. 
3. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-
associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 
1975;292(15):767-70. 
4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation 
of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. 
Science 1989;244(4902):359-62. 
5. Zakim D, Boyer TD. Hepatology. A textbook in liver disease. Philadelphia: 
Saunders; 2003. 
6. Hepatitis C: global prevalence. WHO press release.Weekly Epidemiological 
record. 1997;72:341-438. 
7. Veldhuijzen IK, Conijn-Van Spaendock MAE, Dorigo-Zetsmab JW. 
Seroprevalentie van hepatitis B en C in de Nederlandse bevolking. Inf Ziekten Bull 
2001;10:182-184. 
8. Farci P, Alter HJ, Shimoda A, Govindarajan S, Cheung LC, Melpolder JC, et 
al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 
1996;335(9):631-634. 
9. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5 Suppl 
1):S35-46. 
10. Orlent H, Vrolijk JM, Veldt BJ, Schalm SW. Hepatitis C 2002 Guidelines: 
Summary and annotations. Scand J Gastroenterol 2003;Suppl. 2003;(239):105-10. 
11. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. 
Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. 
A preliminary report. N Engl J Med 1986;315(25):1575-8. 
12. McHutchison J, Davis GL, Esteban-Mur R, Poynard T, Mei-Hsiu L, Garaud JJ. 
Durability of sustained virological response in patients with chronic hepatitis C after 
treatment with interferon a-2B alone or in combination with ribavirin. Hepatology 
2001;34:244A. 
Chapter 1 
 16 
13. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et 
al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for 
chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 
1998;339(21):1485-92. 
14. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. 
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and 
without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 
1998;351(9096):83-7. 
15. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. 
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks 
versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection 
with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). 
Lancet 1998;352(9138):1426-32. 
16. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar 
R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus 
ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 
2001;358(9286):958-65. 
17. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et 
al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J 
Med 2002;347(13):975-82. 
18. Brouwer JT, Hansen BE, Niesters HG, Schalm SW. Early prediction of 
response in interferon monotherapy and in interferon-ribavirin combination therapy 
for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999;30(2):192-
8. 
19. Lee S, Heathcote E, Reddy K, Zeuzem S, Fried M, Wright T, et al. Prognostic 
factors and early predictability of sustained viral response with peginterferon alfa-2a 
(40KD). J Hepatol 2002;37(4):500-6. 
20. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. 
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha 
therapy. Science 1998;282(5386):103-7. 
21. Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, 
Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in 
non-responders to standard therapy. J Hepatol 1998;28(6):960-4. 
General Introduction 
 17
22. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. 
Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 
2000;343(23):1666-72. 
23. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A 
randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon 
alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34(2):395-403. 
 
 
 

  
 
 
 
Part I 
 
 
 
 
 
 
Treatment of non-responders and “difficult to 
treat” HCV patients 

Chapter 2 
 
 
 
The Treatment of Hepatitis C: History, Presence 
and Future 
 
 
 
 
 
Jan M. Vrolijk, Robert J. de Knegt, Bart J. Veldt, Hans Orlent, Solko W. Schalm. 
 
 
 
 
 
 
Department of Gastroenterology & Hepatology, Erasmus Medical Centre, Rotterdam, 
The Netherlands. 
 
 
 
Netherlands Journal of Medicine 2004;62:76-82. 
Chapter 2 
 22 
ABSTRACT  
 
The treatment of chronic hepatitis C has made remarkable progress over the past 
two decades. For interferon-α monotherapy, sustained virological response rates 
were between 2-9% in genotype 1 and between 16-23% in genotype 2 and 3. By 
adjusting treatment duration up to 48 weeks for genotype 1 and combining regular 
interferon-α with ribavirin, sustained response rates could be improved to 28-31% in 
genotype 1 and around 65% in genotype 2 and 3. Attempts to further increase 
efficacy included the addition of amantadine without conclusive evidence up till now. 
With the recent introduction of long acting pegylated interferon-α in combination with 
ribavirin sustained virological response rates of 80% can be obtained in genotype 2 
and 3. However, sustained virological response rates for patients with either 
genotype 1, non-response to prior treatment, cirrhosis or a combination of these 
characteristics are still less than 50%. In view of results with daily high dose 
interferon-α induction in combination with prolongation of treatment duration up to 18 
months such patients might benefit from induction and prolonged PEG-IFN-α 
treatment and should be treated in an experimental setting.  
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2.2  INTRODUCTION 
 
The Netherlands Journal of Medicine is an offspring from the Folia Medica 
Neerlandica (1958). The very first publication in this magazine was entitled: “Viruses 
as a cause of disease”, a topic which has not lost its relevance (1). 
Hepatitis C virus (HCV) is such a cause and currently leading to a global public 
health problem. Worldwide, 150 - 170 million people are estimated to be chronically 
infected with HCV of whom an estimated 5 million are living in Western Europe. 
Twenty percent of those chronically infected will eventually develop cirrhosis of the 
liver and its sequelae within 10-20 years in the absence of treatment (2). Antiviral 
therapy has now been used for nearly two decades to slow down and prevent this 
progression. In the past years, the response rate to antiviral therapy has made 
remarkable progress. 
Originally, the response to antiviral therapy in patients with HCV was expressed in 
terms of biochemical response (normalisation of serum alanine aminotransferase 
(ALT) levels). However, since the introduction of sensitive PCR assays for the 
detection of viral RNA, expression in terms of virological response is preferred. 
Consequently, the success of an antiviral treatment modality is expressed in terms of 
sustained virological response, defined as a negative result of a sensitive PCR assay 
for HCV-RNA after a 24-week treatment-free follow-up period. A sustained virological 
response can be regarded as a surrogate marker for cure of HCV, although it does 
not completely exclude late virological relapse.  
The focus of this review is to summarize past treatments of chronic hepatitis C, to 
describe the present standard of care and to give recommendations how to improve 
therapy in the future. 
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2.3  TREATMENT HISTORY: INTERFERON AND RIBAVIRIN  
 
2.3.1 Interferon 
In 1986, three years before the identification of the hepatitis C virus by molecular 
cloning techniques, Hoofnagle et al. introduced long-term, “low-dose” interferon-α 
(IFN-α) for the treatment of chronic non-A and non-B hepatitis (3). Based on these 
preliminary data, large randomised placebo-controlled trials were performed 
confirming the effectiveness of IFN-α (4, 5). IFN-α given as a single agent 
(monotherapy) dosed 3 million units (MU) thrice a week (tiw) subcutaneously for 24 
weeks induced end of treatment responses (normalisation of ALT levels) in about 
50% of patients. However, in about half of the responding patients a relapse was 
seen within 6 months after discontinuation of treatment. Further experience indicated 
that the sustained virological response was even lower; only 6-18%. Patients with 
genotype 2-3 had higher sustained virological responses (16-23%) than patients with 
the predominant genotype 1 (2-9%, table 1) (6, 7). 
In the years following the introduction of IFN-α, strategies to increase its antiviral 
activity included the optimisation of dose, treatment duration and the combination 
with other antiviral agents. One of the first improvements was made by prolongation 
the treatment duration to 48 weeks. Hereby, post-treatment relapse in HCV-RNA 
could be reduced significantly; resulting in an increased sustained virological 
response rate of 7%-11% in genotype 1 and 29%-33% in genotype non-1 (table 1) (6, 
8). By therapy prolongation beyond 12 months, the ALT relapse rate in IFN-α 
monotherapy could even further be reduced (9, 10).  
 
2.3.2 Ribavirin 
From all the efforts to increase efficacy, the combination of IFN-α with ribavirin has 
been the most fruitful. Ribavirin, a nucleoside analogue in use for the treatment of 
respiratory syncytial virus, lowers ALT levels in many patients with chronic hepatitis 
C; it has however no significant effect on serum HCV-RNA levels (11-13). When used 
in combination with IFN-α, it increases the end of treatment response and reduces 
post treatment relapse (7, 14). Large randomised placebo-controlled trials in the U.S. 
The treatment of Hepatitis C 
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and other countries have confirmed the enhanced efficacy of combined interferon-
ribavirin therapy. Among patients with genotype 1 a sustained virological response  
 
 
was found in 16-23% of those treated for 6 months and in 28-31% of patients treated 
for 12 months. Results in genotype non-1 were around 65% for both 6 and 12 months 
(table 1)(6-8). These findings led to the recommendation that patients infected with 
genotype 1 require a course of 48 weeks IFN-α plus ribavirin therapy whereas 24 
weeks combination therapy was sufficient for patients with genotype 2 and 3 (2). 
 
 
 
 
Table 1.       Effect of ribavirin and treatment duration. 
 Interferon-α2b# Interferon-α2b# and ribavirin$ 
 24 weeks 48 weeks 24 weeks 48 weeks 
Genotype 1 2- 9  7-11 16-23 28-31 
Genotype 
non-1* 16-23  29-33  50-69  64-66  
Sustained virological response rates in percentages in genotype 1 and genotype non-1 for interferon-α 
(IFN) monotherapy and IFN plus ribavirin for 24 and 48 weeks. 
*Reflects data on genotype 2 and 3, data on genotype 4-6 are too limited for inclusion in the table. 
# Interferon-α2b subcutaneously; dosed 3 million units MU three times a week. 
$ Ribavirin orally; dosed 1.0-1.2g in two divided doses according to weight. 
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2.3.3 Amantadine 
Amantadine has been used for many years to prevent infection with influenza A virus. 
Most randomised controlled trials were unable to demonstrate a significant beneficial 
effect of amantadine-IFN-α over IFN-α monotherapy, largely because of small sample 
sizes (15-19). The trials are comparable in design and when the data are pooled –a 
total of 920 patients has been included- a modest improvement can be demonstrated 
(table 2). Health related quality of life analysis showed an improvement of fatigue and 
vigour scores in patients receiving combined IFN-α amantadine treatment compared 
with those treated with IFN-α alone (15, 20). Two trials (one randomised) in IFN-α 
non-responders demonstrated significant benefits of the addition of amantadine to 
the combination of IFN-α and ribavirin (21, 22). The mechanism with respect to this 
improvement in sustained response remains unclear. Currently a Dutch placebo-
controlled multicentre trial on “triple” therapy in naive patients is in progress in more 
than 30 hospitals (CIRA study). This study will need a large sample size to 
demonstrate beneficial effects of amantadine. 
 
Table 2:        Effect of amantadine when added to interferon-α. 
 Interferon-α2b Interferon-α2b and amantadine $ P* 
Zeuzem et al. (15) 13/60   (22) 6/59   (10) 0.087 
Mangia et al. (16) 17/101   (17) 29/99   (29) 0.036 
Caronia et al. (17) 15/89   (17) 21/90   (23) 0.280 
Tabone et al. (18) 15/90   (17) 22/90   (24) 0.197 
Helbling et al. (19) 17/121   (14) 25/121   (21) 0.175 
ALL 77/461   (17)  103/459   (22) 0.028 
Number of patients out of whole group (and percentages between brackets) with sustained 
virological response for Interferon-α2b (IFN) monotherapy and IFN plus amantadine for 48 
weeks. 
$  Amantadine orally; dosed 200mg in two divided doses. 
* Chi-square test 
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2.3.4 High dose induction and prolonged treatment 
Increasing the IFN-α dose or administrating IFN-α daily could be beneficial, because 
of the high viral replication rate and the short half-life of IFN-α (only hours) (23). 
Indeed, high daily dosed IFN-α for several weeks, i.e. induction therapy, has been 
used for years in Japan, resulting in high (more than 80%) initial virological response 
rates (24). High daily dose IFN-α therapy with or without ribavirin in Western Europe 
and the USA, however, had no lasting beneficial effect on sustained virological 
response rates (25, 26). In those early reports, a significant increase of virological 
response rate (% HCV-RNA negative patients) was found during the high daily 
dosing period as compared to IFN-α 3 MU t.i.w. However, this effect did not result in 
an increased sustained virological response. 
This failure to maintain the initial response might be explained by the premature 
lowering of the IFN-α dose within the first week (27) or due to a short duration of 
treatment which was stopped after 24-26 weeks (24). In a later randomised controlled 
trial in 373 patients (28) two experimental induction schedules were compared to a 
regular schedule of 38 weeks IFN-α 5 MU every other day. In genotype 1 patients, 
the sustained virological response was nearly twice as high (SVR: 42% vs. 27%) 
when treated with induction therapy (10 MU IFN-α daily for 2 weeks, followed by 10 
MU every other day for 12 weeks, followed by 5 MU every other day for 24 weeks). 
Sustained virological response rates in the non-1 genotypes varied between 56-76% 
in the three treatment arms but did not differ significantly. These data suggest 
beneficial effects of high dose induction and prolonged daily IFN-α dosing in 
genotype 1 patients in whom success is limited when treated with standard therapy. 
 
In an effort to analyse the above mentioned treatment strategies combining high dose 
induction IFN-α and prolonged daily IFN-α plus ribavirin we performed a meta-
analysis on individual treatment data of an exploratory study performed in our centre 
(29). In total, fifty-four consecutive chronic HCV patients selected for unfavourable 
base-line characteristics associated with therapy resistance such as genotype 1 
infection, cirrhosis, previous non-response to IFN-α or combinations of these, were 
treated intensively for 76 weeks. The first 24 patients were treated with a very 
intensive schedule which resulted in an overall sustained response rate of 67% (95% 
confidence interval: 45-84%) (30). In the following patients, attempts were made to 
decrease morbidity and cost without losing efficacy. However, by shortening the 
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induction period adverse effects decreased somewhat as did the effectiveness (27). 
Thus no clear advantage was found over the original intensive treatment schedule. 
The induction phase of 10 MU IFN-α daily for 2-4 weeks was followed by daily 3-5 
MU IFN-α injections until week 52 and 3 MU daily or thrice weekly until week 76. 
Throughout the study all patients received 1,000 - 1,200 mg ribavirin.  
The overall sustained virological response rate was 57% (95%-CI: 43-71%). 
Sustained virological response varied between 75-83% for patients with 1 
unfavorable characteristic; between 25-60% for patients with 2 unfavorable 
characteristics, but only 17% for those with 3 unfavorable factors. Ten patients had 
detectable HCV RNA at week 12; in whom treatment was discontinued (19%). Two 
patients experienced a virological breakthrough (4%) and 1 patient was HCV RNA 
negative at 72 weeks but relapsed in the 24 weeks of untreated follow-up (2%). Four 
patients were not compliant: they stopped in the first four weeks after discharge from 
the hospital. In six patients (11%), therapy was stopped because of adverse effects 
(hepatic decompensation (n=2), depression (n=2), cardiac complaints (n=1) and 
Staphylococcus sepsis (n=1)). These data indicate that patients with either genotype 
1, cirrhosis or prior non-response can have sustained virological response rates 
approaching those in genotype 2/3 when treated with high-dosed and prolonged IFN-
α based therapy. However, in patients with combinations of these unfavorable 
criteria, sustained virological response rates were low. 
 
 2.4  TREATMENT TODAY: PEG-INTERFERON-α AND RIBAVIRIN 
 
2.4.1 Peg-interferon-α monotherapy 
The covalent attachment of polyethylene glycol (PEG) to IFN-α extends the half-life 
and duration of therapeutic activity of IFN-α in-vivo, allowing less frequent dosing.  
Four randomised controlled trials have compared the efficacy and safety of PEG-IFN-
α monotherapy with standard IFN-α monotherapy (31-34). One of these studies was 
designed to investigate treatment efficacy and safety in patients with bridging fibrosis 
or cirrhosis (32). Administration of PEG-IFN-α once weekly has an increased antiviral 
effect compared to IFN-α 3MU thrice a week in naive patients resulting in a reduced 
breakthrough rate and an increased end of treatment and sustained virological 
response rate. The optimal dose of PEG-IFN-α was found to be 180 ug per week for 
PEG-IFN-α2a and 1.5ug/kg body weight for PEG-IFN-α2b. Sustained response rates 
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in genotype 1 were between 12-31% for PEG-IFN-α and between 2-6% for standard 
IFN-α. In genotype 2 and 3 sustained virological response rates were around 50% 
and 28% respectively.  
 
2.4.2 Peg-interferon-α and ribavirin 
When PEG-IFN-α is combined with ribavirin the sustained response rate is further 
improved. Sustained virological response rates in genotype non-1 were 78% for 6 
and 77% for 12 months PEG-IFN-α2a plus ribavirin therapy. Like the treatment with 
regular IFN-α plus ribavirin, there is no benefit in prolonging treatment till 48 weeks in 
patients with genotypes 2 and 3 (table 3). A reduced ribavirin dosage of 800 mg daily 
was found to be as effective as 1000-1200 mg daily in patients with genotype 2 and 
3, but the standard dosage of 1000-1200 mg yielded better sustained response rates 
in patients with genotype 1 in whom sustained virological response rates were 42-
51% (table 4). These outcomes are improved over standard IFN-α ribavirin therapy 
although still about 50% of genotype 1 patients do not respond (35-37). During 
treatment, a 2 log or more decrease in viral load in the first 12 weeks is predictive for 
sustained virological response. Patients who fail to achieve a 2 log decrease in viral 
load have a limited chance to achieve sustained virological response and should stop 
therapy.  
One of the major differences between the two PEG-IFNs is fixed dosing for PEG-IFN-
α2a and dosing according to weight for PEG-IFN-α2b. Trials comparing efficacy and 
safety of PEG-IFN-α2a to PEG-IFN-α2b with or without ribavirin have not (yet) been 
conducted. However, both PEG-IFNs have been compared to standard IFN-α and the 
increased sustained response rates, safety profile and side effects seem similar. 
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Table 3: Effect of pegylation of interferon-α. 
 
  
Interferon- α2b#  and ribavirin¥ 
 
48 weeks 
 
Peg-interferon-α2a/b and 
ribavirin¥ 
 
48 weeks  
 
Genotype 1 
 
33-36% 
 
42$ -46% 
 
Genotype non-1* 
 
61-79% 
 
76-82$ % 
Sustained virological response rates in genotype 1 and genotype non-1 for interferon-α2b and Peg-
interferon-α2a or Peg-interferon-α2b plus ribavirin for 48 weeks. 
*Reflects data on genotype 2 and 3, data on genotype 4-6 are too limited for inclusion in the table. 
# Interferon-α2b dosed 3 million units three times a week. Peg-interferon-α2a dosed 180mcg per week. 
Peg-interferon-α2b dosed 1.5ug/kg body weight per week. 
¥Ribavirin orally; dosed 1.0-1.2g in two divided doses according to weight. 
$ Ribavirin orally: dosed 800mg/ day in two divided doses. 
 
 
Table 4: Effect of ribavirin dose and treatment duration. 
 
  
Peg-interferon-α2a 180 ug per week  
  
Ribavirin 800 mg 
 
 
Ribavirin 1-1,2 g 
  
24 weeks 
 
48 weeks 
 
24 weeks 
 
48 weeks 
 
Genotype 1 
 
29% 
 
40% 
 
41% 
 
51% 
 
Genotype 2-3 
 
78% 
 
73% 
 
78% 
 
77% 
Sustained virological response rates in genotype 1 and genotype 2 & 3 for Peg-interferon-α2a 180 ug 
per week plus 800 mg vs 1.0-1.2g ribavirin for 24 and 48 weeks. (based on literature reference 36) 
 
The treatment of Hepatitis C 
 31
2.4.2 Consensus guidelines 
The improvement in treatment results necessitated the need of updating the available 
guidelines. Two consensus guidelines, both funded from the public sector to assure 
independence from the pharmaceutical industry, were provided in 2002 (38, 39). 
According to the NIH and French consensus guidelines all patients with chronic 
hepatitis C and an increased risk of developing cirrhosis are potential candidates for 
antiviral therapy. Patients with genotype 2 and 3 should be treated for 24 weeks. The 
NIH guidelines state that sustained virological response for patients with genotypes 2 
or 3 are similar to PEG-IFN-α and ribavirin or standard IFN-α and ribavirin therapy. 
Thus standard IFN-α and ribavirin can still be used in treating patients with genotypes 
2 or 3. Since low dosed ribavirin was found to be as effective as 1000-1200 mg daily, 
24 weeks of treatment and an 800 mg dose of ribavirin is the new standard for 
patients with genotype 2 and 3. According to the consensus statements, patients with 
genotype 1 should be treated with PEG-IFN-α in combination with 1-1.2 g ribavirin for 
48 weeks. 
 
Currently, much attention is focused on patient and virus characteristics to enable 
identification of patients that will or will not benefit from treatment. Major pre-
treatment factors influencing response rates to combination therapy are HCV 
genotypes and the degree of fibrosis. Viremic level, age and gender are of less 
importance in pegylated IFN-α therapy (7, 31, 33, 35, 36, 40). 
Since genotype 1 is the predominant genotype in many parts of the world and the 
improved sustained response rate with PEG-IFN-α -ribavirin therapy is only about 
50%, more effective treatment for this large group is desirable.  
Patients with cirrhosis form another group that currently is in need for better 
treatment options. In view of the fact that morbidity and mortality of chronic hepatitis 
C is predominantly in this category of patients it is of note that most of the large trials 
of interferon-ribavirin combination as well as those assessing PEG-IFN-α with or 
without ribavirin comprised only a minority of patients with cirrhosis. Responses in 
cirrhotic patients are generally less than in non-cirrhotic patients although treatment 
with PEG-IFN-α has diminished these differences. Heathcote et al. treated 271 
patients with bridging fibrosis or cirrhosis with IFN-α2a versus two schedules of PEG-
IFN-α2a. 
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Figure: Individualised approach to treatment of naive patients with chronic hepatitis C according to 
the authors’ interpretation of consensus statements (38, 39). Treatment is recommended for patients 
with an increased risk of developing cirrhosis. # Patients with F0-1 (no or minor fibrosis) have a limited 
risk of developing cirrhosis and should only be treated when highly motivated after complete 
information about side effects. Re-evaluation within 3 to 5 years is recommended. *Patients with 
genotype 1 and cirrhosis (F4) should in view of the limited chance for sustained virological response 
be treated in an experimental setting. $Patients with genotype 2 or 3 in whom cirrhosis is likely should 
be treated for 1 year with PEG-IFN-α and standard dosed ribavirin. 
 
HCV-RNA + (≥ 6 months)
Genotype 1Genotype 2/3
(Peg-)interferon-α
ribavirin 800mg
6 months
ALT testing
Normal Elevated
Liver biopsy
Peg-interferon-α
ribavirin 1-1,2g
12 months
F2-F3 F0-1#
Repeat in 3-5  years
ALT testing
Elevated Normal
Repeat 3 times in 6
months
Repeat 3 times in 6
months
F4*F2-F3
Liver biopsy
F4 $F0-1#
Repeat in 3-5  years
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Sustained response rates of 12% in genotype 1 and 51% in genotype non-1 infection 
were found (32). 
 
2.5  TREATMENT TOMORROW: FURTHER THERAPEUTIC OPTIONS 
FOR GENOTYPE 1 AND CIRRHOSIS  
 
As described above, treatment with high dose induction IFN-α and prolonged daily 
IFN-α plus ribavirin was successful in the majority of patients selected for treatment 
resistant characteristics. Given the increased effectiveness of PEG-IFN-α, a schedule 
of high dose PEG-IFN-α combined with ribavirin for a prolonged period might 
increase response rates. For PEG-IFN-α induction, the optimal PEG-IFN-α dosage 
has to be determined by measuring both the levels of IFN-α and the anti-viral effects 
in vivo during therapy. Currently, a Dutch multicentre randomised trial (PIT study) 
comparing PEG-IFN-α induction and prolonged PEG-IFN-α - ribavirin combination 
treatment to standard therapy in previous non-responders is under way. Until now, 
randomised studies comparing PEG-IFN-α induction to standard PEG-IFN-α therapy 
have not been published yet. 
In naive patients, interferon based treatment strategies can possibly be further 
tailored to each individual patient according to early response dynamics. By 
measuring the decline in viral load in each patient in the first weeks of treatment, 
dose and treatment duration can possibly be optimised.  
Completely different forms of medications, the so-called proteinase-inhibitors, being 
investigated for their (additional) anti-HCV effect. These drugs can be taken orally 
and appear highly effective. Phase II - III clinical trials are currently underway; results 
are pending. Still it is unlikely that such new therapy will be available for routine 
clinical use within the next 3 to 5 years. 
 
2.6  CONCLUSIONS AND RECOMMENDATIONS 
 
In the figure our opinion on how to treat naive patients with chronic hepatitis C is 
shown. Treatment is recommended for patients with an increased risk of developing 
cirrhosis. Therefore patients with F0-1 (no or minor fibrosis) should only be treated 
when highly motivated after complete information about side effects Genotype 2 and 
3 patients without cirrhosis are optimally treated for 24 weeks with (PEG)-IFN-α in 
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combination with a low dose (800 mg/d) of ribavirin resulting in an 80% sustained 
response rate. Patients with cirrhosis and genotype 2 and 3 have a limited chance for 
sustained response when treated for 24 weeks and should therefore be treated with 
PEG-IFN-α2a/2b for 48 weeks in combination with 1000-1200 mg/d of ribavirin. 
Genotype 1 patients are preferably treated with PEG-IFN-α2a/2b in combination with 
1000-1200 mg/d of ribavirin for 48 weeks. “Difficult to treat patients” with either 
genotype 1, non-response to prior treatment, cirrhosis or a combination of these 
characteristics who, despite notable advances, still have a chance of less than 50% 
for sustained virological response might benefit from induction and prolonged PEG-
IFN-α treatment and should preferably be treated in an experimental setting. Further 
research is needed to optimise treatment schedules and to investigate new antiviral 
drugs in clinical practice; Dutch co-operative studies have the potential to solve some 
of these outstanding issues. 
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3.1  ABSTRACT 
 
Background: Chronic hepatitis C patients with genotype 1 infection, liver cirrhosis, 
high viral load, or those who have not responded to anti-viral treatment in the past 
have limited chances of clearing the virus, even with pegylated interferon-ribavirin 
therapy. In this study we treated such patients with a treatment schedule that 
combines high dose induction Interferon (IFN), prolonged daily IFN and ribavirin 
treatment.  
Methods: Twenty-four consecutive patients were included in this study with either 
genotype 1 infection, cirrhosis, previous non-response to IFN or a combination of 
these poor-response characteristics. Patients were treated with 10 million units (MU) 
of IFN daily for 4 weeks followed by 5 MU/d until week 24, 3 MU/d until week 52 and 
3 MU thrice weekly until week 76 in combination with 1-1,2 gram ribavirin daily. HCV 
RNA levels were assessed weekly until week 4 and at least once every 3 months 
thereafter, by a validated assay with a detection limit below 500 copies/ml.  
Findings: Both intention to treat (ITT) and per protocol (PP) analysis showed a high 
sustained virological response (ITT 67%, PP 80%). A virological response occurred 
rapidly (before 8 weeks of treatment) in all patients with a sustained response. 
Relapse after stopping therapy was observed in only 5%. Side-effects were observed 
frequently, 6 patients had to be hospitalised.  
Interpretation: With this new treatment regimen that combines induction-and 
prolonged daily interferon treatment with ribavirin it seems possible to eliminate 
hepatitis C virus in the majority of patients that have an a priori limited chance of 
sustained response. Further clinical evaluation of intensive interferon and ribavirin 
combination therapy (now also including PEG-interferon) is recommended in centres 
that can provide close patient monitoring and experienced hepatological support. 
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3.2  INTRODUCTION 
 
In the first decade after the licensure of interferon as therapy for chronic hepatitis C, 
results of treatment have shown stepwise improvement, firstly by prolongation of 
treatment from 6 to 12 months, secondly by combination of interferon with ribavirin (1, 
2), and thirdly by the current replacement of standard interferon by pegylated 
interferon (3). With current pegylated interferon-ribavirin combination therapy , a 
sustained clearance of the virus is observed up to 65% of patients (4, 5). 
However, for patients that have unfavourable patient or virus characteristics 
(cirrhosis, genotype 1 or 4, non-response to previous antiviral therapy) the sustained 
response rate is much lower and ranges around 40% (4, 5). 
Failure to clear the virus can be observed at 3 different phases: during the initial (4-
12 weeks) treatment period (non-response, 40-50% of patients), during maintenance 
treatment after an initial response (breakthrough, about 10-20% of patients), and 
after treatment discontinuation (relapse, 25-50% of patients) (6, 7). 
This study focuses on patients with a limited chance to response to standard 
combination therapy (2, 4, 5). In 1998 we altered the standard treatment schedule in 
order to reduce the failure to respond at each of the three different phases. High-
dose daily induction therapy was given to optimise the initial response (8, 9). 
Interferon was administrated daily in order to obtain a more constant drug level that 
would optimise viral inhibition and minimise breakthrough. The importance of 
constant antiviral pressure (10) has become clearer since the introduction of 
pegylated interferons resulting in a marked increase in sustained response rates (3-
5). Lastly: in order to prevent relapse, all patients were advised to prolong the 
standard treatment period of 12 months to a total duration of 18 months (11-13). 
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3.3  MATERIALS AND METHODS 
 
3.3.1 Study population 
Twenty-four consecutive patients with documented chronic hepatitis C were included 
in this study. Patients were eligible if their maximal chance of a sustained response 
with 1 year of interferon-ribavirin combination therapy was less than 30% according 
to major studies (6, 7, 14). Such patients had genotype 1, cirrhosis, non-response to 
IFN or combinations of these criteria. Non-response to prior therapy was defined as 
HCV-RNA PCR positivity after at least 12 weeks of IFN therapy or 26 weeks of IFN-
Ribavirin combination treatment. Other clinical relevant concomitant diseases were 
excluded as previously described (15). 
 
3.3.2 Treatment schedule 
All patients were admitted for the first 7 days of treatment and thereafter intensively 
monitored at the outpatient clinic. Patients received 10 million units (MU) of alpha-
interferon (Intron A, Schering-Plough, Kenilworth, NJ, USA) daily for 4 weeks 
followed by 5 MU daily until week 24, 3 MU daily until week 52 and 3 MU thrice 
weekly until week 76. Ribavirin was given twice daily orally in divided doses of 1,000 
mg (weight <75 kg) or 1,200 mg (weight >75 kg). 
Dose reduction was based on clinical intolerance or granulocytopenia below 0.5 x 
106/mm3. In such cases interferon was reduced to the next level of the treatment 
schedule, ribavirin was reduced by steps of 200 mg/day. Combination therapy was 
discontinued in case of virological non-response, defined as detectable HCV RNA at 
week 12 and 16. 
 
3.3.3 Detection of HCV RNA  
Blood was drawn at baseline and at week 1, 2, 3, 4, 8, 12, 16, 24, 32, 48, 52, 76, 88, 
100 and 104. Blood samples were collected in plasma preparation tubes (Becton-
Dickenson, Plymouth, UK) which were spun directly after collection in order to avoid 
RNA breakdown. A qualitative HCV RNA assay was used to asses viremia (Cobas 
Amplicor HCV test, Roche Diagnostics, Almere, The Netherlands). The test was 
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found to have a comparable sensitivity to the NGI assay (less than 500 copies/ml 
when tested in the Eurohep panel). 
 
3.3.4 Descriptive analysis 
The percentage of HCV RNA negativity at various time points was calculated for the 
total population (Intention To Treat analysis) and for those who completed the 
treatment and follow-up according to protocol (Per Protocol analysis). The initial 
response rate was calculated at the end of the induction phase (4 weeks). The 
breakthrough rate was calculated at the end of treatment for those reaching HCV 
RNA negativity during treatment, and the relapse rate at 6 months of follow-up for 
those who were HCV RNA negative at the end of treatment.  
 
3.4 RESULTS 
 
Seventeen patients were males, seven were females; the mean age was 47 years. 
Fifteen patients were of European descent, and 9 were born outside Europe 
(Surinam: 3, Pakistan: 2, and Far East: 4). 
All patients were estimated to have less than 30% chance of a sustained response of 
standard interferon-ribavirin therapy, based on their baseline characteristics (fig 1). 
Of the total group 11 (46%) had genotype 1, 11 (46%) had cirrhosis, of whom 7 could 
be classified as advanced cirrhosis (serum bilirubin >17 µmol/l or platelets 
<130x106/mm3) (16), and 15 were non-responders; 10 patients had 2 and 3 patients 
had 3 poor-response criteria.  
Non-response
N=15
Cirrhosis
N=11
Genotype 1
N=11
2
4 2 
3
7 1 5 
Figure 1: Van diagram dysplaying 
the study population by 
characteristics associated with poor 
response. 
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In addition, 17 patients had a high viral load 
(> 2.0 x 106  copies/ml (2)) at baseline. The 
median viral load was 7.4 x 106 copies/ml. 
The intention to treat population (ITT) 
consisted of 24 patients, 20 completed the 
study according to protocol (PP) (Fig 2). 
The initial response rate at 4 weeks (HCV-
RNA below the threshold of sensitivity) was 
67% (16/24) by intention to treat analysis 
and 75% (15/20) by per protocol analysis. 
This high initial response rate coupled to an 
additional response of 10% during 
treatment and a very low breakthrough of 
5%, led to an end of treatment response of 
75% (18/24,ITT) to 85% (17/20,PP). Due to 
the very low relapse rate (5%) the sustained 
response rate was 67% (16/24,ITT) to 80% 
(16/20,PP) (Fig 3). 
 
 
 
Table I shows the results of treatment according to the baseline characteristics. 
According to the per protocol analysis all predefined sub-groups had a sustained 
response rate of 50% or more. For this intensive treatment schedule a sustained 
virological response was observed in almost all patients without cirrhosis (ITT: 92%; 
PP: 100%); only the patient characteristic, cirrhosis, was a significant predictor for not 
reaching a sustained viral response (p<0,05 fisher-exact test);  
 
 
Adverse events led to hospitalisation in 6/24 patients (hepatic decompensation, de 
novo diabetes mellitus in association with jaundice and ascites, cardiac complaints, 
weight loss of more than 10%, infected injection site and decreased vision); 5 out of 
Figure 2: Trial profile. The Intention To Treat 
population included all 24 patients who 
started treatment. The Per Protocol population 
comprised the 20 patients who completed 
treatment and follow-up according to the 
protocol. 
2 patients stopped
(1 caredial problems, 1 drugs abuse)
1 patients stopped (fatigue, week 6)
1 patient: no follow-up
(liver decompensation)
20 patients completed 26 weeks
of follow-up
21 patients completed therapy
(mean 72)
22 patients completed 4 weeks
of treatment
24 Consecutive patients started
on 10 MU IFN /day for 4 weeks
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these 6 patients had cirrhosis. Combination treatment was discontinued in one of the 
hospitalised patients prior to week 52; discontinuation of therapy occurred in 3 non-
hospitalised patients due to drug abuse, cardiac complaints and fatigue with 
depression in the first 8 weeks. 
The dose of Interferon was reduced in 8/24 and a reduction of ribavirin was observed 
in 5/24 patients; in the group of cirrhosis treatment was discontinued or reduced in 
7/11 versus 4/13 in the non-cirrhotic group.  
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Figure 3. Study profile and percentage of patients with HCV-RNA below detection during 
treatment and follow-up by intention to treat analysis (ITT) and by per protocol analysis (PP). 
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3.5  DISCUSSION 
 
This exploratory study shows that in patients with chronic hepatitis C and a low a 
priori chance of a sustained response with 1 year of standard interferon-ribavirin 
therapy a high rate of sustained response can be obtained. Our favourable results 
(sustained virological response in 67% (ITT)) contrast with the 28% sustained 
virological response rate in patients with unfavourable characteristics as reported in 
the so-called pivotal studies (6, 7) and with the approximately 40% sustained 
virological response rate reported for pegylated interferon-ribavirin combination 
therapy (4, 5). Therefore our results remain also of interest for the immediate future 
now pegylated interferon is replacing standard interferon in many schedules. 
The basis for the high-sustained response rate was the 70% serum negativity for 
HCV RNA by PCR at 4-12 weeks of treatment associated with daily high dose 
induction therapy. High initial response rates have been described previously by 
Japanese investigators (8). The median duration of induction therapy needed to 
reach viral negativity using daily 5-10 MU of interferon combined with ribavirin is 
estimated to be 6-9 weeks in previously untreated genotype 1 patients (17). Induction 
therapy was applied in our study for 24 weeks in contrast to many other studies that 
changed the daily high dose of induction therapy to maintenance therapy after 2-8 
weeks. According to viral kinetics, the effect of induction therapy can be lost by early 
lowering of the dose; not only is the initial drop in viral load partly reversed, the slope 
of the second phase can also become more flat due to the diminished inhibitory effect 
of interferon on viral production (18). 
During maintenance therapy breakthrough is apparently better prevented by daily 
interferon than by interferon thrice weekly. This effect of the more constant presence 
of interferon is also clearly demonstrated by the use of pegylated interferon, leading 
to increased end of treatment responses (3, 10, 19). 
The duration of the maintenance therapy is likely a third independent factor affecting 
the sustained response rate (12). Relapse rates for patient with undetectable HCV-
RNA are about 50% for 6 months therapy, 25% for 12 months and preliminary data 
indicates less  
than 10% for 18 months of combination interferon-ribavirin therapy (15). 
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Our study is one of the first in which daily high dose induction for more than 12 weeks 
was followed by daily interferon therapy to prevent breakthrough till 52 weeks and 
prolonged till 72 weeks to prevent relapse. In these three aspects it differs from major 
studies assessing induction therapies. In two European multicenter studies (20, 21) 
improvement in virological response of high dose daily induction interferon therapy 
plus ribavirin could only be found in patient subgroups. Both studies were conducted 
in treatment naive patients. Daily high induction therapy was changed after 2-4 
weeks to thrice-weekly interferon administration. The total treatment period was 
limited to only 26-38 weeks. In an international multicenter study conducted in North 
America and Europe (22) daily induction therapy was given for 8 weeks and 
maintenance therapy with daily interferon was reduced at 24 weeks to interferon 
thrice weekly for an additional 24 weeks. In these studies the initial higher response 
rates observed with induction therapy faded at the end of treatment and disappeared 
at the end of follow-up. Our exploratory study strongly suggest that daily induction 
therapy might be beneficial for patients with a low chance of a sustained response 
but only when combined with adequate maintenance therapy of long duration. This 
hypothesis needs further testing in a large controlled trial. 
The intensive treatment regiment in our study was expected to be associated with 
clinical significant non-compliance and/or adverse events. The incidence of non-
compliance and intolerability could be kept low by intensive monitoring. Clinically 
relevant adverse events occurred mainly in patients with advanced cirrhosis.  
This early report, in a relatively small number of patients, suggests that the large 
majority of patients with chronic hepatitis C can be cured.  Further clinical evaluation 
of intensive (peg-) interferon/ribavirin combination therapy is recommended in 
centres which can provide close monitoring and experienced hepatologic support. 
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4.1  ABSTRACT 
 
Background and aims: Results of interferon-based treatments of chronic hepatitis C 
have markedly improved except for patients with unfavourable characteristics. To 
assess whether such patients can respond to modified interferon regimens we 
performed a meta-analysis on data of individual patients treated in our center with 
high-dose induction and prolonged daily interferon plus ribavirin. 
Methods: Fifty-four patients selected for poor-response characteristics such as 
genotype 1, cirrhosis or non-response to previous therapy were enrolled sequentially 
to one of three therapy schedules. Treatment consisted of 10 MU interferon-a2b 
(IFN) daily for 2-4 weeks followed by daily 3-5 MU IFN until week 52 and 3 MU daily 
or thrice weekly until week 76 in combination with ribavirin. 
Results: Sustained virological response rate varied between 75-83% for patients with 
1 unfavorable characteristic (n=23). In patients with combination of such 
characteristics, sustained virological response rate were 60%, but only and 21% for 
genotype 1 and cirrhosis (n=14).  Six patients (11%) stopped therapy  because of 
adverse effects; clinically serious adverse events occurred in 2/7 patients with 
advanced cirrhosis. 
Conclusion: High-dose induction and prolonged daily interferon-ribavirin therapy is 
an acceptable and potentially highly effective treatment modality for selected patients 
with unfavourable characteristics. Patients with either genotype 1, cirrhosis or prior 
non-response can have sustained virological response rates approaching those of 
pegylated-interferon ribavirin combination therapy in genotype 2/3 when treated with 
high-dosed and prolonged interferon in combination with ribavirin. However, in 
patients with combinations of these unfavorable criteria, sustained virological 
response rates progressively decrease. 
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4.2  INTRODUCTION 
 
The interferon-based treatment of chronic hepatitis C has made remarkable progress 
over the past ten years. Since the introduction of pegylated interferon (PEG-IFN-α) 
ribavirin combination therapy, results of large international trials indicate cure-rates of 
77-82% in genotype 2 and 3 infection. However, the predominant genotype in many 
parts of the world is genotype 1 and the sustained response rate in this type of 
infection is still only 42-46% (1, 2). 
Morbidity and mortality of chronic hepatitis C is predominantly in patients with 
cirrhosis (3). Responses in patients with cirrhosis are generally less than in those 
without cirrhosis although treatment with pegylated interferon diminishes the 
difference (4). It is therefore of note that the large trials of interferon-ribavirin 
combination as well as those assessing PEG-IFN-α with or without ribavirin 
comprised only a small number of patients with cirrhosis (1, 2, 5, 6).  
Earlier, we reported an improved efficacy with high induction dose (10 MU daily) and 
prolonged (12-18 months) interferon therapy in combination with ribavirin in a small 
pilot study (7). To assess whether patients with unfavorable characteristics might 
benefit from such a modified treatment regimen in subsequent experience, we 
analyzed individual data of all patients with unfavourable baseline characteristics 
such as genotype 1, cirrhosis, non-response to IFN-α or combinations of these 
criteria treated in our centre with high-dose induction, daily and prolonged daily 
interferon-ribavirin combination therapy. 
Three treatment schedules of high dose induction and prolonged daily IFN-α in 
combination with ribavirin were used. The initial study (8) was designed to explore by 
viral kinetics the IFN-α induction dose leading to a maximal initial response. The 
patients were treated with a relative intensive and long induction regimen of IFN-α. 
Subsequently, two other regimens were designed to preserve the favourable results 
in terms of viral kinetics but to reduce the intensity in terms of side effects and costs. 
In all three protocols the administration of IFN was given daily during at least 12 
months in order to maintain a constant drug level and thereby maximise viral 
inhibition and to minimise virological breakthrough. Thereafter, treatment was 
continued up to 76 weeks in an attempt to reduce viral relapse (9, 10). 
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4.3  PATIENTS AND METHODS 
 
4.3.1 Study population 
Between February 1998 and March 2001, 55 consecutive patients with documented 
chronic hepatitis C were enrolled in a program of high dose induction and prolonged 
daily IFN-α in combination with ribavirin therapy. The ethical committee approved the 
study and patients gave written informed consent for inclusion. Patients were eligible 
if their maximal chance of reaching a sustained response with standard therapy 
according to the 1998 EASL consensus statement (11) was considered less than 
30%. Such patients had genotype 1 or 4, cirrhosis, non-sustained response to prior 
treatment or combinations of these criteria. In this study non-sustained response was 
defined as a positive HCV-RNA serum test after at least 6 months of IFN-α 
monotherapy (3 MU t.i.w.) or a relapse after 12 months of IFN-α ribavirin combination 
treatment. Patients with clinical relevant concomitant diseases were excluded 
according to criteria previously described (10, 12). 
 
4.3.2 Study design 
Patients were allocated successively to receive one of the following treatment 
regimens (figure 1). The first 24 consecutive patients received 10 million units (MU) 
IFN-α2b (Intron A, Schering-Plough, Kenilworth, NJ, USA) daily for 4 weeks followed 
by 5 MU daily until week 24, 3 MU daily until week 52 and 3 MU thrice weekly until 
week 76 (group A). The next fifteen patients were assigned to receive 10 MU IFN-α 
daily for 10 days followed by 3 MU daily until week 52 and 3 MU thrice weekly until 
week 76 (group B). The following 16 patients were assigned to receive 10 MU IFN-α 
daily for 2 weeks followed by 5 MU daily until week 4 and 3 MU per day until week 76 
(group C). Ribavirin was supplied to all patients as 200-mg capsules given orally in 2 
divided daily doses of 1,000 mg (weight <75 kg) or 1,200 mg (weight >75 kg) 
throughout the entire treatment period.  
 
All patients were admitted to the ward for the first 7 days of treatment and thereafter 
intensively monitored on an outpatient basis. Clinical and biochemical assessments 
were conducted every 4 to 6 weeks during therapy and during a 6-month follow-up 
period. 
 
High dose induction therapy 
 59
 
A. 
 
 
 
B. 
 
 
 
C. 
 
 
 
 
 
Figure 1. Schematic overview of 3 treatment arms.  
The first 24 consecutive patients were included in group A, the next fifteen patients were assigned to 
group B and the last 15 patients were assigned to group C.  
 
Dose adjustment was based on clinical intolerance, granulocytopenia below 0.5 x 
106/mm3 (IFN-α) or hemoglobin below 6 mmol/l (ribavirin). In such cases interferon 
was reduced to the next level of the treatment schedule, ribavirin was reduced by 
steps of 200 mg/day. Combination therapy was discontinued in case of virological 
non-response, defined as detectable HCV RNA at week 12. 
 
4.3.3 Histology 
All patients underwent liver biopsy before the start of therapy. An experienced 
pathologist who was unaware of the clinical outcome evaluated each liver biopsy for 
the presence of cirrhosis, comparable to Metavir F4. 
 
4.3.4 Virology 
Blood was drawn at baseline and at week 4, 12, 16, 24, 48, 76, 88 and 100. Blood 
samples were collected in plasma preparation tubes (Becton-Dickenson, Plymouth, 
IFN 5 MU/ day
10 MU/day
10 MU/day
10 MU/day
5 MU/ day
24 52 76
weeks
40 2
IFN 3 MU / day
IFN 3 MU / day
IFN 3 MU t.i.w.
Ribavirin 1 - 1.2 gram daily
Ribavirin 1 - 1.2 gram daily
IFN 3 MU / day
Ribavirin 1 - 1.2 gram daily
IFN 3 MU t.i.w.
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UK), which were spun directly after collection in order to avoid RNA breakdown. A 
qualitative HCV RNA assay was performed in a single local laboratory to assess 
viremia (Cobas Amplicor HCV test, Roche Diagnostics, Almere, The Netherlands). 
Genotypes were identified before the start of treatment by in-house sequence 
analysis. 
 
4.3.5 Descriptive analysis 
The primary end point of this analysis was the rate of sustained response after a 24-
week treatment free follow-up period. Results were calculated for the total population 
(Intention -to-treat analysis). The breakthrough rate was calculated at the end of 
treatment for those reaching HCV RNA negativity during treatment and the relapse 
rate at 24 weeks of follow-up for those who were HCV RNA negative at the end of 
treatment. 
 
4.3.6 Statistics 
Data were analysed using SPSS for Windows (Version 10.1 SPSS Inc, Chicago, IL, 
USA). Percentages are given with 95% confidence intervals (CI). 
 
4.4  RESULTS  
 
4.4.1 Patient characteristics 
In table 1, baseline characteristics of the study population are shown per treatment  
schedule and for the whole group. One patient, who was assigned to treatment 
regimen C and who had a sustained response, did on retrospect not comply with the 
inclusion criteria associated with poor response and was excluded from the analysis. 
The intention to treat population (ITT) consisted of 54 patients of whom 44 completed 
the study (81%) according to the protocol.  
 
The proportion of cases with cirrhosis was 46%. Genotype 1 was the predominant 
genotype (69%). More than half of the patients (54%) had a failure to prior IFN 
treatment. Fourteen patients (26%) had both a genotype 1 and cirrhosis. The majority 
of patients (81%) had a high viral load (≥ 2 x 106 copies/ml). 
 
4.4.2 Outcome  
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In table 2, intention-to-treat results are shown per treatment arm and for the total 
study population. The ITT sustained response rates were 67% (95% CI: 45-84%), 
53% (95% CI: 27-79%), 47% (95% CI: 21-73%) for respectively treatment regimen A, 
B, C. The outcomes for the three treatment regimens were not significantly different 
according to multivariate logistic regression analysis performed to correct for 
differences in baseline characteristics and study groups.  
 
 
Table 1.   Baseline characteristics of the total study population and by treatment regimen. 
Treatment regimen  
Group A Group B Group C All 
Patients  24 15 15 54 
 Mean age (years ± SD) 47 ± 10 45 ± 7 45 ± 10 46 ± 9 
 Sex (M / F) 17 / 7 11 / 4 12 / 3 40 / 14 
 ALT (mean IU ± SD) 103 ± 83 125 ± 78 117 ± 51 113 ± 73 
     
Histology     
 Cirrhosis (%) 12 (50%) 1 (7%) 12 (80%) 25 (46%) 
     
Serum HCV-RNA     
 Median (copies/ml)  7.4x106 3.2x107 7.9x106 1.4x107 
 ≥ 2 x 106 (%) 17 (71%) 14 (93%) 13 (87%) 44 (81%) 
     
Genotype     
 1 and 4* (%) 12 (50%) 15 (100%) 10 (67%) 37 (69%) 
 2 & 3 (%) 12 (50%) 0 (0%) 5 (33%) 17 (32%) 
     
Non-responders 15 (63%) 11 (73%) 3 (20%) 29 (54%) 
     
Plus-minus values are means ± SD. For details of the treatment regimen see figure 1. For details of 
“overlap in unfavourable baseline characteristics” see figure 2.* only one patient had genotype 4. 
 
The overall sustained virological response rate was 57% (95%-CI: 43-71%) and 
varied between 75-83% for patients with 1 unfavorable characteristic; 25-60% for 
patients with 2 unfavorable characteristics, and 17% for those with 3 unfavorable 
factors (figure 2).  
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Ten patients had detectable HCV RNA at week 12; in whom treatment was 
discontinued prematurely (19%; 95% CI: 9-31%). Two patients experienced a 
virological breakthrough (4%) and 1 patient was HCV RNA negative at 72 weeks but 
relapsed in the 24 weeks of untreated follow-up (2%). Four patients were not 
compliant: they stopped in the first four weeks after discharge from the hospital. In six 
patients (11%; 95% CI: 4-23%), therapy was stopped because of adverse effects 
(hepatic decompensation (n=2), depression (n=2), cardiac complaints (n=1) and 
Staphylococcus sepsis (n=1)). Both patients that developed decompensated liver 
disease, had advanced cirrhosis: according to the Child-Pugh classification their 
baseline scores were 6, but both had elevated bilirubin and low platelets (3). All other 
adverse effects occurred within the first 8 weeks of treatment.  
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Figure 2. “Van diagram” displaying the study population: number of unfavorable 
baseline characteristics and accompanying sustained response rates (%).  
For example, the study population consisted of thirty-seven patients infected with genotype 1; eight of 
them also had cirrhosis, fifteen were also prior non-responders. Six patients had three unfavorable 
characteristics: genotype 1, cirrhosis and prior non-response. 
The sustained response rate varied between 75-83% for patients with 1 unfavorable characteristic; 
genotype 1: 75%, cirrhosis: 77%, prior non-response: 83%. For patients with 2 unfavorable 
characteristics sustained response rates were between 25-60%: genotype 1 and cirrhosis: 25%, 
genotype 1 and prior non-response: 60%. In the 6 patients with 3 unfavorable characteristics the 
sustained response was only 17%. 
Genotype 1 (n=37)
Prior Non-response
(n=29)
Cirrhosis (n=25)
83%
5/6
75%
6/8
25%
2/8
60%
9/15
50%
 1/2
17%
 1/6
77%
7/9
Chapter 4 
 64 
 
4.5  DISCUSSION 
 
This study documents the efficacy rates of high dose induction and prolonged daily 
interferon plus ribavirin treatment in patients with baseline characteristics associated 
with poor response. The overall sustained virological response rate was 57% (95%-
CI: 43-71%) and varied between 75-83% for patients with 1 unfavorable 
characteristic. Results with modern schedules of PEG-IFN-α and ribavirin yield 
similar percentages, but the baseline characteristics in our study population were 
vastly more unfavourable. In patients with combinations of these unfavourable 
criteria, sustained virological response rates were considerably decreased: 25-60% 
for patients with 2 unfavorable characteristics, and 17% for those with 3 unfavorable 
factors. 
 
The studies were originally designed to explore the optimal IFN-α induction dose by 
viral kinetics (7, 8, 13). The first group of patients was treated with an intensive 
schedule resulting in a sustained response rate of 67% (7). The next two strategies 
were attempts to decrease morbidity and cost without loosing efficacy. However, by 
shortening the induction period adverse effects were somewhat decreased but also 
effectiveness was reduced in some patients (13). No clear advantage of either 
treatment schedules B or C was found over treatment schedules A. 
 
How can these favourable results be explained? First, in all three treatment groups, 
therapy was started with a daily high-dose interferon “induction” period in order to 
reach early HCV-RNA negativity. Early viral response is a strong predictor for 
sustained response (1, 7, 14). In this study, 17 patients were HCV-RNA negative 
after 4 weeks of treatment. Fourteen of them had a sustained response (82%) as 
compared to 17 out of 37 patients (46%) who had their HCV RNA response after 
week 4. Second, given the short half-live of IFN-α, daily IFN-α injections were given 
to obtain a more constant drug level in order to optimise viral inhibition and minimise 
viral breakthrough. The importance of constant antiviral pressure has become more 
clear since the introduction of PEG-IFN-α with its prolonged half-life (1, 2). Third, we 
prolonged the treatment duration in order to prevent relapse (9, 10). As a result, the 
relapse rate could be reduced to less than 5% in this study.  
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The intensive treatment schedules were expected to be associated with an increased 
rate of intolerance and side effects. Due to intensive monitoring the rate of non-
compliance could be kept low. Clinically serious adverse effects occurred in 2 
patients with impaired liver function due to advanced cirrhosis. Since the sustained 
response rate in patients with advanced cirrhosis was limited to 1 out of 7, we 
conclude that risks outweigh benefits in this category of patients. 
 
How should these results be implemented into future treatment schedules? The 
results of this study show that patients with either genotype 1, cirrhosis or non-
response to previous therapy can have sustained virological response rates 
approaching those of pegylated-interferon ribavirin combination therapy in genotype 
2/3 when treated with high-dosed and prolonged interferon in combination with 
ribavirin. However, in patients with combinations of these unfavorable criteria, 
sustained virological response rates progressively decrease. Given the augmented 
efficacy of peginterferon, we think our results should stimulate further research on 
initial high-dose peginterferon with and without therapy prolongation in combination 
with ribavirin for the treatment of “difficult-to-treat” hepatitis C patients. 
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5.1 ABSTRACT  
 
Background: Standard dosed peginterferon-ribavirin therapy has a limited success 
in the retreatment of hepatitis C patients who failed to achieve a sustained response 
with previous therapy. Since daily high dosed interferon induced early clearance of 
hepatitis C virus RNA in a small number of patients, we investigated high-dose 
peginterferon in comparison to standard dose peginterferon with regard to early viral 
clearance and its impact on health related quality of life. 
Methods: 40 patients who previously failed interferon therapy were randomly 
assigned to high-dose Peginterferon-α2b (3.0 µg/kg) or standard dose Peginterferon-
α2b (1.5 µg/kg) during the study period of 28 days. Both groups received 1-1.2 gram 
ribavirin daily. HCV RNA levels were assessed at baseline, t=2, 7, 14, 28 days and 
12 weeks. Health related quality of life was assed using the SF-36 at baseline and 
t=28 days.  
Results: 19 patients were randomized to high-dose and 21 to standard dose therapy. 
At the t=7 the decrease in HCV-RNA compared to baseline for high-dose 
peginterferon vs. standard dose peginterferon was 1.73 ± 0.42 Log vs. 1.06 ± 0.35 
Log (p=0.12) and at 28 days 3.10 ± 0.51 Log vs. 2.78 ± 0.57 Log (p=0.65). Most 
patients (25/40; 63%); 13/19 high-dose peginterferon treated vs. 12/21 standard dose 
peginterferon (p=0.53) showed peginterferon sensitivity. Nine high-dose treated vs. 8 
standard treated patients reached HCV-RNA levels below the limit of detection (rapid 
response). Four patients in both groups showed a partial response (p=1.00). Fifteen 
patients, 6 treated with high-dose peginterferon and 9 with standard dose 
peginterferon (p=0.53) were non-responders. Quality of life measured decreased 
considerably in both groups; a dose dependant effect could not be observed.  
Conclusions: High-dose peginterferon appears approximately 10% more effective in 
initially suppressing viral replication, predominantly due to a differential effect in 
genotype 1 and 4.  
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5.2 INTRODUCTION 
 
Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and the 
most common indication for liver transplantation in Europe and the United States (1). 
Currently, the most effective available therapy for HCV is the combination of 
pegylated interferon-α (peginterferon) and ribavirin. With its introduction, sustained 
virological response (SVR) rates were significantly improved with roughly 10% 
compared to (non-pegylated) interferon therapy (2, 3). As a consequence, there is 
interest in re-treating patients who did not achieve SVR with previous non-pegylated 
therapy. However, preliminary reports on peginterferon-ribavirin re-treatment mention 
SVR rates of only 7-15% (4, 5). 
One of the major causes of treatment failure is incomplete blockage of viral 
replication resulting in suboptimal decline of HCV-RNA during the first weeks. It is 
therefore notable that with 4 weeks of daily high dosed interferon therapy, HCV-RNA 
had become undetectable in 80% of “difficult-to-treat” patients eventually leading to a 
SVR of 65% (6). 
The rate of serum HCV-RNA decline proved to be dose dependant (7, 8). However, 
initial efficient blockage of viral replication by daily high dosed interferon can be lost 
later in treatment by premature dose reduction (9) and the same appears to be true 
for Peginterferon-α2b (8). Whether high-dose peginterferon for a prolonged period 
has improved efficacy over standard peginterferon therapy remains to be established. 
In the current study the efficacy of prolonged high-dose Peginterferon-α2b on the 
early virological response was compared to standard therapy; the safety and impact 
on “health related quality of life” were also compared. 
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5.3 METHODS 
 
5.3.1 Participants  
Outpatients with chronic hepatitis C infection, elevated serum ALT activity 
documented on at least 2 occasions, liver biopsy findings consistent with active 
fibrosis (not obligatory in hemophiliacs) and a history of non-response or relapse to at 
least 3 months of interferon therapy were potentially eligible for the study. Patients 
were excluded if they had evidence of severe concomitant illness, if they had used 
any investigational drug or any systemic anti-viral, anti-neoplastic or 
immunomodulatory treatment within 12 weeks prior to the first dose of the study, if 
they were pregnant or breast feeding, if they were under 18 or over 70 years of age, 
if they had decompensated liver disease or if they refused or were unable to give 
consent. 
 
5.3.2 Setting and Locations  
The patients were recruited from the departments of Gastroenterology and 
Hepatology of six Dutch health centers. The Central Committee on Research 
Involving Human Subjects (known by its Dutch initials, CCMO) assessed the study in 
terms of medical ethics, the ethics committee of each institution evaluated the local 
feasibility, and all participants gave written informed consent. 
 
5.3.3 Study design and Interventions 
This is a randomized controlled investigator-initiated multi center study. Patients were 
randomly assigned to receive standard combination therapy or an experimental 
schedule. Standard therapy consisted of Peginterferon-α2b 1.5 µg per kg body 
weight (PEG-Intron; Schering-Plough, Kenilworth, NJ) once weekly (QW). The 
experimental schedule started with high-dose Peginterferon-α2b 3.0 µg/kg QW for 12 
weeks. Therapy was continued thereafter at a lower dosage for at least 36 weeks. 
During treatment, ribavirin (Rebetol, Schering-Plough) was administered orally twice 
daily at a total daily dosage of 1-1.2 gram according to weight.  
During the study period, patients were seen every week as outpatients. At each visit 
blood was drawn to monitor possible hematological side effects. Dose adjustment 
was based on clinical intolerance, hemoglobin below 5 mmol/l (ribavirin), white blood 
cell count below 1.5 x 109/l (peginterferon), granulocytopenia below 0.75 x 109/l 
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(peginterferon) or platelets below 50 x 109/l (peginterferon). In such cases the 
peginterferon dose was reduced by 50%, ribavirin was reduced by steps of 200 
mg/day. If a laboratory adverse event necessitated dose reduction the patient 
returned for assessment at intervals of every 2 weeks.  
 
5.3.4 Randomization 
Participants had an equal probability of assignment to the groups. Randomization 
was performed in computer-generated blocks, with block sizes of 4 and with 
stratification according to center, genotype (1 or 4 vs. other) and previous response 
(responder-relapsers versus non-responders). The randomization assignments were 
concealed in opaque envelopes. A centrally located data manager opened the 
envelopes sequentially after the patient’s consent form had been approved eligible 
and signed by the treating physician and the study coordinator. The treating 
physician was informed of the randomization result by fax-message. 
 
5.3.5 Virology 
To assess the effects of treatment, samples for quantitative HCV RNA 
measurements were drawn during screening, at baseline and during treatment at 
days 2, 7, 14 and 28. The assay (Cobas Amplicor HCV test, Roche Diagnostics, 
Almere, The Netherlands) was performed in a single central laboratory (Institute of 
Virology, Erasmus MC, Rotterdam, The Netherlands). Genotypes were identified 
before the start of treatment by in-house sequence analysis. 
 
5.3.6 Health related Quality of life 
The impact of both treatment arms on the patients' health related quality of life 
(HRQoL) was measured by the generic Short Form 36 (SF-36) questionnaire during 
screening (before randomization) and at 28 days. The SF-36 questionnaire measures 
eight multi-items: physical functioning (PF), role physical (RP), role emotional (RE), 
bodily pain (BP), mental health (MH), vitality (V), social functioning (SF), and general 
health (GH) and was analyzed as recommended by the originators (10). 
 
5.3.7 Statistical Analysis 
The primary analysis compared the effect of high-dose peginterferon to standard 
dose treatment on the decline in HCV RNA over 28 days and the number of patients 
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who were peginterferon sensitive or became HCV RNA negative for every time point 
using the non parametric Mann-Whitney t-test and the Pearson’s Chi-square test 
respectively. Baseline characteristics were compared using the 2-sided Fisher’s 
exact test or the 2-tailed Mann-Whitney U test when appropriate. SF-36 scores were 
compared using the 2-tailed Mann-Whitney U test (between treatment arms) and the 
Wilcoxon signed rank test (between baseline and t=4 weeks). Viral load data were 
log 10 base transformed; viral loads below the limit of detection were transformed to 
1 log. Missing viral load data were substituted by the average of the preceding and 
the following data with correction for time. Statistical significance was inferred if P 
was <0.05 (2-tailed/2-sided).  
 
 
Table 5.1. Baseline characteristics 
 Standard therapy 
(1.5ug/kg) 
High dose therapy 
(3.0ug/kg) 
P 
Sex; male/female 18/3 12/7  
Age in years ± SD 48 ± 8 47 ± 8 .68# 
Length in cm ± SD 174 ± 6 174 ± 8 .77# 
Weight in kg ± SD 81 ± 18 78 ± 14 .67# 
BMI (kg/m2) ± SD 26 ± 4 26 ± 4 .81# 
Cirrhosis (%) ± SD 7 (26) 5 (33) .53* 
ALT in U/l ± SD 128 ± 113 91 ± 45 .63# 
Viral load (copies /ml; ) ± SE 6.87 Log ± 1.31 6.61 Log ± 1.82 .38# 
Genotype 1 (%) 9 (43) 11 (58) .53* 
 
* Fisher’s exact test (2-sided); # Mann-Whitney U test (2-tailed) 
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5.4 RESULTS 
 
5.4.1 Patients 
Forty patients (10 women; 30 man) with chronic hepatitis C (median age: 47 years; 
range 26-68 years) who previously failed to achieve a sustained virological response 
(including 9 IFN-α -monotherapy non-responders, 5 IFN-α -monotherapy responder-
relapsers, 23 IFN-α ribavirin non-responders and 3 IFN-α ribavirin responder-
relapsers) were included. Of these patients, 21 were randomized and assigned to 
receive the standard dose Peginterferon-α2b (1.5 µg/kg body mass per week) and 19 
to receive the experimental Peginterferon-α2b schedule (3.0 µg/kg QW). Genotypes 
were equally divided among the treatment arms. In total 20 patients (50%) were HCV 
genotype 1, 9 patients (22%) genotype 3, 6 patients (15%) genotype 4, 4 patients 
(10%) genotype 2 and 1 patient (3%) genotype 6 infected. No differences were found 
between the treatment groups with regard to previous treatment and type of response 
failure, sex, age, length, weight, BMI, histology, ALT and viral load levels. 
Demographic and baseline characteristics of the patients per study arm are shown in 
table 5.1. 
 
5.4.2 Descriptive response  
During the study period of 28 days, twenty five patients (13/19 high-dose 
peginterferon vs. 12/21 standard dose peginterferon; p=0.53) showed peginterferon 
sensitivity. Seventeen patients, 9 treated with high-dose and 8 with standard dose 
peginterferon reached HCV RNA levels below the limit of detection and were 
considered “rapid-responders” (p=0.75; table 5.2). Rapid responders (n=17) were 
predominantly infected with genotypes other than 1/4 (n=12, p=0.00). The majority of 
rapid genotype 1/4 responders were treated with high-dose peginterferon (4 high-
dose peginterferon vs. 1 standard dose peginterferon; p=0.33). 
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Tabel 5.2. Response pattern throughout the study period relative to treatment arm for all 
patients and genotype 1 and 4 patients between brackets. 
 
 High dose therapy 
(3.0ug/kg) 
Standard therapy 
(1.5ug/kg) 
P* 
Rapid response 9 (4) 8 (1) 0.75 (0.33) 
Partial response 4 (4) 4 (2) 1.00 (0.65) 
Non response 6 (6) 9 (9) 0.53 (0.13) 
 19 (14) 21 (12)  
Rapid response = HCV RNA below the limit of detection (103 copies/ml), Non response = HCV RNA 
decline less then 1 Log, Partial response = Between Rapid response and Non response 
* Fisher’s exact test (2-sided) 
 
Fifteen patients, 6 treated with high-dose peginterferon and 9 with standard dose 
peginterferon (p=0.53) were “non-responders”; they showed a decline in HCV RNA 
less than 1 Log. All non-responders (n=15) were infected with genotype 1/4 (p=0.00).  
A partial response (between “rapid-” and “non response”) was seen in 4 patients of 
both groups (p=1.0) (table 5.2). Among the 8 partial responders, 6 were genotype 1/4 
infected (p=0.69).  
 
5.4.3 Quantitative HCV RNA kinetics 
The average decline in HCV RNA during the study period was 2.94 ± 0.38 Log (Mean 
± Std. Error of the mean). Both treatment groups showed an initial response between 
day 0-2 with a rapid decline in HCV RNA (first phase), followed by a distinct phase of 
HCV RNA increase between day 2 and 7 (rebound) where after the viral load 
decreased steadily (second phase) (figure 5.1). 
The initial response or first phase was more pronounced in the high-dose 
peginterferon group than in the standard dose peginterferon; at 2 days a mean 
reduction in HCV RNA of 2.01 ± 0.37 Log and 1.66 ± 0.33 Log was observed in the 
high-dose peginterferon group and standard dose peginterferon group respectively 
(p=0.23).  
Between day 2 and day 7, a period of HCV RNA increase or “rebound” could be 
observed. In the high-dose peginterferon group HCV RNA increased slightly: 0.36 ± 
0.27 Log. In the standard dose peginterferon group the increase in HCV RNA was 
more pronounced: 0.60 ± 0.27 Log (p=0.52). 
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Subsequently, HCV RNA declined steadily in both treatment groups. At the end of the 
first (t=7), second (t=14) and fourth (t=28) week a decrease in HCV RNA compared 
to baseline could be seen in both groups; 1.73 ± 0.42 Log vs. 1.06 ± 0.35 Log 
(p=0.12); 2.37 ± 0.51 Log vs. 2.05 ± 0.48 Log (p=0.67) and 3.10 ± 0.51 Log vs. 2.78 ± 
0.57 Log (p=0.65) in the high-dose peginterferon group and standard dose 
peginterferon group respectively. The average second phase slope between day 7 
and 28 were comparable; 0.46 ± 0.1 Log and 0.58 ± 0.1 Log decline per week for 
high-dose peginterferon and standard dose peginterferon.  
Within genotype 1/4 infected patients, high-dose peginterferon induced a stronger 
suppression of HCV RNA replication than standard dose peginterferon. At t=2 the 
decrease in HCV RNA was 1.64 ± 0.33 Log vs. 0.78 ± 0.21 Log (p=0.03) for high-
dose peginterferon vs. standard dose peginterferon and 1.36 ± 0.48 Log vs. 0.21 ± 
0.16 Log (p=0.02), 1.79 ± 0.54 Log vs. 0.82 ± 0.31 Log (p=0.25), 2.36 ± 0.57 Log vs. 
1.20 ± 0.55 Log (p=0.08) at t=7, 14 and 28 respectively (table 5.3). 
  
 
Tabel 5.3. HCV RNA decrease in Logs throughout the study period relative to treatment arm 
for genotype 1 and 4. 
 High dose therapy 
(3.0ug/kg) 
Standard therapy 
(1.5ug/kg) 
P# 
Baseline 0 0 1.00 
Day 2 1.64 ± 0.33 0.78 ± 0.21 0.03 
Day 7 1.36 ± 0.48 0.21 ± 0.16 0.02 
Day 14 1.79 ± 0.54 0.82 ± 0.31 0.25 
Day 28 2.36 ± 0.57 1.20 ± 0.55 0.08 
 
# Mann-Whitney U test (2-tailed) 
Chapter 5 
 78 
Figure 5.1. 
Viral load in log over time in days for the two 
study arms: High dose peginterferon therapy 
(3.0ug/kg body weight; straight line) and 
standard dosed peginterferon therapy (1.5ug/kg 
body weight; dashed line). Patients treated with 
high-dose peginterferon showed a stronger 
response at all time points. Significance could 
however not be reached because beneficial 
responses in patients infected with other 
genotypes then 1 or 4. 
 
5.4.4 Health related Quality of life 
HRQoL scores were comparable between the two treatment regimens at baseline 
and t=28 days, except for vitality (VT) which scored lower in the high-dose 
peginterferon group at baseline (p=0.05) and at t=28 days (p=0.03). Scores for 
general health (GH), physical functioning (PF), role physical (RP), role emotional 
(RE), and bodily pain (BP) decreased significantly during the study period (figure 
5.2). Mental health (MH), vitality (VT) and social functioning (SF) scores were 
unchanged. 
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 Figure 5.2.  
Change in health related quality between baseline and four weeks of treatment relative to treatment 
arm. General health (GH), physical functioning (PF), role physical (RP), role emotional (RE) and bodily 
pain (BP) were decreased considerably during the study period. Mental health (MH), vitality (VT), 
social functioning (SF), and scores were unchanged. Scores were comparable between the two 
treatment regimens except for vitality (p=0,05 at baseline and p=0,03 at t=28 days).  
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5.5 DISCUSSION 
 
With the introduction of peginterferon, SVR rates improved with roughly 10% over 
non-pegylated interferon (2, 3). As a consequence, there is interest for re-treating 
patients who did not achieve SVR with preceding non-pegylated interferon. However, 
expectations were tempered by reports revealing SVR estimates of only about 7-15% 
for standard dosed peginterferon (4, 5). We assessed whether high-dose 
peginterferon has beneficial effects in the early suppression of HCV RNA replication 
because of its high predictability for SVR (11, 12). 
The effect of high dosed therapy has been controversial since the beginning of 
interferon therapy. Most studies, with a short period of high dosed interferon have 
shown high initial virological response rates (13). However, without lasting beneficial 
effects on SVR rates (14, 15). The initial beneficial effects were lost to premature 
lowering the interferon dose (virological breakthrough) (9) or due to the short duration 
of treatment of only 24-26 weeks  leading to an end of treatment relapse (13). 
Indeed, we found that with 4 weeks of daily high dosed interferon therapy, HCV RNA 
had become undetectable in 80% of “difficult-to-treat” patients eventually leading to a 
SVR of 65% (6). Results that were confirmed by a randomized controlled trial in 373 
patients showing beneficial effects of high dosed interferon when continued for a 
longer period in genotype 1 patients (16).  
Our study is the first with high-dose peginterferon therapy in interferon non-
responders revealing that in most previous non-responders a peginterferon response 
can be obtained (25/40; 63%). High-dosed peginterferon showed an averaged 
beneficial effect over standard dosed peginterferon of 10%; 13 out of 19 high-dosed 
peginterferon treated patients vs. 12/21 standard dose treated patients responded 
(68% vs. 57%, difference 9%) of whom 9/19 vs. 8/21 were even able to reach HCV 
RNA negativity within the treatment period (rapid responders; 47% vs. 38%, 
difference 11%). Especially genotype 1/4 patients had benefit from high-dosed 
peginterferon.  A stronger suppression of HCV RNA replication could be measured at 
all time points.  
By responding to therapy, most high-dose treated patients (13/19; 68%) obtained a 
fair chance to achieve an end-of-therapy sustained response. After all, non-response 
is the most common reason for failure of clearing the virus and even with a high 
breakthrough or end-of-treatment relapse rate, the SVR will be considerably higher 
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than the SVR rates of 7-15% reported for standard therapy by other groups (4, 5). 
Due to the constant anti viral pressure of peginterferon ribavirin therapy virological 
breakthrough has become a rarity and even if the end of treatment relapse will be as 
high as 10%, the end of follow-up results of this study will still be above 50%.  We are 
the first to report such favorable results and we think the results indicate than in a 
selected subset of patients, who non-responded to prior therapy, high dosed 
peginterferon therapy should be considered.  
High-dosed peginterferon was expected to be associated with an impaired quality of 
life. Indeed, quality of life, measured at baseline and during treatment, considerably 
decreased following treatment. A dose dependant effect could however not be 
observed. 
In conclusion, the results of our study show that in the majority of patients who 
previously failed to achieve a sustained response, an initial response could be 
obtained when retreated with Peginterferon-ribavirin therapy. High-dosed 
peginterferon is more beneficial than standard dosed peginterferon with an average 
extended effect of 10%. Especially genotype 1 infected patients might benefit from 
high-dose peginterferon. Ten percent beneficial effect can be compared to effect of 
pegylating interferon. Therefore we believe that, since due to the small sample size of 
this study significance could not be reached, a prospective randomized study with an 
estimated sample size of 300-350 patients, needs to be conducted.  
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The role of T-cells in hepatitis C virus infection 
 
The components of the antiviral immune response are schematically displayed for 
hepatitis C infection in figure 1. T-helper cells (Th) play a central role in the 
coordination of the anti-viral immune response. Naïve Th are not activated by 
infected tissue cells, but only by professional Antigen-Presenting Cells (APC), i.e. 
macrophages and dendritic cells. The APC recognize the virus by specific Pattern 
Recognition Receptors (PRR), endocytose it, and process the viral proteins to 
peptides which are displayed on their MHC class II molecules. Upon recognition of 
the viral peptides by their T cell receptor (TCR), the naïve Th are stimulated to 
differentiate to effector Th. Depending on the virus Pathogen Associated Molecular 
Pattern (PAMP) as recognized by PRR, the APC produce either interleukin 10 (IL-10) 
or IL-12. IL-10 and IL-12 stimulate the differentiation of naïve CD4+ Th to effector 
helper type 2 T-cells (Th2) or effector helper type 1 T-cells (Th1), respectively.  This 
interaction between APC and Th takes place in secondary lymphoid organs, like 
lymph nodes and spleen. 
CD4+ Th2 effector-cells produce IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 that stimulate 
B-cells (humoral response) and down-regulate the Th1 response. B-cells need 
stimulatory signals from Th2 cells for differentiation into antibody-producing cells. The 
antibody response serves to opsonize circulating virus particles for elimination by 
macrophages, neutralization of viral proteins and prevention of virus entry into host 
cells. 
CD4+ Th1 effector-cells secrete IL-2, interferon-gamma (IFN-γ) and tumor necrosis 
factor-alpha (TNF-α) which stimulate CD8+ cytotoxic T-cells and macrophages. 
Subsequently, the CD8+ cytotoxic T-cells migrate through the blood stream to the 
infected organ. Parenchymal cells (such as liver cells) infected with a virus can be 
recognized  by CD8+ cytotoxic T-cells upon recognition of viral peptides presented on 
MHC class I molecules by their TCR CD8 complex (cellular response). For this 
purpose, infected cells cleave viral proteins proteolytically, and insert the resulting 
peptides in the groove of MHC class I molecules. Upon recognition, the cytotoxic T-
cells either lyse the infected cells, or inhibit the viral replication within these cells by 
local secretion of antiviral cytokines like TNF-α.  
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Figure 1. Components of the antiviral immune response. 
APC = Antigen Presenting Cell, DC = dendritic cell, MØ = macrophage, CD8+ CTL=cytotoxic T cell; 
CD4+ Th cell = T helper cell; Th1 = helper T cells with a type 1 cytokine profile; Th2 = helper T cells 
with a type 2 cytokine profile; IL = interleukin; IFN = interferon, TNF = tumor necrosis factor; MHC = 
major histocompatibility complex; TCR = T cell receptor. 
 
HCV infection elicits an active humoral as well as a cellular immune response. It is 
however, not precisely understood which role the immune system plays and why 
approximately 85% of infected persons who are otherwise considered 
immunocompetent is unable to clear the virus. 
Most studies have concentrated on the virus-specific  CD4+  Th and CD8+ cytotoxic 
T-cells in peripheral blood (1). Studies with chimpanzees, who successfully had 
recovered from acute hepatitis C, demonstrated an early and strong cytotoxic T-cell 
response against multiple HCV epitopes in blood. In contrast, chimpanzees that 
develop a chronic HCV infection showed a weak peripheral cytotoxic T-cell response 
in the early stages of the disease in peripheral blood (2). The same has been seen in 
humans who clear HCV during acute infection and in those who develop chronic 
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infection, and a relation between IFN-therapy induced control of hepatitis C viremia 
and HCV-specific T-cells responses in blood has been suggested (3, 4). 
However, within the liver, HCV-specific CD8+ cytotoxic T-cells have  been detected 
during chronic HCV infection (4, 5), in a significantly higher frequency than in 
peripheral blood (6, 7); suggesting a specific compartmentalization at the site of 
infection. It is thought that in the infected liver, there is a balance between viral 
replication and the host immune response. This balance may be of importance for the 
outcome of anti-viral treatment. We therefore quantified diverse subsets of 
intrahepatic immune cells (CD4+, CD8+ and CD68+ cells) by immunohistochemistry in 
pre- and end of treatment liver biopsies and established their association to therapy 
response for chronic HCV-infection. For comparison also peripheral immune 
parameters such as plasma interleukin (IL)-10, IL-12, IFN-γ levels and circulating 
HCV-specific T cells were determined (chapter 7). Because of the patient discomfort 
accompanying the liver biopsy procedure we also explored the feasibility of a less 
invasive and traumatic fine-needle aspiration biopsy technique (FNAB) as a tool for 
monitoring the cellular immune status in the liver during chronic HCV-infection 
(chapter 8). 
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6.1  ABSTRACT 
 
Interferon-ribavirin therapy is successful in only half of the chronically infected 
hepatitis C patients. We analyzed the relationship between virological response and 
baseline immune factors in 17 chronically infected patients who completed 26 weeks 
of interferon-ribavirin therapy. Numbers of intrahepatic CD8+ cells located in the 
portal tracts of pre-treatment liver biopsies were found to be significantly higher in 
patients responding to therapy than in non-responders  (p=0.002). The relation 
between portal CD8+ cells and chance of response could be described by a logistic 
curve (univariate logistic regression analysis); its prognostic value was superior to 
that derived from genotype and other baseline factors (multivariate analysis). In 
contrast, neither peripheral cytokine levels nor HCV specific T cell reactivity in 
peripheral blood mononuclear cells did show a relationship to therapy response. 
These findings suggest that significant prognostic immune markers are to be found in 
the liver. 
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6.2  INTRODUCTION 
 
The potency of interferon (IFN) to inhibit hepatitis C virus (HCV) replication and to 
stimulate the clearance of infected cells is the basis of current standard antiviral 
therapy using IFN-α and ribavirin. The majority of patients show an initial response 
with loss of circulating HCV-RNA. Unfortunately, complete viral clearance is not 
observed in all patients (8, 9). Although the mechanism responsible for the 
eradication of HCV-infected hepatocytes is not well understood, there is consensus 
that this process is immune-mediated. Revealing mechanistic studies have been 
hampered by the lack of representative laboratory models and by difficulty of studying 
the intrahepatic compartment.  
In peripheral blood, HCV specific T lymphocytes are easily detected during acute 
HCV infection, mostly exhibiting a broad reactivity towards different HCV antigens (2, 
10). In chronic hepatitis HCV-specific T cell frequencies are low (11), and response to 
subsequent IFN-α therapy is difficult to predict on the basis of this parameter. Higher 
frequencies of HCV-specific T cells may be found in the liver (6, 7). Accordingly, liver 
biopsies may prove to be instrumental to study immune factors associated with 
response to subsequent IFN-α therapy. Not only the frequency of virus specific 
intrahepatic T cells (5, 12) but also absolute numbers of these cells present in the 
liver can possibly mirror the ability of the immune system to generate a sufficient anti-
viral response after start of antiviral therapy. We therefore examined localization of 
diverse subsets of intrahepatic immune cells by quantitative immunohistochemistry 
(CD4+, CD8+ and CD68+ cells) in pre- and end of treatment liver biopsies and 
causality to response to therapy for chronic HCV-infection. For comparison also 
peripheral immune parameters such as plasma interleukin (IL)-10, IL-12, IFN-γ levels 
and circulating HCV-specific T cells were determined. 
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6.3  PATIENTS, MATERIALS AND METHODS 
 
Seventeen patients with chronic HCV infection who were assigned to 26 weeks of 
therapy combining IFN-α2b 3MU thrice a week with ribavirin 1000-1200mg/d 
(Schering-Plough, Kenilworth, USA) in our center and from whom a pretreatment 
biopsy was available were subject of the current study. 
All were treatment naive patients, HCV-RNA positive, had biopsy proven chronic 
HCV infection, and were seronegative for HBV and HIV. None had clinical or 
biochemical evidence of other liver diseases. Blood samples for HCV-RNA 
quantification were taken at 0, 4, 12 and 26 weeks of therapy. Response to treatment 
was defined as HCV-RNA levels below 100 copies/ml at the end of therapy, 
determined using the Superquanttm assay (National Genetics Institute, USA; 
detection limit 100 copies/ml).  
Before and in the last week of treatment, biopsies were obtained percutaneously with 
a 14 Gauge tru-cut needle. Immunohistochemistry was performed on formalin-fixed 
paraffin-embedded liver biopsy sections. After an over-night incubation at 37 oC, 4 µm 
thick sections were dewaxed in xylene and rehydrated in graded alcohols. Epitope 
retrieval was achieved by temperature-controlled incubation for 20 minutes at 98oC in 
citrate-buffer (pH 6.0). The primary antibodies against CD8 (clone cd8/144B, DAKO), 
CD68 (clone PG-M1, DAKO) and CD4 (clone NCL-CD4-1F6, NovaCastra) were 
applied and visualised as described previously (13). 
The number of cells staining positive within the portal tract and lobular area was 
determined by counting the number of positive cells per equivalent microscopic field 
at a magnification of 400x using a Zeiss light microscope. In every slide, 10 fields for 
the lobular region and 3 equivalent fields for the portal tracts were examined and the 
mean count of these fields was expressed as cell number per microscopic field. The 
cell counting was performed on slides blinded by codes, by two investigators in an 
independent fashion (inter observer correlation was 0.996). HCV-hepatitis activity, 
interface hepatitis, intralobular degeneration, fibrosis and the number of apoptotic 
bodies were histologically assessed and graded routinely in all specimens according 
to the Knodell classification by an experienced liver pathologist blinded to the clinical 
status of the patient.  
Peripheral blood mononuclear cells (PBMC), obtained at start of the therapy, were 
isolated from heparinized blood by density gradient centrifugation after which cells 
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were frozen in liquid nitrogen. After thawing, PBMC were cultured in 96-well microtiter 
plates (NUNC, Breda, The Netherlands) using 6 replicates for each condition with 2 x 
105 cells/well. Cells were cultured in RPMI 1640, supplemented with 10 % heat 
inactivated human serum at 37 oC with 5% CO2 and 100% humidity for 6 days in the 
presence or absence of HCV proteins at a concentration of 3 µg/ml. Recombinant 
HCV proteins used included HCV core (amino acid [aa] 2-120), and NS3-NS4 (aa 
1192-1931), which were kindly provided by dr. M. Houghton (Chiron, Emeryville, 
USA). All antigens were expressed as COOH-terminal fusion proteins with human 
superoxide dismutase (SOD) in yeast. Controls included phytohemagglutinin-L, 
inactivated influenza virus (Duphar, Weesp, The Netherlands) and SOD. After 6 days 
cultures were labeled by incubation for 16 h with 1µCi 3H-thymidine (Amersham, 
Breda, The Netherlands). Cells were harvested and radioactive incorporation was 
estimated using a beta counter (Wallac, Helsinki, Finland). Results were expressed 
as mean counts per minute (cpm). The stimulation index was calculated as the ratio 
between cpm obtained in the presence of antigen and that obtained without antigen; 
a stimulation index >3 was considered significant. 
Plasma obtained from EDTA blood, taken before the start of treatment, was stored at 
–70o C. Plasma cytokine concentrations were measured using commercially available 
ELISAs for IFN-γ, IL-10 and IL-12-p40 (CLB, Amsterdam, The Netherlands). 
Data were analyzed using SPSS for Windows (Version 10.1, Chicago, USA). Mann-
Whitney non-parametric rank sum tests and Pearson correlation analyses were 
applied. Logistic-regression models with backward selection procedures were used to 
explore baseline factors (viral load, genotype, sex, lobular and portal CD8+ cell 
number) predicting response. P-values of <0.05 were considered statistically 
significant.  
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6.4 RESULTS 
 
Baseline patient characteristics as well as outcome and immunohistochemistry 
results are presented in table 1. The median duration of infection was 14.5 years 
(range 5 to 30 years); in three patients the duration of infection could not be 
estimated. Median baseline viral load was 9.0 x 105 copies/ml (range 8.0 x 104 to 3.5 
x 107, mean 5.3 x 106 copies/ml); eleven patients were infected with genotype 1a/b.  
All patients completed 26 weeks of IFN-ribavirin therapy. Nine patients responded by 
the end of therapy (HCV-RNA < 100 copies/ml), whereas in eight HCV-RNA 
remained detectable during the entire treatment period. No significant differences 
were observed with respect to pretreatment viral load or genotype between 
responders and non-responders. The average rate of viral load decline within the first 
4 treatment weeks was 2.32 log; 1.45 log in non-responders compared to 3.32 log in 
responders (p=0.015). The rate of decline in viral load was not different between 
genotypes 1 and non-1. In four patients, the quantitative PCR assay for HCV-RNA 
was negative after a 24 week treatment-free follow-up period. 
No significant difference was observed between responders and non-responders in 
baseline ALT levels (p=0.321). HCV specific lymphoproliferative responses were 
detected in 6/17 patients. However, baseline HCV specific lymphocyte proliferation 
did not differ significantly between responders and non-responders (table 1). 
Additionally, other pre-treatment peripheral markers of immune activity like numbers 
of circulating CD8+ T-cells ( p=0.535), plasma IL-12-p40 (p=0.336), IL-10 (p=0.321) 
and IFN-γ (p=0.236) levels did not differ significantly. 
Liver biopsies were evaluated histologically by determination of the Knodell score 
and the presence of CD4+, CD8+ and CD68+ cells. Knodell scores were similar in 
responders and non-responders (table 1). CD8+ and CD68+ cells were present both 
in the portal tract and intralobular, but CD4+ cells were observed less frequently; 
mostly in the portal tracts. Numbers of CD68+ or CD4+ cells did not differ significantly 
between responders and non-responders. Numbers of lobular CD8+ cells in pre-
treatment liver biopsies were similar in both groups (p=0.815), but the numbers of 
CD8+ cells within the portal tracts were higher in responders compared to 
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non-responders (p=0.002) (figure 1a). Based on univariate logistic regression 
modeling a scatterplot displaying the predicted probability of response to following 
therapy as a function of the number of CD8+ cells in the portal tract in biopsies taken 
before treatment could be made (figure 1b). The number of pre-treatment CD8+ cells 
in the portal tract alone predicted response better than viral or patient characteristics 
(multivariate logistic regression analysis including sex, age, genotype, stage of 
fibrosis and viral load). Numbers of intrahepatic CD8+ cells were not significantly 
different in responders and non-responders in end of treatment biopsies (figure 1a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A)         (B) 
 
 
Figure 1. Numbers of intrahepatic CD8+ cells in the portal tract of liver biopsies in relation to 
interferon response. (A) Boxplots of intrahepatic CD8+ cells in the portal tract of pre-treatment (open 
boxes) and end of treatment (closed boxes) biopsies in relation to interferon response. The CD8+ cell 
count in pre-treatment portal tracts is significantly higher in responders than in non-responders 
(p=0.002*). The upper and lower limits of the boxes and the middle line across the boxes indicate the 
75th and 25th percentiles and the median (the 50th percentile), respectively. The length of the box is 
thus the interquartile range; the box represents 50% of the data. The upper and lower horizontal bars 
indicate the 90th and 10th percentiles, respectively. Comparison of end-of-treatment non-response 
and response data was performed by Mann-Whitney non-parametric rank sum tests. (B) The predicted 
probability of response to following therapy displayed as a function of the number of CD8+ cells in the 
portal tract in biopsies taken before treatment. The curve is based on univariate logistic regression 
modeling (log likelihood: p<0.001; score test 0.002).  
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6.5  DISCUSSION 
 
Intrahepatic localization of HCV specific T cells may be crucial to control acute 
hepatitis C (2, 10), but also augment inhibition of viral replication and clearance of 
infected hepatocytes when chronic hepatitis C patients are treated with IFN-α and 
ribavirin (3, 4). In this report we demonstrate that, when analyzed by quantitative 
immunohistochemistry, the number of intrahepatic CD8+ cells present in the portal 
tract before the start of IFN-ribavirin therapy is significantly higher in patients 
responding to treatment. Based on univariate logistic regression modeling an S-
shaped logistic curve displays the predicted probability of response to following 
therapy as a function of the number of portal CD8+ cells in biopsies taken before 
treatment. The number of CD8+ cells in the portal tract alone predicts response better 
than viral characteristics or patient features. From our immunohistochemical analysis 
we did not observe any correlation of other subsets analyzed (CD4+ and CD68+ cells) 
with response to antiviral treatment.  
The patients described in this study were assigned to an experimental treatment 
schedule of 26 weeks of therapy combining Interferon-α2b 3MU thrice a week with 
ribavirin 1000-1200mg/d. Only 4 out of 17 patients were sustained responders, 
making the analysis with respect to the end of follow up status difficult. The results 
suggest that the number of pre-treatment intrahepatic CD8+ cells in the portal tract is 
a significant and independent predictor for the impairment of viral replication leading 
to undetectable HCV RNA levels at the end of treatment. However, in the end of 
treatment biopsies portal CD8+ cell numbers were comparable in responders and 
non-responders (figure 1a). Reduced intrahepatic CD8+ cell numbers in responders 
at the end of therapy might relate to the high relapse rate observed (5 out of 9 
patients showed a virological relapse). 
IFN-α most likely has a pronounced direct antiviral activity in patients with HCV. The 
first dose dependent phase of the HCV decay curve which lasts approximately 24 
hours, can be explained assuming IFN-mediated direct antiviral activity (14). The 
slower subsequent second phase is thought to be partly immune-mediated. Indeed 
we observed a significant correlation between pre-treatment CD8+ cell numbers and 
the decay of viral titers during the first month of therapy (r=0.514, p=0.05). Both 
innate and virus specific immune responses may further amplify HCV clearance 
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during antiviral therapy either because of their presence already at the start of 
therapy or by IFN-ribavirin mediated activation. Several reports have demonstrated 
the appearance of HCV-specific T cell activity after treatment with IFN-α (3, 4, 15), 
even when baseline HCV-specific T cell reactivity was undetectable (11). We could 
not differentiate responders based on LST responses measured at start of therapy. 
Rather, actual numbers of infiltrating CD8+ cells may have to be taken into account. 
Our observations are consistent with a study by Nelson et. al., who demonstrated 
that the presence of HCV specific cytotoxic T cells in the liver was associated with 
biochemical response to IFN-α (5). CD8+ cells could be directly involved in the 
clearance of HCV from the liver during antiviral treatment through production of 
antiviral cytokines or killing of infected hepatocytes. Alternatively CD8+ cell number 
may correlate with other antiviral mechanisms implicated in the clearance of HCV 
during therapy.  
The portal localization of CD8+ cells is of interest. As demonstrated in HBV infection, 
patients with high viral load were characterized by the presence of high numbers of 
CD8+ cells located in the portal tracts, whereas relatively more CD8+ cells were found 
intralobular in patients controlling HBV (12). Possibly, high numbers of CD8+ cells in 
the portal tract may benefit patients at later stages during therapy when viral load is 
diminished and the migration of CD8+ cells into the lobular area may have been 
facilitated. Future studies need to further analyze frequency and localization of HCV 
specific CD8+ cells in the liver. 
In conclusion, the pretreatment number of CD8+ lymphocytes in the liver, but not in 
peripheral blood is higher in patients who will respond to IFN-ribavirin therapy than in 
patients who don’t. We suggest that immunohistological evaluation of biopsies may 
be considered with respect to factors reflecting a patient’s immune system capacity to 
respond adequately to therapy. Moreover, these findings suggest that significant 
prognostic immune markers are to be found in the liver, and should encourage further 
study of hepatic immune cells as important predictive factors. 
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 7.1 ABSTRACT 
 
Infection of the liver with hepatitis C virus causes compartmentalization of CD8+ 
cytotoxic T-cells to the site of disease. These cells are thought to be involved in viral 
clearance during interferon therapy. The repetitive analysis of the intrahepatic immune 
response is hampered by the difficulty to obtain the intrahepatic T-cells. The fine 
needle aspiration biopsy (FNAB) technique was evaluated for its use to obtain liver-
derived CD8+ T-cells in a minimally invasive way. In 26 chronic HCV-patients who were 
evaluated for Peg-interferon and ribavirin combination therapy, pre-treatment FNABs 
and peripheral blood specimens were obtained simultaneously with liver tissue 
biopsies, and CD3+ and CD8+ T-cells were quantified by immunocytochemistry. The 
CD8+/CD3+ ratio was significantly higher in the FNABs than in peripheral blood 
(p<0.01), and similar to those in portal areas in the tissue biopsies. A significant 
correlation was observed between numbers of CD3+CD8+ T-lymphocytes in the FNABs 
and the numbers of CD8+ cells in the lobular fields or in the portal tracts of the liver 
tissue biopsies, but not with CD3+CD8+ T-lymphocytes in peripheral blood. Finally, the 
ratio of CD8+/CD3+ T-lymphocytes in FNABs was significantly higher in those patients 
who responded rapidly to therapy as compared to slow responders at 4 weeks of 
treatment (p=0.02). These findings demonstrate that the intrahepatic T-cell composition 
is reflected in FNABs, and that the FNAB-technique can be used for predicting early 
virological response to therapy of patients chronically infected with HCV. 
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7.2  INTRODUCTION 
 
In chronic hepatitis C infection, virus-specific T-cells are predominantly found in the 
liver and are almost absent in peripheral blood (1, 2). Intrahepatic localization of 
CD8+ hepatitis C virus (HCV) specific cytotoxic T-cells is thought to be crucial to 
control acute hepatitis C infection (3), and also augment inhibition of viral replication 
and clearance of infected hepatocytes when chronic hepatitis C patients are treated 
with interferon-α and ribavirin (4-6). Both total as well as virus-specific intrahepatic 
CD8+ T-cell numbers in pretreatment liver tissue biopsies as determined by 
respectively quantitative immunohistochemistry (7) or tested in vitro against target 
cells (4) are associated with virological response to interferon-α therapy. To study 
intrahepatic T-cell kinetics during acute or therapy of chronic infection, the cellular 
immune status in the liver should be monitored on a repetitive basis. The liver tissue 
biopsy technique is the golden standard for obtaining liver tissue. Unfortunately, the 
biopsy procedure is accompanied with considerable patient discomfort. Therefore we 
investigated the feasibility of a less invasive and traumatic fine-needle aspiration 
biopsy (FNAB) technique as a tool for monitoring the cellular immune status in the 
liver during chronic HCV-infection. Since the early eighties, the FNAB has been used 
for monitoring rejection activity after liver transplantation (8, 9). The FNAB is 
performed with a 25 Gauge needle (diameter 0.5mm) and therefore hardly traumatic. 
Our aim was to investigate whether intrahepatic T-cells as determined by quantitative 
immunohistochemistry (CD3+ and CD8+ cells) in liver tissue biopsies are reflected in 
FNABs, and whether intrahepatic T-cells assessed by FNAB could be used to predict 
response to interferon-α therapy. 
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7.3  METHODS 
 
7.3.1 Patients  
The study group consisted of patients from a single hospital, who were screened for 
participation in a multicenter clinical study in which the efficacy of treatment with Peg-
interferon-α2a 180mcg per week (Pegasys, Roche, Basel, Switzerland) in 
combination with 1000-1200mg ribavirin (Copegus, Roche) was evaluated. A liver 
biopsy was part of the evaluation. Standard inclusion and exclusion criteria were 
used. In brief, all patients were interferon-naive, anti-HCV antibody positive and had 
detectable HCV RNA by PCR and elevated serum alanine aminotransferase levels 
(>30 U/l) for at least 6 months on at least two occasions. Patients with 
decompensated liver disease, co-infection with hepatitis B or human 
immunodeficiency virus, alcohol abuse or any other relevant comborbidity were 
excluded. Within two months after the liver biopsy, treatment was started when 
indicated according to the current treatment consensus (10). The study was in 
accordance with the Helsinki Declaration of 1975 and approved by the in-house 
medical-ethical committee. All patients gave written informed consent for 
participation. 
 
7.3.2 Fine-needle aspiration and liver tissue biopsies  
Pre-treatment two FNABs were obtained. The full details of this procedure are 
described elsewhere (11, 12). Briefly, a mandarin containing 25-gauge needle 
(diameter 0.5 mm) is punctured in the 8th or 9th right intercostal space. After removal 
of the mandarin, liver cells are aspirated by negative pressure into a syringe filled 
with culture medium. Blood was collected in 4 mL EDTA plasma tubes (Vacutainer 
Systems, Plymouth, England). FNABs and blood cells were centrifuged on to glass 
slides using a cytocentrifuge. One cytospin preparation of each specimen was 
stained according to the May-Grünwald-Giemsa procedure. FNABs were considered 
to be representative if the aspirate contained at least seven hepatocytes per 100 
leukocytes. If both FNABs were representative, the specimen with the highest 
hepatocyte/leukocyte ratio was used in the study. 
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Directly after the FNAB procedure, a liver tissue biopsy was obtained percutaneously 
with a 14 Gauge Tru-cut needle. The liver specimen was fixed in phosphate-buffered 
formalin and embedded in paraffin.  
 
7.3.3 Immunocytochemistry fine-needle aspiration biopsies 
CD3+ and CD8+ cells present on cytospin slides were visualized by an 
immunocytological double stain technique. The slides were fixed in 4% 
paraformaldehyde in phosphate-buffered saline pH 7.3. Subsequently, endogenous 
peroxidase was blocked by incubation with citric acid buffer pH 5.8 supplemented 
with 0.03% hydrogen peroxide containing 0.2% (w/v) sodium azide for 15 seconds. 
To reduce aspecific antibody binding, slides were incubated with TBS supplemented 
with 10% normal rabbit serum (Life Technologies, Inc, Gaithersburg, USA) and 10% 
normal human plasma (CLB). Subsequentially, the slides were incubated overnight 
at 4°C with CD8 mAb (clone C8/144B, DAKO, Glostrup, Denmark). Detection of 
primary antibody was performed with rabbit-anti-mouse immunoglobulins (RAM, 
DAKO) for one hour followed by alkaline-phosphatase-anti-alkaline phosphatase 
complex (APAAP, Serotec, Oxford, UK).  
At the end of day 2, the slides were incubated overnight with the second primary 
mAb CD3-FITC (clone UCHT1, Immunotech, Marseille, France) at 4°C. At day 3, one 
hour incubation of rabbit-anti FITC-HRP (DAKO) was used to detect CD3. 
Visualization was performed by incubation of the slides firstly in Fast Blue salt / 
naphtol AS-BI followed by 3-amino-9-ethylcarbazole (AEC). Slides were 
counterstained with methylgreen 1% for 10 seconds and mounted in glycerol. 
Negative controls were either performed by replacement of the primary mAb by an 
isotype matched control mAb or by leaving out the primary antibody.  
 
7.3.4 Immunohistochemistry liver tissue biopsies  
The distribution of CD3+ and CD8+ cells in the liver was visualized in consecutive 
sections of formalin-fixed, paraffin-embedded liver specimens. The liver sections 
were firstly deparaffinized with xylene (Lab Scan Ltd, Dublin, Ireland) and ethanol 
(Merck, Darmstadt, Germany). Thereafter antigen retrieval was performed by a 15 
minutes incubation at 99°C in citrate buffer (pH 6.0) under intermittent microwave 
exposure. Overnight, the paraffin slides were incubated with CD3mAb (clone 
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F7.2.38, DAKO) and CD8mAb (clone C8/14415, DAKO) at 4°C. Slides were washed 
with Tris-buffered saline (TBS) pH 7.3 supplemented with 0.1% Tween-20. CD3 
expression was demonstrated by a goat anti-mouse Ig conjugated to a peroxidase 
labeled polymer (En Vision HRP system, DAKO) and CD8 antigen was detected with 
the RAM-APAAP procedure. Histochemical revelation was performed by incubation 
with diaminobenzidine (DAB) or Fast Blue salt / naphtol AS-BI phosphate. Negative 
controls were performed by replacement of the primary mAb by an isotype-matched 
control mAb. Slides were counterstained in case of DAB staining with Mayer's 
solution (Merck) or in case of Fast Blue staining with nuclear Fast Red (Fluka 
Chemie, Buchs, Switserland). 
 
7.3.5 Quantification of Immunohisto- and Immunocytochemistry positive cells 
Two investigators independently examined and counted CD3+ and CD8+ cells in all 
consecutive liver tissue biopsy slides, and CD3+CD8+ and CD3+CD8- cells in FNAB 
and peripheral blood cytospin preparations microscopically at a magnification of 
400x. FNAB cytospin preparations and tissue biopsy sections were examined 
independently and in separate sessions. The investigators were blinded to the 
virological and clinical biochemical conditions of the patients. In every paraffin biopsy 
slide 8 microscopic fields within the liver lobuli were randomly selected to count CD3+ 
or CD8+ T-lymphocytes. In addition at least 3 portal tracts were counted. 
Since the numbers of leukocytes on individual cytospin preparations may vary, the 
numbers of positive cells counted were normalized to the number of leukocytes. For 
that purpose, in every FNAB cytospin preparation, 6 microscopic fields were 
randomly selected to count the number of leukocytes. The count was multiplied with 
104 (total number of high power fields in a cytopsin slide) to obtain the total number 
of leukocytes per cytospin slide. For analysis, the numbers of positive cells were 
expressed per 1000 leukocytes.  
 
7.3.6 Virological assessments 
A quantitative HCV RNA assay was performed to assess viremia (Cobas Amplicor 
HCV test, Roche Diagnostics, Almere, The Netherlands) within one week before or 
after the liver biopsy. In addition these tests were performed at the start of treatment 
and at 4 and 12 weeks during treatment. 
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7.3.7 Statistical analysis 
Data are expressed as mean ± standard deviation, unless otherwise indicated. 
Pearson’s correlation coefficients (r) were used to investigate the correlation between 
liver, peripheral blood and FNAB cell counts. Mann-Whitney tests were performed to 
investigate differences in CD3+/CD8+ ratios between FNAB, peripheral blood and 
liver tissue biopsies, and between treatment response groups. P-values (p) of < 0.05 
(two sided) were considered to be statistically significant. 
 
7.4  RESULTS 
7.4.1 Patients 
Twenty-six patients with chronic hepatitis C who underwent a FNAB and a liver tissue 
biopsy in the evaluation for the necessity of antiviral treatment were included in this 
study. According to the most recent treatment consensus (10) therapy was indicated 
and sequentially started in 23 patients. There was no indication for treatment in 2 
patients, 1 patient was lost prior to therapy for further follow-up. 
 
7.4.2 Relation between T-cells in liver FNAB, liver tissue biopsy and peripheral 
blood 
CD8+ and CD3+ T-cells were immunocytochemically detected in FNABs, liver tissue 
biopsies, and peripheral blood specimens (Figure 1). In peripheral blood, about forty 
percent of the CD3+ T-cells were cytotoxic T-cells bearing the CD8 marker. In 
contrast in the liver, both in the portal tracts as well as intralobular, the CD8+/CD3+ 
ratio's were significantly higher (both p<0.01; figure 2). 
FNABs are cytological aspirates and will therefore contain liver-derived as well as 
blood-derived leukocytes. To investigate whether the leukocytes in FNABs reflect 
intrahepatic inflammatory cells, we first compared the CD8+/CD3+ ratios found in 
FNAB, liver tissue biopsies, and blood. The CD8+/CD3+ ratio in the FNAB was 
significantly higher than that in peripheral blood (p<0.01), significantly lower than that 
in the lobular fields (p<0.01), but not different from that in portal tracts of the liver 
tissue biopsies (p=0.46), indicating that T-lymphocytes in FNAB originate primarily 
from the liver (Figure 2). The difference in CD8+/CD3+ between lobular fields and 
FNAB may be due to the fact that in the liver the majority of both the CD8+ and CD3+ 
cells were present in the portal tracts (Figure 1).
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Figure 1. 
a)       b) 
 
  e)      f)
c)       d) 
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Next, we investigated whether variations in numbers of CD8+ T-lymphocytes in the 
liver were reflected in the FNAB. Significant correlations between the numbers of 
CD8+ cells in the lobular fields (r=0.52, p=0.02; figure 3a) or in the portal tracts 
(r=0.58, p=0.01; figure 3b) with the numbers of CD8+CD3+ T-lymphocytes in the 
FNAB (expressed as number per thousand leukocytes) were found. CD3+CD8+ T-
lymphocytes in the FNAB did not correlate with CD3+CD8+ T-lymphocytes from 
peripheral blood (r=0.37, p=0.11; figure 3c).  
The numbers of CD3+ T-lymphocytes in the FNAB were also correlated with CD3+ T-
cells in the portal tracts (r=0.47, p=0.04), but in addition these were weakly 
associated with those in lobular fields (r=0.40, p=0.08) and peripheral blood (r=0.38, 
p=0.06), indicating that CD3+ T-lymphocytes in FNAB originate both from liver and 
blood. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The median CD8+/CD3+ ratio in peripheral blood, FNABs, portal tract and lobular fields. 
The upper and lower limits of the boxes and the middle line across the boxes indicate the 75th and 
25th percentiles and the median (the 50th percentile), respectively. The length of the box is thus the 
interquartile range; the box represents 50% of the data. The upper and lower horizontal bars indicate 
the 90th and 10th percentiles, respectively. 
 
Legend to Figure 1 (opposite page). Immunohistochemical CD8 (A) and CD3 (B) stainings 
of lobular fields and CD8 (C) and CD3 (D) stainings of portal tracts in consecutive slides of a formalin-
fixed and paraffin-embedded liver tissue biopsy. Fine-needle aspiration biopsy cytospin preparations 
stained with May-Grunwald-Giemsa solution (E), or immunocytochemically for CD3 (red) and CD8 
(blue) (F).  
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Figure 3. Variations in numbers of CD8+ T-lymphocytes in the liver tissue biopsies were reflected in 
the FNAB. 
CD8+ cells peripheral blood
70605040302010
C
D
3+
 C
D
8+
 c
el
ls
 F
N
A
B
s
120
100
80
60
40
20
0
CD8+ cells portal tracts
100806040200
C
D
3+
 C
D
8+
 c
el
ls
 F
N
A
B
s
120
100
80
60
40
20
0
R=0.58; p=0.01*
R=0.37; p=0.11
R=0.52; p=0.02*
CD8+ cells lobular fields
50403020100
C
D
3+
 C
D
8+
 c
el
ls
 F
N
A
B
120
100
80
60
40
20
0
, .
CD8+ cells in FNAB 
  119
 
7.4.2 T-cells in pretreatment FNAB in relation to response  
T-cell parameters in FNAB, liver tissue biopsy and peripheral blood as well as 
treatment data such as HCV RNA levels at baseline and at 4 and 12 weeks of 
treatment and were available in 20 out of 23 treated patients. In order to investigate 
differences between treatment response groups we divided the patients on treatment 
into two groups according to the decline in HCV RNA at 4 and 12 weeks of therapy. 
The average decline in HCV RNA within the first month of treatment was 2.7-log 
(range: 0.45-5.27). Patients who had a serum HCV RNA decline of less than 2.7-log 
within this period were considered “slow responders” (n=7) and those with a decline 
of more than 2.7-log as “rapid responders” (n=13). The relative numbers of CD8+ T-
cells were not associated to response (p=0.94), but the ratio of CD8+/CD3+ T-
lymphocytes in FNABs was significantly higher in responders than in non-responders 
(p=0.02; figure 4a). At 12 weeks of therapy 4 patients did not have at least a 2-log 
drop of HCV RNA. All 4 were “slow responders” at week 4. In these patients the 
CD8+/CD3+ T-lymphocytes ratio in FNABs was lower compared to the group with 
more then 2-log decline, although with borderline significance (p=0.06; figure 4b). 
 
 
 
Figure 4. In FNABs a significantly higher median CD8+/CD3+ T-lymphocyte ratio was found in “rapid 
responders” than in “slow responders” at 4 weeks of treatment (p=0.02)(A). At 12 weeks the 
CD8+/CD3+ T-lymphocyte ratio was lower in patients who did not have a 2-log drop with borderline 
significance (B). For explanation on boxes and lines see figure 2. 
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7.5  DISCUSSION 
 
In the present study we investigated whether the minimal invasive fine needle 
aspiration biopsy (FNAB) technique could be used as a tool to monitor CD8+ T-
lymphocytes in the liver during chronic HCV-infection. Comparison of the ratio's and 
numbers of CD8+ and CD3+ T-cells in simultaneously obtained FNABs, liver tissue 
biopsies and peripheral blood specimens showed that CD8+ T-cells in FNABs were 
primarily liver-derived. Since, in contrast to circulating T-cells, the majority of 
intrahepatic T-cells are CD8+ T-cells (13, 14), first the CD8+/CD3+ ratio's in the three 
sources were compared. In the FNABs these were similar to those in portal tract, 
where the majority of the intrahepatic CD8+ T-cells reside, but different from that in 
the blood samples. Second, the relative numbers of CD3+CD8+ T-cells in the FNABs 
correlated significantly with the absolute CD8+ T-cell numbers in the lobular fields 
and the portal tracts of simultaneously obtained liver tissue biopsies, while there was 
no correlation with numbers in peripheral blood. On the other hand, variations in 
numbers of CD3+ T-lymphocytes in the FNABs were associated with variations in 
both peripheral blood and liver tissue biopsies, indicating that CD3+ cells in the 
FNABs originated from the liver and blood. Recently we found that numbers of CD8+ 
T-cells in portal tracts of pre-treatment liver tissue biopsies were associated to the 
occurrence of response of HCV-infection on interferon-α therapy (7). To investigate 
whether quantification of T-cells in FNABs showed association with early virological 
response during therapy, the patients were divided into two response groups 
according to their individual decline in HCV RNA within the first 4 treatment weeks. 
We choose the average decline of HCV-RNA within the first month as value to divide 
the patients into "rapid" and "slow" responders. According to this limit, a significantly 
higher FNAB CD8+/CD3+ T-lymphocyte ratio was found in “rapid responders” than in 
“slow responders”. 
 For 12 weeks of therapy, a drop in HCV RNA of at least 2-log recently proved to be 
essential for obtaining a sustained virological response recently (15). Dividing our 
patients according to this limit, a borderline significant lower CD8+/CD3+ T-
lymphocyte ratio was found in patients who did not have at least a 2-log drop of HCV 
RNA as compared to the other patients. Therefore, whether the CD8/CD3 ratio in 
pretreatment FNAB is predictive for long-term virological response to therapy needs 
to be investigated in a larger patient population. 
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It is not allowed to compare the present finding directly to our previous finding on the 
association between the numbers of CD8+ T-cells in pre-treatment liver biopsies and 
response to anti-HCV therapy (7), since absolute numbers of cells cannot be 
measured in FNABS and the therapies in both studies are different. In the previous 
study the patients were treated with interferon-α and in the present study with Peg-
interferon. The determining role of the immune system in obtaining a sustained 
response is probably much smaller in Peg-interferon therapy because of the long 
lasting and constant antiviral pressure and the relatively high dose when compared 
to 3 MU t.i.w of conventional interferon-α therapy. 
In conclusion, we demonstrated that differences in numbers of intrahepatic CD8+ T-
cells during chronic HCV-infection are reflected in FNABs, and that there is an 
association between the composition of the T-cell population contained in pre-
treatment FNABs and early response to subsequent anti-viral therapy. We therefore 
postulate that the FNAB-technique can be used as a tool for monitoring the cellular 
immune status in the liver during chronic HCV-infection on a frequent basis.
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8.1  ABSTRACT 
 
Overall treatment results of chronic hepatitis C have improved markedly with the 
introduction of pegylated interferon-alpha (PEG-IFN-α) and ribavirin combination 
therapy. However, cure rates in the most common genotype 1 infection are still 
unsatisfactory. IFN-α dose-response studies on viral kinetics suggest that inadequate 
dosing might be a key factor but drug levels have hardly been tested, which is in part 
due to difficulties in measuring this cytokine in patient samples. We have shown 
recently that hepatitis C virus (HCV) replicons are highly sensitive to IFN-α. In this 
report we tested whether the replicon system could be used as a sensitive bioassay 
to determine the amount of biologically active IFN-α in serum or heparinized plasma 
of patients under therapy. To facilitate the measurements, a stably replicating 
subgenomic HCV RNA was developed that carries the gene encoding the firefly 
luciferase. Dose response studies with IFN-α demonstrate that the amount of 
expressed luciferase directly correlates with the level of HCV replication. By using 
this cell-based assay, serum samples of HCV patients treated with different types 
and doses of IFN-α were analyzed in parallel to IFN-α standards made by serial 
dilutions of the same type of IFN-α the patient was treated with. Based on nonlinear 
logistic models serum concentrations corresponding to 1.3 to 19 units per ml were 
determined in patients under standard or high dose IFN-α therapy, and from 3.8 and 
4.1 ng/ml in patients treated with PEG IFN-α. In conclusion, the HCV-replicon based 
bioassay allows determining the levels of biologically active IFN-α in serum and 
heparinized plasma of patients under treatment. 
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8.2  INTRODUCTION 
 
Since the first clinical trial of treating patients with non-A, non-B hepatitis in 1986 (1), 
successful treatment of this disease caused by infection with the HCV, has been 
improved steadily, particularly with the introduction of the combination therapy of IFN-
α and ribavirin (2, 3). Recently, new forms of IFN-α became available. Results of 
large clinical trials indicate cure-rates of 76 to 82% with genotype 2 and 3, but only 42 
to 46% with genotype 1 infections (4, 5). A possible explanation is a decreased 
sensitivity of genotype 1 infection for IFN-α, as suggested from studies on viral 
kinetics(6). However, high dose IFN-α treatment of these patients might still be 
effective in virus suppression (7, 8). Consequently, the study of correlations between 
suppression of genotype 1 virus replication and the levels of IFN-α in treated patients 
might provide more insight into this possibility. 
Studying blood levels of biologically active molecules is preferably done by a 
bioassay, but replaced commonly by an immunoassay for reasons of ease and costs. 
However, the use of immunoassays for IFN-α measurements has two problems. 
First, all immunoassays make use of antibodies to immobilize the cytokine, but false-
positive signals can be obtained if binding occurs to an inactive protein. Secondly, 
and most importantly, unmodified IFNs are standardized biologically and expressed 
in (international) units per ml whereas pegylated (PEG-) IFNs are specified on the 
basis of their molecular weights (ng/ml). Consequently, a direct comparison of the 
biological activities of the different IFNs has been difficult. The availability of a simple 
bioassay that allows the determination of the number of biologically active molecules 
present in a given sample would therefore be very helpful. In the case of IFN-α, many 
bioassays are based on the protection of cultured cells against the cytopathic effect 
of a challenge virus (9). However, in addition to working with infectious agents, 
another drawback is that these assays do not necessarily reflect the ability of IFN-α in 
suppressing HCV replication. 
It has been shown recently that HCV replicons are highly sensitive to IFN-α (10-12). 
Therefore, the usefulness of the replicon system was assessed for measuring the 
amount of biologically active IFN-α in serum and heparinized plasma of patients 
under treatment. A rapid quantitative assay was developed which is based on 
measuring the activity of a luciferase reporter gene that was integrated into a 
subgenomic selectable HCV replicon. By using this system, the (bio) activities of 
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different forms of recombinant IFNs and PEG-IFNs in serum and heparinized plasma 
were compared and interferon levels in patients treated for chronic hepatitis C were 
determined. 
 
8.3  MATERIALS AND METHODS 
 
8.3.1 Patient sera 
Serum samples obtained at various time points during different IFN-α treatment 
schedules were prepared within 2 hours of blood sampling and stored at -70oC until 
assayed. All patients were infected chronically with HCV and enrolled in investigator 
initiated clinical trials after having given informed consent (Table 1). The trials were 
approved by the local ethical committee. Patient A, a virological non-responder to 
IFN-α monotherapy was enrolled in a study combining high-dose induction and 
prolonged IFN-α2b and ribavirin therapy (13). Blood samples used in this assay were 
drawn 24 hours after the third daily subcutaneous injection of 10 million units (MIU), 
12 hours after 1 month of 3 MIU daily injections and 12 hours after the administration 
of 3 MIU three times a week. Patients B to E were included in a study designed to 
explore treatment strategies during PEG-IFN-α2a and ribavirin (14). In patient B and 
C, blood samples used in this assay were drawn 12 hours after the third weekly 
injection of PEG-IFN-α2a (180 µg) and in patient D and E after the seventh weekly 
injection of the same dose. 
 
8.3.2 Generation of a selectable HCV replicon with a reporter gene.  
The basic replicon construct pFK-I389/NS3-3’/5.1 has been described recently (15). 
This construct carries three cell culture-adaptive mutations that enhance RNA 
replication cooperatively (E1202G, T1280I, and S2197P). The reporter gene 
luciferase from the firefly (Photinus pyralis) and the coding sequence for ubiquitin 
were inserted upstream of the neo gene by using standard recombinant DNA 
technologies (Fig. 1a). Details of the cloning procedure will be described elsewhere. 
Cell clones derived from Huh-7 cells that carry persistently replicating HCV replicons 
were generated as reported recently (16)
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Figure1. Antiviral activity of IFN-α2a on a HCV replicon carrying a reporter gene. (A) A schematic 
presentation of the HCV genome organization, with the structural proteins core to E2, the nonstructural 
proteins NS2 to NS5B, and the nontranslated regions (thick lines) flanking the polyprotein is shown at 
the top. The structure of the HCV replicon used in this study is shown below. It contains the HCV 5’ 
nontranslated region directing translation of a fusion protein that is composed of the first 16 amino acid 
residues of the HCV core protein, the firefly luciferase (Ff-luc), ubiquitin (ubi), and the selectable 
marker neomycin phosphotransferase (neo). The EMCV IRES mediates translation of NS3 to NS5B. A 
combination of three cell culture adaptive mutations (E1202G, T1280I, S2197P) derived from the 
highly adapted subgenomic replicon rep 5.1 was introduced to increase RNA replication (15). (B) Cells 
persistently carrying the replicon shown in panel A were treated with 0, 0.5, 1, 2.5, 5, 7.5, 10, 25, 50, 
and 100 U of IFN-α2a/ml for 72 hours. The inhibition of translation and replication was determined by 
measuring the amount of firefly luciferase activity (circles) and the amounts of replicon RNA (squares), 
respectively. Note that the copy numbers of replicon RNA as determined by quantitative RT-PCR were 
normalized to 1 µg of total RNA by using GAPDH that was co-amplified in the same reaction. 
 
8.3.3 Cell culture and dose-response assays 
Huh-7 human hepatoma cells carrying the HCV replicon were grown in Dulbecco's 
modified Eagle medium (DMEM; Life Technologies GmbH, Karlsruhe, Germany) 
supplemented with 2 mM L-glutamine, non-essential amino acids, 100 U of penicillin, 
100 µg streptomycin, 10 % fetal calf serum (complete DMEM) and 250 µg/ml G418 
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(Life Technologies). Cells were passaged twice per week at a dilution of 1:3 – 1:5, 
depending on cell growth by using PBS containing 0.05% trypsin and 0.05% EDTA 
(Life Technologies). For the luciferase/ RT-PCR assay, cells were seeded in 9.6 cm2 
dishes at a density of 200,000 cells in complete DMEM supplemented with 250 µg/ml 
G418 (Life Technologies, Germany). After 24 hours, medium was replaced by 
complete DMEM without G418 and containing 100, 50, 25, 10, 7.5, 5, 2.5, 1 or 0 U/ml 
of IFN-α2a (Roche Applied Science, Mannheim, Germany) in triplicates. In all other 
cases, cells were seeded in 24-well plates (2 cm2 per well) at a density of 40,000 
cells per well. After 24 hours, medium was replaced by 1ml complete DMEM per well 
containing 10% human serum and one of the following concentrations of interferon: 
1000, 500, 250, 100, 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78, 0.39, 0.20 or 0 U/ml of IFN-
α2a (kindly provided by K. Weyer and E. K. Weibel, Hoffmann-La Roche AG, Basel) 
or IFN-α2b (Schering-Plough), or 180, 60, 30, 15, 7.5, 3.75, 1.88, 0.94, 0.47, 0.23, 
0.12, 0.06, 0.02 or 0 ng/ml PEG-IFN-α2a (Roche Applied Science). All experiments 
were carried out at least twice each in sextuple and on several plates, such that the 
positions of individual samples relative to the controls were varied in order to reduce 
positional effects. In case of the cell proliferation assay, the medium in triplicate wells 
was replaced by 1 ml complete DMEM containing increasing concentrations of 
ribavirin (Schering-Plough). Proliferation was determined by measuring the optical 
density after staining the cells with the tetrazolium salt WST-1 (Roche Applied 
Sciences). A positive (1,000 U/ml IFN-α) and a negative control (no IFN-α) was 
included on each plate such that the position was different from plate to plate. 
 
8.3.4 Incubation of cells with patient sera 
Twenty four hours after seeding, cells in each well of a 24-well plate were incubated 
with 0.9 ml complete DMEM and 0.1 ml serum from patients specified in Table 1. All 
experiments were carried out in triplicate. On each plate a positive (1,000 U/ml IFN-α) 
and a negative control (no IFN-α) was included. 
 
8.3.5 Cell harvesting and measurement of luciferase activity 
Cells were harvested after 48 - 50 hours incubation (or after 72 hours in case of 
luciferase/ RT-PCR assays). After removal of the medium, cells were washed twice 
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with phosphate buffered saline (PBS) and incubated with 180 µl, or 350 µl in case of 
the experiment shown in Fig. 1, ice cold luciferase lysis buffer (1% Triton X100, 25 
mM glycylglycine, 15 mM MgSO4, 4 mM EGTA, and 1 mM DTT added just before 
usage) for 10 min., after which the lysate was harvested. After 15 min. centrifugation 
at 13,000 g and 4 oC, 100 µl lysate was mixed with 360 µl assay buffer (25 mM 
glycylglycine, 15 mM MgSO4, 1 mM DTT, 2 mM ATP, 15 mM potassium phosphate 
buffer, pH 7.8) and 200 µl of a 200 mM luciferin stock solution (PJK Chemikalien, 
Kleinbitterdorf, Germany) in 25 mM glycylglycin was added. Luminescence was 
measured in a luminometer (Lumat LB9507 from Berthold, Freiburg, Germany) for 20 
seconds and expressed as the number of relative light units (RLU) detected. 
 
8.3.6 RNA preparation and quantitative RT-PCR 
150 µl of cell lysate were mixed with 600 µl of GITC buffer (4 M guanidinium 
thiocyanate, 25 mM sodium citrate, 0.5% sarkosyl, 0.1 M 2-mercaptoethanol), 1/10 
volume of 2 M sodium acetate (pH 4.5), 1 volume of phenol, and 1/5 volume of 
chloroform. After a 15 min. incubation on ice, samples were centrifuged for 15 min. at 
13,000 g and 4°C. Nucleic acids in the aqueous phase were transferred to a fresh 
tube, precipitated with 1 volume of isopropanol, washed once with 70% ethanol and 
resuspended in 50 µl of doubly distilled water. Three µl of the sample were used for 
quantitative RT-PCR analysis using an ABI PRISMTM 7700 Sequence Detector 
System (Applied Biosystems, Foster City, USA). The HCV- and GAPDH-specific RT-
PCRs were conducted in duplicates with the One step RT-PCR kit (Qiagen, Hilden, 
Germany) using the following probes and primers (TIB Molbiol, Berlin, Germany): 
HCV, 5´-6FAM (6-Carboxy-Fluorescine)- TCC TGG AGG CTG CAC GAC ACT CAT- 
TAMRA (Tetra-Chloro-6-Carboxy-Fluorescine)-3´; HCV-S66, 5´-ACG CAG AAA GCG 
TCT AGC CAT-3´; HCV-A165, 5´-TAC TCA CCG GTT CCG CAG A-3´; GAPDH, 5´- 
TET (6-carboxy-4, 7,2’, 7’-tetra-chlorofluorescein) -CAA GCT TCC CGT TCT CAG 
CCT-TAMRA-3´; GAPDH-S, 5´-GAA GGT GAA GGT CGG AGT C-3´; GAPDH-A, 5´-
GAA GAT GGT GAT GGG ATT TC-3´. Reactions were performed in three stages by 
using the following conditions: stage 1, 60 min at 50°C (reverse transcription); stage 
2, 15 min at 95°C (heat inactivation of RT and activation of Taq-polymerase); stage 3, 
15 sec 95°C, 1 min 60°C, 40 cycles (amplification). The total volume of the reaction 
mix was 15 µl and contained the following components: 2.66 µM 6-Carboxy-X-
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rhodamine (Rox, passive reference), 4 mM MgCl2, 0.66 mM dNTPs, 0.266 µM HCV 
probe, 0.3 µM GAPDH probe, 1 µM of each HCV and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) primer, 0.6 µl enzyme mix. The amount of HCV RNA was 
calculated by comparison to serially diluted in vitro transcripts and the amount of 
GAPDH RNA by comparison to serially diluted HuH-7 total RNA. Both RNA species 
were included in the RT-PCR amplifications. 
 
8.3.7 Calculations 
The IFN-α and PEG-IFN-α dose dependent inhibitory activity in terms of percentage 
was calculated by the following equation: 
% Inhibition = ((log10 (PC) - log10 (Sn)) / ((log10 (PC) – log10 (NC)) * 100% 
Where PC is the number of RLU after incubation with the positive control (1,000 U/ml 
IFN-α or 180 ng PEG-IFN-α2a), NC is the number of RLU after incubation with the 
negative control (no IFN-α2a/α2b or PEG-IFN-α2a), and Sn is the number of RLU 
after incubation with samples from the dilution range (as mentioned above). A 
nonlinear logistic model expressing the relationship between the inhibition and 
concentration of IFN-α and PEG-IFN-α, respectively, was estimated using the 
program SPSS for Windows (Version 10.1 SPSS Inc, Chicago, IL, USA). 
 
8.3.8 Vesicular stomatitis virus cytopathic effect reduction assay 
The vesicular stomatitis virus (VSV) bioassay used in this study is based on the 
reduction of cytopathogenicity by treatment of cells with IFN-α prior to VSV infection 
(9). In brief, 4 x 10e4 Hep-2 cells seeded in 96-well plates were incubated at 37oC 
with IFN-α2b or PEG-IFN-α2a diluted in 10 twofold steps in DMEM with or without 
10% human serum or with serum samples from patients under treatment. On all 
plates, controls were added (no IFN-α2b or PEG-IFN-α2a). After 6 hours the 
supernatant was removed, VSV (Indiana strain) was added in a volume of 100 µl 
DMEM (m.o.i. of 1) and incubated overnight. To visualize vital cells, the overlay was 
removed and cells were stained and fixed with 1% crystal violet in 1% formaldehyde. 
The virus-induced cytopathic effect was quantified by measuring the optical density at 
595 nanometer. 
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8.4  RESULTS 
 
8.4.1  Development of a selectable HCV replicon carrying a reporter gene 
The usefulness was explored of the HCV subgenomic replicon system that is based 
on the autonomous replication of genetically modified ‘minigenomes’ in the human 
hepatoma cell line Huh-7 for determining the amount of biologically active IFNs. 
Originally, these replicons that were derived from a cloned genotype 1b HCV full 
length genome carried the following elements: the HCV 5’ non-translated region that 
directs the expression of a selectable marker (the neo gene), the internal ribosome 
entry site (IRES) from another virus (encephalomyocarditis virus, EMCV) directing 
translation of the HCV NS3 to 5B region and the authentic 3’ non-translated region. 
These replicons were transfected into Huh-7 cells and after G418 selection cell 
clones were established that carry HCV RNAs replicating autonomously to very high 
levels (15). However, direct determinations of RNA replication e.g. by Northern 
hybridization or quantitative RT-PCR are time consuming and they require technical 
skills and certain equipment that are not readily available in every laboratory. 
Therefore, a novel replicon was devised which carried in addition to the neo gene a 
reporter gene that could be used as a marker for RNA replication. For this purpose, 
we chose the firefly luciferase for several reasons: (1) it can be easily measured, (2) 
it is very sensitive, and (3) it has a very short half life which is important when 
measuring rapid changes of RNA translation/replication in a cell. Ubiquitin was 
inserted between this reporter and the selectable marker to enable proteolytic 
separation of the luciferase from the neomycin phosphotransferase (Fig. 1a). 
In the first set of experiments, the sensitivity of this replicon towards inhibition by IFN-
α was determined. Since WHO international standards for interferons were not used 
but rather interferons specified by different commercial suppliers, all values given 
below are expressed in units per ml (U/ml) rather than international units. Cells were 
incubated with different concentrations of IFN-α, or were left untreated, and after 72 
hours cells were lysed and luciferase activity was determined. In order to verify that 
the amount of luciferase activity correlates directly with the amount of replicon RNA, 
quantitative RT-PCR was carried out with total RNA isolated from the same cell 
lysate The data in Fig. 1b demonstrate that luciferase activity and replicon RNA 
decreased with increasing concentration of IFN-α albeit with different kinetics. At 
concentrations up to 7.5 U/ml, luciferase and RNA amounts were reduced in parallel. 
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Interestingly, at higher concentrations, luciferase activity was reduced further 
whereas the amount of RNA was affected to a much lesser extent. This may be due 
to a preferential inhibition of RNA translation by higher concentrations of IFN-α. 
However, within the concentration of up to 7.5 U/ml IFN-α, both RNA and luciferase 
were reduced with comparable efficiency. In fact, the IC50 we determined from this 
assay was 1 – 2.5 U/ml when measuring HCV RNA and about 1 U/ml when using 
luciferase assays. In summary, these data demonstrate that the luciferase activity is 
a simple and reliable indicator for HCV RNA replication in this model system. 
Next the dose response curves of different IFN-α formulations in this HCV replicon 
system were determined. Cells were incubated with various concentrations of IFN-
α2a, IFN-α2b, or PEG-IFN-α2a and replication was determined by measuring the 
luciferase activities (Fig. 2). To express the relation between inhibition and 
concentration, a nonlinear logistic growth model over a polynomial fit was chosen 
because the first is based on the interpretation of biological parameters producing the 
response and can thereby be considered as mechanistic. Moreover, a nonlinear 
model requires only half of the amount of parameters and provides more reliable 
predictions of the response variable outside the observed range (17). A disadvantage 
of nonlinear logistic growth models is that classical analysis criteria such as 
parallelism of dose-response lines can not be used due to the absence of linearity. 
The correlation between inhibition and concentration of (PEG-) IFN-α/ml was 
expressed as: 
% Inhibition = 100/ ( 1 + exp ( - (log10(Concentration) - β)/ δ)) 
where β is the concentration at which 50% of inhibition is reached, thereby including 
the IC50 in the equation, and δ is the difference in log concentration between 50% 
and about 75% [1/(1 +e -1 )] inhibition. The estimated concentration of cytokine 
required for a 50% reduction of RLU (IC50) by IFN-α2a, IFN-α2b and PEG-IFN-α2a 
was 4.1 U/ml (asymptotic 95% confidence interval: 3.4 - 4.9 U/ml), 2.3 U/ml 
(asymptotic 95% confidence interval: 1.9 - 2.7 U/ml)) and 1.7 ng/ml (asymptotic 95% 
confidence interval: 1.5 - 1.9 ng/ml), respectively. The estimated δ for IFN-α2a, IFN-
α2b and PEG-IFN -α2a were 3.3 U/ml (asymptotic 95% confidence interval: 1.6 - 3.9 
U/ml), 3.3 U/ml (asymptotic 95% confidence interval: 2.8 - 4.0 U/ml) and 3.2 ng/ml 
(asymptotic 95% confidence interval: 2.9 - 3.6ng/ml), respectively. IFN-α2a and IFN- 
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Figure 2. Dose response curves of recombinant IFN-α2a (a), IFN-α2b (b) and PEG-IFN-α2a (c). 
Cells carrying the HCV replicon were incubated with various concentrations of IFNs in a mixture of 0.9 
ml complete DMEM and 0.1 ml human serum. The dose dependant inhibition by IFN-α2a, IFN-a2b and 
PEG-IFN-α2a, was calculated by the reduction of relative light units as determined by luciferase 
assays. 
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α2b appear similar in biological activity and based on the IC50 approximately 2 ng 
PEG-IFN-α2a can be compared to 2 - 4 U IFN-α2a or IFN-α2b. 
 
8.4.2 Evaluation of the HCV replicon to measure biologically active IFN-α in 
patient samples 
Having established a highly sensitive assay to measure the amount of biologically 
active IFN-α, it was determined whether this test could also be used to determine 
IFN-α in sera of patients under therapy. Therefore, sera from patients that were 
treated with different regimes of IFN-α (Table 1) were applied to cells with the HCV 
replicon as described in the Materials and Methods section. For comparison, on each 
plate a serial dilution of the same type of (PEG-) IFN-α the patients were treated with 
was analysed in parallel. The results are summarized in Table 2. Estimated serum 
concentrations in patients on treatment ranged from 1.3 - 19 U/ml (standard vs. high 
dose IFN-α) and from 3.8 - 4.1 ng/ml (standard PEG-IFN-α). The measured serum 
levels fell in the highest sensitivity range of the assay with inhibition of the replicon 
between 15 and 85%. Thus, the HCV replicon system can be used to determine the 
amount of biologically active IFN-α in sera of chronic hepatitis C patients that are 
under treatment. 
Standard antiviral therapy consists currently of PEG-IFN-α in combination with 
ribavirin (4, 5). Pharmacokinetic studies have shown that ribavirin serum 
concentrations range from 1,000 to 2,750 ng/ml when measured after 4 weeks of 
daily administration of 1,200 mg (18). Since the patient sera which were used also 
contained ribavirin, tests were carried out to determine whether this drug would affect 
HCV replicons. However, it was found that concentrations up to 3,000 ng/ml did not 
inhibit HCV replicons nor did it affect Huh-7 cell proliferation as determined with a 
WST cell proliferation assay (data not shown). Thus, the inhibition we measured was 
only due to IFN-α present in patient samples. 
Since in most cases plasma is prepared from blood samples of patients instead of 
serum, it was necessary to determine whether the replicon-based biotest could also 
be used to measure IFN-α and PEG-IFN-α in plasma samples. In the first set of 
experiments we performed IFN-α and PEG-IFN-α dose response assays in serum, 
EDTA plasma and heparinized plasma samples in parallel as described in the 
Materials and Methods section. Briefly, 24 hours after seeding, cells were incubated 
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with concentrations ranging from 0 to 1,000 U/ml IFN-α and from 0 to 180 ng/ml 
PEG-IFN-α added to cell culture medium that contained 1/10 volume of EDTA 
plasma or heparinized plasma or serum of naive patients. After 2 hours incubation, 
the cell culture medium containing 10% human EDTA plasma was gel, which was 
most likely due to coagulation that was induced by the fetal calf serum in the cell 
culture medium. Consequently, the medium could not be aspirated without affecting 
the cell monolayer making an analysis of these samples impossible. In contrast, cells 
incubated with serum or heparinized plasma could be easily harvested and 
replication was determined by measuring the luciferase activities after a 52 hours 
incubation. The results in Fig. 3 show that in spite of some variation cytokine activity 
in heparinized plasma and serum are comparable showing that the assay can be 
used for the measurement of IFN-α in both patient materials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Dose response curves of recombinant IFN-α2b (a) and PEG-IFN-α2a (b) in serum and 
heparinized plasma. Cells carrying the HCV replicon were incubated for 52 hours with given 
concentrations of IFNs in a mixture of 0.9 ml complete DMEM and 0.1 ml human serum (grey dots) or 
heparinized plasma (black squares). The experiments were performed in triplicates and the medians 
are shown. RLU as determined by luciferase assays are displayed as a function of IFN-α 
concentration. 
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The biological activity of interferons is often determined by antiviral assays in which 
the reduction of virus yield or cytopathogenicity is used as an indicator for the activity 
of a given IFN-α preparation. Therefore, a comparison of the HCV replicon system 
was made with the VSV cytopathic effect reduction assay. This assay is based on the 
inhibition of cytolysis of infected cells by treatment with interferon and subsequent 
measurement of viable cells with a vital dye stain. In the first set of experiments, Hep-
2 cells were treated with increasing concentrations of IFN-α2b or PEG-IFN-α2a in the 
presence or absence of human serum and subsequently infected with VSV. As 
shown in Fig. 4, in the absence of human serum, cells were gradually protected 
against VSV with increasing concentrations of IFN-α2b whereas only high 
concentrations of PEG-IFN-α2a confered antiviral resistance. However, in the 
presence of human serum, the cells were completely protected against VSV. The 
same was true when sera from patients under therapy (Table 2) were used. The 
assay could therefore not be used for the measurements of IFN-α2b or PEG-IFN-α2a 
levels in patient sera. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. VSV cytopathic effect reduction assay. Hep-2 cells pretreated with given concentrations of 
IFN-α2b (A) or PEG-IFN-α2a (B) in the absence (black dots) or presence (black squares) of 10% 
human serum were infected with VSV (Indiana strain). After overnight incubation the virus-induced 
cytopathic effect was determined by optical density reading at 595 nanometer after staining of viable 
cells with the vital dye crystal violet. The experiments were performed in duplicates and the medians 
are shown.  
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Table 2. Estimated serum interferon concentrations 
 
Patient Medication % 
inhibition1
Concentration  
(U or ng per ml)2 
A IFN-α2b 10 MIU/d + 1200mg Rbv/d 85 19 U/ml 
A IFN-α2b 3 MIU/d + 1200mg Rbv/d 69 6.3 U/ml 
A IFN-α2b 3 MIU tiw +1200mg Rbv/d 39 1.3 U/ml 
B PEG-IFN-α2a 180 ug QW + 1000mg Rbv/d 68 4.10 ng/ml 
C PEG-IFN-α2a 180 ug QW + 1000mg Rbv/d 67 3.85 ng/ml 
D PEG-IFN-α2a 180 ug QW + 1000mg Rbv/d 68 4.10 ng/ml 
E PEG-IFN-α2a 180 ug QW + 1000mg Rbv/d 67 3.85 ng/ml 
 
1Reduction of luciferase activity relative to cells treated with naive human serum. 
2Serum interferon concentrations as determined by comparison with cells that were treated with a 
serial dilution of the homologous interferon. 
 
8.5  Discussion 
 
In this study, a new bioassay for the measurement of IFN-α in serum and heparinized 
plasma of patients treated with this cytokine for chronic hepatitis C is described. The 
assay that is based on the inhibition of a subgenomic HCV replicon is sensitive and 
can be used for the measurement of IFN-α activity in clinical practice. The levels of 
IFN-α found in patient samples fell within the test range and could be determined by 
comparison with a dilution series of the homologous interferon analysed on the same 
plate. Compared to other bioassays (19), the HCV replicon system has the following 
advantages: First, it directly measures the inhibition of HCV RNA replication; second, 
it is very sensitive and allows measurements in patient samples, i.e. in the presence 
of human serum; third, it is easy to perform because HCV replication can be 
measured by simple bioluminescense assays; fourth, HCV replicons are non-
infectious which is an advantage over the Sendai virus growth inhibition assay or the 
VSV cytopathic effect reduction assay that are often used to measure IFN-α levels. 
As an alternative to these antiviral assays, IFNs can be measured by immunoassays 
such as enzyme-linked immunosorbent assay (ELISA), immunoradiometric assay 
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(IRMA) and radioimmune assay (RIA). These assays are precise and accurate for 
measuring IFNs in vitro but loose sensitivity when measuring this cytokine in patient 
samples. This may be due to certain inhibitors such as heterophile antibodies, 
rheumatoid factors, or a soluble form of IFN-α/β receptors interfering with sensitivity 
(20, 21). Moreover, results obtained in those assays do not necessarily reflect the 
amount of the biologically active fraction of IFN-α in a given sample. Finally, 
immunoassays depend on the specific recognition of an antigen by the antibodies 
used. Therefore, apparent differences in amounts can be the result of differences in 
sensitivity and specificity with which the antibodies recognize a particular IFN. 
Inspite of the benefits discussed above, potential drawbacks of using the HCV 
replicon system as a bioassy should also be mentioned. First, bioassays are often 
sensitive to culture conditions and therefore somewhat variable in outcome. 
However, with a strict standardization of the assay as described here, the variations 
can be kept at a minimum. Moreover, in spite of some interassay variability in the 
absolute amounts of luciferase activity detected in replicon cells, the linear range of 
this assay is very stable throughout continued passage of the cells. The assays 
described here were performed multiple times in the course of about one year and in 
two different laboratories with good reproducibility of linearity as long as samples 
were measured against a dilution series of an internal standard that was added on 
each plate. A gradual reduction in the absolute amounts of luciferase activity was 
observed which was most likely due to the emergence of mutations in the luciferase 
gene. These mutations probably accumulated during prolonged cell passage and led 
to a successive loss of reporter activity. However, this reduction took several months 
and in case that absolute values were too low, the cells in culture were replaced by a 
lower passage of the same cell clone that had been stored frozen in liquid nitrogen. It 
should be pointed out that cells carrying the HCV replicon described in this study 
could be frozen and thawed without loosing the replicon and luciferase activity. In a 
well growing culture of Huh-7 cells carrying this replicon, luciferase activity was about 
5 x 10e5 RLU per 10e5 cells, which corresponds approximately to the total number of 
cells in a single well of a 24-well plate. 
Second, it is possible that the inhibition we observed is not the result of an inhibition 
of HCV RNA replication but rather due to a block of the EMCV IRES. However, since 
monocistronic HCV replicons that lack this element and in which translation and 
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replication are exclusively controlled by HCV sequences are also blocked efficiently 
by IFN-α, this possibility is ruled out (A.K. and R.B., unpublished). Third, HCV RNA 
replication depends very much on host cell growth (22) and therefore, it is important 
to standardize the cell culture conditions and to avoid the use of over confluent cells. 
Moreover, substances inhibiting cell proliferation apparently block replicons. 
However, proliferation of Huh-7 cells is not substantially affected by IFN-α or naive 
patient samples, at least in the concentration ranges used here. 
Huh-7 cells carrying stably replicating HCV replicons are robust and easy to handle. 
In fact, their growth properties and morphology are very similar to that of naive Huh-7 
cells. When cells with the replicon are kept under continuous selective pressure 
(G418), the replicon is maintained for several years. An important parameter is 
passaging the cells at regular intervalls, because cell density very much affects HCV 
RNA replication. When cells are kept in a confluent state for prolonged times, 
replicon RNA levels are reduced drastically (22). Therefore, cells are passaged at 
regular intervalls at a dilution of 1:3 to 1:5, usually twice per week. However, even 
when replicon RNA levels (luciferase activities) were low, the linearity of this bioassay 
was not affected. 
For high throughput analyses, one limitation of this bioassay in its current form is the 
preparation of cell lysates and the measurements of luciferase activities in lysates. In 
this study, we analysed and measured a total of 300 samples within a day which is at 
the limit a single person can do manually. However, the preparation of the lysate and 
the measurements can probably be automated which allows a much higher 
throughput of samples. 
By using the replicon based bioassay, it was possible to measure and compare the 
inhibitory effects exerted by IFN-α2a, IFN-α2b, and PEG-IFN-α2a, in samples of 
patients treated with these cytokines. Because of its high sensitivity, this bioassay 
could be used for the establishment of international biological standards, and for 
comparing and standardizing relative activities of different IFN-α preparations, as 
approved by the WHO (19). In clinical healthcare, such standards can be important to 
correlate viral kinetics and drug levels, thereby contributing to the optimization of 
treatment in patients prone to non-response. 
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9.1 ABSTRACT 
 
Background/Aims: Responses to combination therapy of peginterferon and ribavirin 
in chronic hepatitis C are variable. The objectives of this study were to describe the 
population pharmacokinetics of peginterferon-α2a and to correlate pharmacokinetic 
parameters with outcome like early virologic response (EVR), end of therapy (EoT) 
and end-of-follow-up (EFU) treatment results.  
Methods: Two hundred seventy patients were treated with peginterferon-α2a (180 
mcg QW) and ribavirin (1-1.2g qd). Based on the first month viral kinetics all patients 
were classified into one of three EVR categories (rapid (RVR), slow (SPR) or flat-null 
(FPR/NUR) responders) and thereupon randomized to either standard or tailored 
therapy. During the first month of therapy serial blood sampling was performed and 
serum interferon levels were quantified in 255 patients using a sandwich enzyme-
linked immunosorbent assay (ELISA) at 7 time points. Population pharmacokinetics 
were assessed by nonlinear mixed effects modeling. Secondary parameters, a.o. 
AUC (area under the plasma concentration versus time curve), were derived.  
Results: Clearance of peginterferon-α2a was significantly correlated with weight; 
clearance for a typical 74 kg patient was 1.36 L/day. Inter- and intra-patient variability 
of clearance was considerable with values of 35% and 25%, respectively. The AUC 
in week 4 was approximately 2-fold higher than in week 1, indicating accumulation of 
peginterferon-α2a. Combined over the first 4 weeks AUC was higher for patients with 
RVR than for SPR (borderline sign.:p=0.07) or FPR/NUR (sign.:p<0.01). Within the 
group treated with standard therapy (n=126), response categories were highly 
predictive for outcome (p<0.01). However, a relationship between the first 4 weeks 
AUC and EoT or EFU could not be found.  
Conclusions: There is considerable inter- and intra-patient variability in the 
pharmacokinetics of peginterferon-α2a. Exposure during the first month of treatment 
can predict early virological response but appears not to be correlated with treatment 
outcome. Pharmacokinetic variability of peginterferon-α2a does not appear to explain 
variability in treatment response in patients with chronic hepatitis C. 
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9.2  INTRODUCTION 
 
The most effective and current standard therapy for chronic hepatitis C virus (HCV) 
infection is the combination of peginterferon-α2a or -α2b and ribavirin with sustained 
viral response (SVR) achieved in more than half of treated patients (1, 2). The two 
peginterferon-α molecules used in the registration studies clearly differ in 
pharmacokinetic characteristics but the significance of this difference remains 
unclear. Detailed information on peginterferon-α2b pharmacokinetics has been 
published in the recent years (3-5). In contrast, the pharmacokinetics of 
peginterferon-α2a have only been investigated in a single published study in which a 
limited number of patients with renal cell carcinoma received the compound with 
escalating doses (6). 
To test the hypothesis that pharmacokinetic variability may explain variations in 
treatment response, we performed a pharmacokinetic study ancillary to an 
investigator-initiated multicenter clinical trial (7, 8). In this randomized controlled 
study the efficacy of a dynamically individualized treatment schedule according to the 
early virologic response was evaluated against that of standard combination therapy 
with peginterferon-α2a plus ribavirin for 48 weeks. The objectives of this ancillary 
analysis were to describe the population pharmacokinetics of peginterferon-α2a and 
to correlate pharmacokinetics with outcome like early virologic response (EVR), end 
of therapy (EoT) and end-of-follow-up (EFU) treatment results. 
 
9.3 MATERIALS AND METHODS 
 
9.3.1 Patients 
270 consecutive patients with chronic hepatitis C were recruited from nine university 
hospitals in France, Germany, Greece, Israel, Italy, Spain, Sweden, Switzerland and 
The Netherlands. Patients were eligible if they complied with the following inclusion 
criteria: age over 18 years, two serum alanine aminotransferase values above the 
upper limit of normal within 6 months of treatment initiation; a positive test for anti-
HCV antibody; a HCV RNA level greater than 1000 IU/mL by PCR; liver-biopsy taken 
in the preceding 12 months compatible with the diagnosis of chronic hepatitis C, 
compensated liver disease and for women a negative urine or blood pregnancy test. 
Major exclusion criteria included interferon or ribavirin therapy at any previous time, 
Chapter 9 
 152 
advanced cirrhosis or decompensated liver disease, co-infection with hepatitis B or 
human immunodeficiency virus, alcohol abuse or any other relevant comorbidity. All 
patients gave written informed consent before inclusion and the medical-ethical 
committees of participating hospitals approved the study. 
 
9.3.2 Treatment 
All patients were initially treated with peginterferon-α2a (Pegasys, Roche, 
Switzerland) 180 µg once weekly (QW) subcutaneously injected (injections on day 0, 
7, 14, 21, 28, etc.) in combination with twice daily orally taken ribavirin capsules 
(Copegus, Roche; 1-1.2g per day) for 6 weeks. A physician or a trained nurse 
instructed the patients how to perform the injection and administered the first injection 
of peginterferon-α2a. Initial viral kinetics were defined on samples taken on day 0, 1, 
4, 7, 8, 15, 22 and 29. 
After 6 weeks patients were classified into one of three early viral response 
categories as rapid viral responder (RVR), slow partial responder (SPR) flat partial or 
null responder (FPR/NUR) and randomized within each viral class to continue either 
with an individualized regimen or standard peginterferon-ribavirin combination 
therapy (48 weeks). Individualized treatment tailoring included discontinuation of 
ribavirin or shortening of treatment duration to 24 weeks in RVRs; the addition of 
histamine or prolongation of treatment to 72 weeks in SPRs; the addition of histamine 
in FPRs and retreatment with high-dose of PEG-IFN (360 µg QW) plus ribavirin in 
NURs (7, 8). 
The primary end point was end of follow-up (EFU) treatment results, the secondary 
end point virologic end of therapy (EoT). Both end points were defined as 
undetectable serum HCV-RNA at the end of follow-up or the end of therapy, 
respectively (Cobas AmplicorTM HCV, version 2.0, lower limit of detection 50 IU/mL).  
 
9.3.3 Peginterferon-α2a measurements 
Concentrations of peginterferon-α2a were measured in serum on day 0 (direct before 
the first injection) and days 1, 4, 8, 15, 22 and 29 using a quantitative sandwich 
enzyme-linked immunosorbent assay (ELISA) method (BMS216INST, Bender 
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Figure 1. A) Flow diagram showing the classification and B) randomization outcome of all patients 
included in the study. 
 
MedSystems Diagnostics GmbH, Vienna, Austria). The assay uses a murine 
antihuman interferon-α2 monoclonal antibody adsorbed onto microwells which 
captures interferon-α present in the samples or controls. A horse radish peroxidase-
conjugated monoclonal anti-interferon-α antibody binds to captured interferon-α. After 
addition of substrate and activator a colored product is formed in proportion to the 
amount of interferon-α in the sample and determined photometrically as specified by 
the manufacturer. A calibration curve was prepared plotting optical density vs. the 
concentration of the standards. Standards containing 100.000pg–100pg/mL were 
prepared by diluting peginterferon-α2a in normal human serum (CLB, Amsterdam, 
the Netherlands). 5µl serum samples obtained from the patients on treatment were 
incubated on the same plates as the standards, all in duplicates. The detection limit 
of the assay is 3pg/mL and the assay is linear up to a concentration of 10.000pg/mL. 
In a subset of 55 patients sampling of blood and measurements of interferon-α levels 
was done more frequently; on days 0, 1, 2, 3, 4, 7, 8, 9, 11, 14, 15, 18, 21, 22, 25, 29. 
 
 
A. 
B. 
255 Patients
161 
Rapid viral responders
31 
Flat partial/ Null 
responders 
61 
Slow partial 
responders 
2 
No classification 
could be made 
126 
Standard therapy 
129 
Individualized therapy 
Classification 
270 Patients
15 
No sample for PK analysis 
Randomisation78 30 16 
2
83 
15
31
2 
Viral response 
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9.3.4 Pharmacokinetic analysis 
Pharmacokinetic models were fitted to data from all individuals simultaneously using 
nonlinear mixed-effect modelling (NONMEM). Measurements of the subset of 55 
more frequently sampled patients were used for balancing the model. The NONMEM 
model accounted for inter-patient, intra-patient and residual pharmacokinetic 
variability (random effects) as well as pharmacokinetic differences predicted by 
patient factors (fixed effects). The typical population parameters, inter- and intra-
patient and residual variances were estimated using the NONMEM software program 
(double precision; version V, level 1.1) (9). The first-order conditional estimation 
(FOCE) method was applied with the INTERACTION option. A one-compartment 
pharmacokinetic model with first-order absorption and elimination was used to 
describe the time profiles of peginterferon-α2a plasma concentration. The 
pharmacokinetics were parameterized in terms of absorption rate constant (Ka), 
volume of distribution (V/F) and clearance (CL/F). F refers to the unknown 
bioavailability. Inter- and intra-patient variability of the pharmacokinetic parameters 
was estimated using exponential error models. For instance, inter-patient and intra-
patient individual CL/F was described using CL/F=CL/Fpop e (η + κ), in which CLpop is 
the typical population value and η and κ are the inter- and intra-patient random 
effects with mean 0 and variances ω2 and π2, respectively. The difference between 
the observed concentration (Cobs) and its respective prediction (Cpred) was 
modeled with a combined additive plus proportional error model: Cobs = Cpred * (1 + 
ε1) + ε2, where ε1 and ε2 are independent random variables.  
On basis of the derived structural population model and the observed individual 
concentrations, individual pharmacokinetic parameter estimates were obtained by 
Bayesian (POSTHOC) analysis. The individual estimates were plotted against 
demographic and pathophysiologic factors (Table 1) for visual inspection according to 
the method described by Maitre et al. (10). Covariates that showed a correlation with 
a pharmacokinetic parameter were entered into the population pharmacokinetic 
model. In the NONMEM model the relationship between covariates (gender, weight, 
etc) and pharmacokinetics was statistically tested using the log-likelihood test (9). 
Both categorical and continuous variables were evaluated. For instance, a difference 
in the Cl between male and females was evaluated using the following equation: CL= 
θ1 x θ2FLAG, where the indicator variable FLAG has the value 0 (female) or 1 (male), 
θ1 is the typical Cl of females (FLAG = 0) and θ2 is the fractional change in θ1 with 
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males. The relationship between Cl/F and weight (WT) was described as follows: 
CL/F = θ3 x (WT/74) θ4,where Cl/F is a typical population value of clearance, θ3 is the 
Cl/F of a patient with WT of 74 kg and θ4 is an exponent. 
Using the final population model (with significant co variables included) individual 
plasma concentration versus time profiles were generated by Bayesian analysis. On 
the basis of these individual profiles secondary parameters were generated as the 
area under the concentration-time curve (AUC), both over 1-week periods and 
cumulative, the maximal plasma concentration (Cmax), the time to maximal plasma 
concentration (Tmax). 
 
9.3.5 Calculations and Statistics 
Possible relationships between the pharmacokinetic parameters and early viral 
response (EVR) and end of therapy response (EoT) and end of follow-up (EFU) 
response were analyzed using the program SPSS for Windows (Version 10.1 SPSS 
Inc, Chicago, IL, USA). Groups were compared by parametric and non-parametric 
tests. Values of p<0.05 were considered to be statistically significant. 
Chapter 9 
 156 
9.4  RESULTS 
 
9.4.1 Patient characteristics 
Of the 270 patients that entered the study, samples for virological and peginterferon-
α2a measurements from the first treatment month were available in 255 patients. 
Demographic and baseline characteristics are shown in table 1. The mean (±1 SD) 
age of these 255 patients who are considered as the study group was 41.2±10.1 
years. 172 patients were male (68%), 83 female (32%). 95% were Caucasians. The 
mean (±1 SD) weight, length and BMI were 74.3±13.5kg, 172±10cm and 
25.1±3.6kg/cm2. The average baseline ALT level was 2.6±1.8 times the upper limit of 
normal when corrected for center specific normal values, the log transformed serum 
viral load was 6.1±0.8 IU/mL. 167 patients were genotype 1 (66%), 22 genotype 2 
(9%), 51 genotype 3 (20%), 14 genotype 4 (6%) and 1 genotype 5 (0%) infected. 
 
Based on the first month viral kinetics, patients were classified into early viral 
response categories according the study protocol (figure 1A). 161 patients were 
classified as rapid viral responders (RVR; 63%), 61 as slow partial responders (SPR; 
24%) and 31 as flat partial responders or null responders (FPR / NUR; 12%). After 
classification into response categories, patients were randomized to continuation of 
standard therapy to a total of 48 weeks (n=126) or individualized therapy (n=127). 
Two patients that could not be classified received standard therapy (figure 1B)(7, 8). 
 
9.4.2 Pharmacokinetics 
The time profiles of peginterferon-α2a plasma concentration for the first treatment 
month are shown in figure 2 (page 165). The population pharmacokinetic parameters 
of peginterferon-α2a are given in table 2 (page 162). In the structural model (no 
covariates included: model 1) considerable inter- and intra-patient variability in 
clearance was observed; respective values were 39% and 25% with a typical Cl/F 
value of 1.34 L/day. This indicates that within the studied population CL/F may vary 
from 0.29 to 2.39 L/day between patients (95% confidence interval: 1.34 ± 2 x 0.39 x 
1.34). Within 
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Table 1. Baseline demographic and viral characteristics of the study group (n=255).  
 
Population parameters   
 Mean (range) SD 
Weight (kg) 74.4 (946-126) 13.5 
Height (cm) 172 (146-196) 10 
BMI 25 (19-40) 3.6 
age (years)  41 (18-66) 10 
ALT (xULN) 2.6 (0.8-11.3) 1.77 
Gender n (%) 
male 172 68 
female 83 33 
Race n (%) 
Caucasian 243 95 
Asian 8 3 
Black 4 2 
Virological parameters   
Log Viral load (IU/mL) 6.8 (2.9-7.4) 0.8 
Genotypes n (%) 
genotype 1 167 66 
genotype 2 22 9 
genotype 3 52 20 
genotype 4 14 6 
genotype 5 1 0 
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a patient with average CL/F of 2 L/day this parameter may vary from 1 to 3 L/day 
(95% confidence interval: 2.00 ± 2 x 0.25 x 2.00). 
 
Weight, body surface area and BMI correlated with clearance and volume of 
distribution when separately included in the NONMEM model (p<0.01). Due to the co 
linearity of these factors only weight was included in the final model as summarized 
in table 2 (model 2). For the other patient factors as listed in table 1 no significant 
relationships were detected. When weight is included in the model (unexplained) 
inter-patient variability in Cl/F decreases from 39% to 35%. The relationship between 
drug exposure and body weight is illustrated in Figure 3. Cumulative AUC over 1 
month were lower in patients weighting between 80-100kg than in patients of 50-
70kg (average: 382.000 vs. 514.000 pg/mL ; p≤0.01; figure 3b). 
By application of Bayesian analysis individual time profiles of peginterferon-α2a were 
generated and secondary parameters as Tmax, Cmax and AUC were derived (Table 
3). Cmax and AUC over 1 week increased approximately 2-fold from week 1 to week 
4. Following subcutaneous administration maximal concentrations were obtained 
after 2-3 days. 
 
 
Figure 3: Cumulative AUC of Peginterferon-α2a from day 0 to day 28 in relation to body 
weight. A) Shown are the predicted regression line (straight line) and its 95% confidence 
interval (bent line). B) and box plots showing two weight categories significantly different in 
average cumulative AUC.
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Table 4. Exposure to peginterferon-α2a. Compared are values from two early response 
categories. 
 
 Rapid viral responders  
(n=161) 
Flat partial / Null responders  
(n=31) 
p-value* 
AUC day 0-7 78612 62816 0.004 
AUC day 7-14 114060 92924 0.003 
AUC day 14-21 133307 106880 0.003 
AUC day 21-28 143212 114565 0.006 
AUC= area under the curve (pg/mL). 
* Mann-Whitney test. 
 
 
9.4.3 Pharmacodynamics 
Significant differences between the cumulative first month AUC values were found 
between early viral response categories RVR, SPR, FPR / NUR (Kruskal-Wallis one-
way analysis of variance (K-W test): p=0.006); figure 4a), indicating that higher 
serum peginterferon-α2a concentrations result in better early viral response. Detailed 
analysis for two response categories is displayed in table 4. Increasing weekly AUC 
values for FPR / NUR are 80% of RVR patients. Differences are highly significant 
(p<0.01). 
Within the group treated with standard therapy (n=126), response categories were 
highly predictive for end of follow-up response outcome (Chi-square test: p<0.01). A 
relation between the cumulative first month AUC values value and the end of therapy 
or end of follow-up could however not be found ((K-W test): p=0.7; figure 4b). No 
significance for other pharmacokinetic parameters could be found; weight and BMI 
had no effect on treatment outcome. 
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Figure 4: 
A) Box plots of cumulative AUCs of Peginterferon-α2a measurements from day 0 to day 28 
per response class based on first month viral kinetics. Testing for multiple independent 
samples (Kruskal-Wallis one-way analysis of variance (K-W test)) learned that the three 
response classes differ significantly in average cumulative AUC (p=0.006). The cumulative 
AUC is significantly higher in rapid viral responders (RVR) than in flat partial responder / non-
responders (FPR/NUR) (Mann-Whitney test; p=0.004). RVR and slow partial responders 
(SPR) or SPR and FPR/NUR do not differ significantly. Displayed are data from 253 patients; 
data of 2 patients are missing. 
B) Box plots of cumulative AUCs of Peginterferon-α2a values from day 0 to day 28 per 
treatment result (end of follow-up) for those treated for 48 weeks with standard therapy. No 
significance was observed (K-W test; p=0.9) between patients with a sustained virological 
response (SVR), response relapse (RR) or non-response (NR). Displayed are data from all 
126 patients treated with standard dosed Peginterferon-α2a-ribavirin. 
 
Explanation on boxes: The upper and lower limits of the boxes and the middle line across the 
boxes indicate the 75th and 25th percentiles and the median (the 50th percentile), 
respectively. The length of the box is thus the interquartile range; the box represents 50% of 
the data. The upper and lower horizontal bars indicate the 90th and 10th percentiles, 
respectively.  
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Table 2. Population pharmacokinetic parameter estimates for peginterferon-α2a. 
 
 Model 1 Model 2 
 Estimate (CV%) Mean (CV%) 
   
Population parameters   
Ka (1/day) 0.673 (6%) 0.673 (6%) 
V/F (L) 10.1 (6%) 10.3 (6%) 
Cl/F (L/day) 1.34 (3%) 1.36 (3%) 
   
Fractional change in clearance (Cl/F)   
   
Exponent V-weight - 0.697 (41%) 
Exponent Cl-weight - 0.868 (18%) 
   
Between-patient variability   
Ka (%) 33 (53%) 35 (49%) 
V/F (%) 71 (17%) 70 (17%) 
Cl/F (%) 39 (17%) 35 (20%) 
   
Between-dose variability   
V/F (%) 21 (41%) 21 (40%) 
Cl/F (%) 25 (32%) 25 (32%) 
   
Residual error   
Additive (pg/ml) 2090 (13%) 2080 (13%) 
Proportional (%) 17.8 (21%) 17.6 (22%) 
   
Minimal value objective function   
   
Value 35279.8 35237.4 
   
 
Ka = absorption rate constant; V = volume of distribution; Cl = clearance; CV = coefficient of variation; 
F refers to the unknown bioavailability. 
Model 1 and 2 were fitted to data from all individuals (n=255) simultaneously using nonlinear mixed-
effect modelling. Model 1 is the structural population model with no covariates included and model 2 
with the significant covariate "weight" entered in the model. Note that weight does not affect Ka, V, CL 
in a significant way since differences in model 1 and 2 are very similar 
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9.5  DISCUSSION 
 
This study provides the first detailed description of peginterferon-α2a 
pharmacokinetics and pharmacodynamics in the treatment of a large cohort of 
chronic hepatitis C patients. Until now, the only fully published peginterferon-α2a 
pharmacokinetic data are from a small dose escalating study in renal cell carcinoma 
compromising only 6 patients treated with the dose standard used in HCV (6). Our 
study confirms the published data on mean level but also clearly shows the large 
variability between and in- patients. Subcutaneous administration of peginterferon-
α2a led to rapid absorption from the injection side. After each peginterferon-α2a 
injection maximal concentrations for every week appeared between day 2 and 3 after 
each dose with declining intervals with chronic dosing, suggesting an increased 
absorption rate relative to treatment duration. Both Cmax and AUC increased with 
chronic dosing to about 2 fold in 4 weeks due to accumulation. Variability in 
clearance between patients was 39% and only decreased to 35% when corrected for 
weight. The variability between doses within a patient was about 25%. The 
considerable intra-patient variability suggests other factors responsible for the great 
variance than included in the multivariate analyses. Both the intra- and inter-patient 
variability might be explained by the variability inherent to the process of 
subcutaneous administration of peginterferon-α2a. Local tissue blood flow, side and 
depth of injection as well as diffusion through the interstitial space and temperature 
of the farmacon might affect absorption rates. 
Within the study group individual weight varied widely. Variance in serum 
concentration could therefore be expected since all patients were treated with the 
same fixed dose. Indeed, a negative correlation between weight and CAUC was found 
(figure 3). However, although lower serum concentrations of peginterferon-α2a were 
found in heavier patients, its significance on treatment outcome was lost. Therefore 
weight adjusted dosing are not expected to have beneficial effects in the average 
population. However, the results do not exclude that a small proportion of non-
responder patients might be related to low drug levels. Only the heavier patient with 
more characteristics associated with unfavorable treatment response such as  
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A) 
 
B) 
 
Figure 2.  A) Time profile of Peginterferon-α2a plasma concentration of 255 patients. The patients 
received 180 mcg sc once weekly. The solid lines indicate the time profiles of 3 random patients 
showing the variation in intra- and inter-patient variability.B) Time profiles for two typical patients. The 
symbols are the determined concentrations. The solid lines represent the individual Bayesian 
pharmacokinetic fits. 
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genotype 1, male gender, high viral load, etc. might benefit from higher dosing or 
longer therapy duration. 
A significant effect of CAUC on early outcome but not on final outcome was found. The 
AUC in patients with favorable early responses (RVR) who more often became 
sustained virological responders were higher than in those without (FPR / NUR). 
Significance however declined with increasing treatment duration and was lost at the 
end of the treatment free follow up period. This could partly be explained due to 
power loss after halving the study group since the individualized tailored treatment 
patients could not be taken into the end of treatment and at the end of the treatment 
free follow up period analysis because the therapy they received was not comparable 
in length, intensity or dose. However, similar effects have been seen with non-
pegylated interferon studies comparing high dosed daily interferon to standard dosed 
thrice a week interferon. In those reports, a significant increase of early virological 
response was found in the high dosed daily group although this effect did not result 
in an increased sustained virological response (11, 12). A possible explanation might 
be that the initial therapy results are (peg)-interferon serum level dependant and that 
the end of therapy result is determined by intracellular ribavirin levels.  
In summary, the population pharmacokinetics of peginterferon-α2a have been 
characterized. Considerable inter-and intra-patient variability is present for clearance. 
Some of this variability can be explained by the relationship of clearance and weight. 
Variability in pharmacokinetic is also reflected in parameter describing drug 
exposure. There appears to be a correlation between exposure during the first month 
and early virological response. However no relationship has been demonstrated 
between the first months exposure and treatment outcome. 
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10.1  INTRODUCTION 
 
In the treatment of chronic HCV, interferon based antiviral therapy has now been 
used for nearly two decades to slow down and prevent the progression to cirrhosis of 
the liver. In the past years, it’s success rate has made remarkable progress from less 
than 10% up to 80% in selected patients (1). However, for patients that have 
unfavorable patient, disease or virus characteristics, sustained response rates are 
much lower. Major unfavorable characteristics are genotype 1 or 4 infection, liver 
cirrhosis or non-response to prior antiviral therapy. Among the minor but still 
important factors are high viral load, male gender and obesity. In patients with a 
single or combination of “difficult to treat” characteristics, the a priori chance to 
respond to standard therapy is considerably lower between 10 and 40%.  
 
To overcome the effect of unfavorable characteristics and to identify factors 
associated with response we performed the studies described in this thesis. We 
imagined that response is the positive outcome after weighing the combination of 
“difficult to treat” characteristics   
 
Figure 10.1. In patients with a single or combination of “difficult to treat” characteristics, the a priori 
chance to respond to standard therapy is limited. 
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on one side and the basic factors responsible for suppression of the virus and its 
replication on the other. Within these basic factors, we shared host immunity and in-
vivo interferon level (figure 10.1).  
 
Therefore, we a) treated prior non-responders and patients with unfavorable viral 
characteristics long-lasting and with high-dose (Peg-) interferon. We b) determined 
Peginterferon pharmacokinetics and dynamics and its relation to patients’ 
characteristics and c) identified immunological factors in peripheral blood and in the 
liver associated with (non-) response. The thesis is therefore divided in three parts, 
each discussed here separately. 
 
10.2  Treatment of non-responders and “difficult to treat” patients 
 
When the first study described in this thesis (chapter 3) was designed, standard 
therapy for HCV was interferon-α 3 MU injected 3 times per week in combination with 
capsules of ribavirin taken twice daily. At that time the SVR for patients with “difficult 
to treat” criteria was about 28% (2, 3). 
 
Failure to clear the virus during therapy was observed at 3 different phases: during 
the initial (4-12 weeks) treatment period (non-response, 40-50% of patients), during 
maintenance treatment after an initial response (breakthrough, about 10-20% of 
patients), and after treatment discontinuation (relapse, 25-50% of patients) (2, 3). 
 
To reduce response failure at each phase an experimental treatment schedule was 
designed and investigated in a small exploratory non-controlled pilot study. Therapy 
started with high-dose daily induction to optimize the initial response (4, 5). After the 
initial phase, interferon administration was kept daily to obtain a more or less 
constant drug level that would optimize viral inhibition and minimize breakthrough. 
Moreover, all patients were advised to continue therapy for a total duration of 76 
weeks. This schedule proved to be effective: the intention to treat sustained 
virological response was 67%. 
 
Chapter 10 
174 
 
To assess whether patients with unfavorable characteristics might benefit from such 
a modified treatment regimen in subsequent experience, we later analyzed the 
individual data of all patients (n=54) treated in our hospital with high-dose induction, 
daily and prolonged interferon-ribavirin combination therapy (chapter 4). The overall 
sustained virological response rate was somewhat lower than in the pilot study 
though still considerably improved over standard therapy: 57% (95%-CI: 43-71%).  
 
Sustained virological response varied between 75-83% for patients with 1 
unfavorable characteristic such as cirrhosis or non-response or genotype 1. 
However, in patients with combinations of such criteria the sustained virological 
response rates were considerably decreased: between 25-60% for patients with 2 
unfavorable characteristics, and only 17% for those with 3 unfavorable factors.  
 
At the moment of analysis (spring 2003) the superior treatment results of pegylated 
interferon (peginterferon-α) ribavirin therapy came available (6, 7). With high-dose, 
daily and prolonged interferon-ribavirin combination therapy we obtained similar 
 
Figure 10.2. Patients with combination of “difficult to treat” characteristics might benefit from high-
dose, daily and prolonged interferon-ribavirin combination therapy. 
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results as with modern schedules of peginterferon-α and ribavirin although baseline 
characteristics in our population were vastly more unfavourable. The intensive and 
long treatment schedules were expected to be associated with an increase of 
intolerance and side effects compared to standard treatment and the rate of non-
compliance could only be kept low due to intensive monitoring. Given the augmented 
efficacy of peginterferon-α our results were no longer interesting for a wider 
audience. However, the results stimulated us to further research on initial high-dose 
peginterferon-α for the treatment of “difficult to treat” hepatitis C patients. 
 
The early results of the first Dutch multicenter randomized trail considering the 
retreatment of hepatitis C patients with high or standard dosed peginterferon-α are 
described in chapter 5. Due to the improved treatment results with the introduction of 
peginterferon-α there was interest for re-treating patients who did not achieve SVR 
with previous therapy. However, although no conclusive results had been reported 
then, early Peginterferon-ribavirin re-treatment SVR estimates were only about 7-
15%. We therefore assessed whether high-dosed Peginterferon-α2b (3.0 µg/kg once 
weekly; twice the standard dose) for 1 month had improved efficacy over standard 
Peginterferon-α2b therapy (1.5 µg/kg once weekly) on early virological response as 
earlier observed for high-dosed interferon. The safety and impact on “health related 
quality of life” of high dosing were also assessed.  
 
Patients treated with high-dosed peginterferon showed a stronger response at all 
time points during the 29 days study period. Significance could however not be 
reached because of the limited sample size (n=40) and treatment success in patients 
infected with other genotypes then 1 or 4 of whom most were rapid responders 
independent of treatment arm.  
 
High-dosed peginterferon was especially beneficial for genotype 1 or 4 infected 
patients. Most genotype 1/4 patients who were rapid responders were treated with 
high-dose peginterferon and within genotype 1/4 patients high-dose peginterferon 
induced a significant stronger suppression of HCV RNA replication at t=2, 7 (and 
borderline significant at t=29 days). Surprisingly, high-dosed Peginterferon-α2b 
therapy did not worsen the quality of life more than standard dosed Peginterferon-
α2b.  
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The results of this study showed that in the majority of patients who previously failed 
to achieve a sustained response, an initial response could be obtained when treated 
with Peginterferon-ribavirin therapy. The decrease of HCV RNA was stronger in 
patients treated with high-dosed peginterferon than in those treated with the standard 
dose and especially genotype 1 and 4 infected patients might benefit from high-dose 
peginterferon. This finding should however be interpreted with caution, given the 
small number of patients included and the short study period. The end of treatment 
results are expected to become available in December 2005. 
 
10.3  Immunological factors associated to (non-) response  
 
Most patients in whom interferon therapy is unsuccessful are non-responders. (Some 
patients in whom interferon therapy is unsuccessful are responders who have a 
virological relapse after stopping interferon). In these non-responder patients, HCV 
RNA is detectable during the entire treatment period (2, 3) due to a lack of in-vivo 
interferon in combination with an inadequate host antiviral immune response (figure 
10.3).  
 
Figure 10.3. Patients with the combination of an adequate immune system and in-vivo interferon 
dose are thought to be more likely to have a beneficial virological response. 
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Although the immune-mediated mechanism responsible for the eradication of HCV is 
not well understood, there is consensus that intrahepatic localization of HCV specific 
T cells may be crucial to augment inhibition of viral replication and to clear infected 
hepatocytes during therapy (introduction to part II) (8, 9).  
 
We therefore examined baseline localization of diverse subsets of intrahepatic 
immune cells by quantitative immunohistochemistry (CD4+, CD8+, and CD68+ cells) 
in pre- and end of treatment liver biopsies and its causality to therapy response. For 
comparison also peripheral immune parameters (plasma interleukin (IL)-10, IL-12, 
IFN-γ levels) and circulating HCV-specific T cells were determined (chapter 7). 
 
Numbers of intrahepatic CD8+ cells located in the portal tracts of pre-treatment liver 
biopsies were found to be significantly higher in patients responding to therapy than 
in non-responders. The relation between portal CD8+ cells and chance of response 
could be described by a logistic curve (univariate logistic regression analysis); its 
prognostic value was superior to that derived from genotype and other baseline 
factors (multivariate analysis). In contrast, neither peripheral cytokine levels nor HCV 
specific T cell reactivity in peripheral blood mononuclear cells did show a relationship 
to therapy response. These findings suggest that significant prognostic immune 
markers are to be found in the liver.  
 
The liver biopsy procedure is however accompanied with considerable patient 
discomfort. We therefore investigated the feasibility of a less invasive and less 
traumatic fine-needle aspiration biopsy (FNAB) technique as a tool for monitoring the 
intrahepatic cellular immune status (chapter 8). Differences in numbers of 
intrahepatic CD8+ T-cells during chronic HCV-infection are reflected in FNABs, and 
an association between the composition of the T-cell population contained in pre-
treatment FNABs and early response to subsequent anti-viral therapy was found. We 
postulated that the FNAB-technique could be used as a tool for monitoring the 
cellular immune status in the liver during chronic HCV-infection on a frequent basis. 
Whether FNABs are predictive for long-term virological response to therapy needs to 
be investigated in a larger patient population.  
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10.4  IFN pharmacokinetics and its relation to (non-)response 
 
The third part of this thesis compromises the studies on plasma (peg-) interferon 
pharmacokinetics and its relation to (non-)response. Why HCV RNA falls rapidly in 
one and slowly or even not at all in comparable patients treated with the same (peg-) 
interferon dose remains unclear. It appeared that, on group level, the rate of decline 
was dependent on the administered dose of Peginterferon-α (12). We therefore 
tested the hypothesis that pharmacokinetic variability may explain variations in 
treatment response and affect its chance to achieve SVR. 
 
To measure levels of biologically active IFN-α in serum we first developed a sensitive 
assay (chapter 8) not disturbed by the limitations of an ELISA. Therefore, we tested 
whether hepatitis C virus replicons, which are highly sensitive to IFN-α, could be used 
as a sensitive bioassay to determine the amount of biologically active IFN-α. 
 
The developed HCV-replicon based bioassay allowed determining the levels of 
biologically active IFN-α in serum and heparinized plasma of patients under 
treatment. It was however replaced by an ELISA for reasons of ease and costs 
esteemed the enormous workload. 
 
In more than 5000 samples from 255 patients sampled at 7 time points serum 
interferon levels were quantified during the first month of Peginterferon-ribavirin 
therapy. Population pharmacokinetics and secondary parameters were assessed and 
correlated to response characteristics.  
 
Pharmacokinetics could predict early virological response at week 4. Significance 
however declined with increasing treatment duration and was lost at the end of the 
treatment free follow up period; pharmacokinetics had no effect on treatment 
outcome.  
Loss of significance could partly be explained by the loss of statistical power after 
halving the study group. Our study was ancillary to a randomized controlled trial in  
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which half of the patients were treated with a dynamically individualized treatment 
schedule according to their virologic response and the other half with standard dose.  
The variation in the individualized treatment schedules was so large that the patients 
treated accordingly (n=126) could not be taken into the pharmacodynamic study. 
Another reason of the loss of significance during the study might be that the end of 
therapy result are determined more by intracellular ribavirin levels than by 
peginterferon levels alone. Whereas the initial therapy results are more (peg)-
interferon serum level dependant. 
 
Our study confirmed the earlier published data of Peginterferon-α kinetics on mean 
level. We were however surprised by the inter-and intra-patient variability present for 
clearance. Some of this variability could be explained by the relationship of clearance 
and weight.  
 
 
10.5  Finally 
 
In the last five years we conducted several studies to improve and understand 
response and non-response in the treatment of HCV. Most studies were performed 
with emphasis for those who are in the greatest need for therapy; patients with 
cirrhosis, genotype 1/4 and others with major and minor difficult-to-treat 
characteristics.  
 
Success in the treatment of difficult-to-treat patients can only take place under the 
right circumstances with the right combination of factors like sufficient serum 
interferon levels and an adequate host antiviral immune response. 
 
We believe future strategies in HCV patients should include pretreatment screening 
and identification of difficult-to-treat patients. When as such identified, difficult-to-treat 
patients should (when indicated) be treated in an experimental setting with an 
intensified regimen under close monitoring of viral kinetics and pharmacodynamics. 
At this moment, we postulate for combining one month of daily interferon-α induction 
on top of Peginterferon-ribavirin standard therapy. 
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Hopefully, in the future in all patients a sustained virological response will possible 
(figure 10.4. Currently, completely different forms of medications are being 
investigated. It is however unlikely that such new therapy will be available in the next 
5 years.  
 
 
 
Figure 10.4. Some day, with the help of new therapeutic agents even in all patients who are now 
considered as difficult-to-treat a sustained response will be available.  
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10.6  Inleiding 
 
Sinds bijna twintig jaar wordt ter behandeling van chronische hepatitis C virus (HCV) 
infectie gebruik gemaakt van op interferon gestoelde therapie om progressie tot lever 
cirrose tegen te gaan. De kans op succesvolle behandeling is de afgelopen jaren 
gestegen van minder dan 10% tot bijna 80% in geselecteerde patiënten (1). Echter, 
bij mensen met ongunstige kenmerken liggen de kansen op blijvende virale response 
(SVR; van het Engelse “sustained virological response”) aanzienlijk lager. Belangrijke 
ongunstige kenmerken zijn infectie met HCV genotype 1 of 4, het al hebben van 
cirrose van de lever of in het verleden niet gereageerd hebben op antivirale 
behandeling (zogenaamde non-responders). Minder belangrijk maar toch nog 
wezenlijke factoren zijn onder andere drager zijn van een groot aantal virale deeltjes 
in het bloed, man zijn en het hebben overgewicht. In dergelijke patiënten met één of 
een combinatie van dergelijke “moeilijk te behandelen” criteria ligt de a-priori kans te 
reageren op de standaard behandeling aanzienlijk lager namelijk tussen 10 en 40%. 
 
Om het nadelige effect van de ongunstige kenmerken te niet te doen, en om factoren 
die samenhangen met een goede response te identificeren werden de studies zoals 
beschreven in dit proefschrift uitgevoerd. We stelden ons voor dat virale respons een 
positieve uitslag is na afweging van het totaal aan nadelige kenmerken tegen het 
totaal aan basale factoren verantwoordelijk voor onderdrukking van het virus en zijn 
vermenigvuldiging. Onder de basale factoren schaarden wij de immunologische 
afweer van de gastheer en de in-vivo (Latijn voor “in de patiënt”), aanwezige 
hoeveelheid interferon (figuur 10.1; pagina 172). 
 
Zodoende werden a) non-responders en patiënten met ongunstige virale kenmerken 
langdurig en met hoge doses (peg-) interferon behandeld. Bepaalden wij b) de 
farmacokinetiek en dynamiek van Peginterferon en haar relatie met patiënt 
kenmerken en c) werden immunologische factoren samenhangend met (non-) 
respons in perifeer bloed en de lever geïdentificeerd. Dit proefschrift is daarom 
verdeeld in drie delen, hier elk afzonderlijk samengevat en bediscussieert. 
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10.7 De behandeling van non-responders en andere “moeilijk te behandelen” 
patiënten. 
 
Op het moment dat de eerste studie zoals beschreven in dit proefschrift (hoofdstuk 3) 
werd ontworpen bestond de standaard behandeling van chronische HCV uit drie 
maal per week 3 miljoen units (MU) geïnjecteerde interferon-α gecombineerd met 
twee maal daags te slikken capsules ribavirine. De kans op een blijvende virale 
response bedroeg toen voor “moeilijk te behandelen” patiënten om en nabij de 28% 
(2,3). 
 
Onvermogen het virus te klaren werd tijdens drie verschillende fasen van de 
behandeling waargenomen: wanneer tijdens de initiële (4-12 weken) behandel 
periode geen of onvoldoende daling van het aantal virus deeltjes plaats vond (non-
response, 40-50% van de patiënten), wanneer na een initiële response de 
hoeveelheid virus deeltjes weer toenam tijdens de behandeling (breakthrough, 
ongeveer 10-20% van de patiënten), en wanneer nadat de behandeling werd 
gestaakt het aantal virus deeltjes weer meetbaar werd na een aanvankelijke 
response (relapse, 25-50% van de patiënten (2,3). 
 
Met als doel de kans op falende therapie in elk van de drie fasen te reduceren werd 
een experimenteel behandel schema ontworpen en getest in een kleine exploratieve 
niet-gecontroleerde pilot studie. Om de initiële therapie kans te optimaliseren werd 
begonnen met een inductie fase bestaande uit dagelijks toegediende interferon in 
hoge dosering (4,5). Na de initiële fase werd de dagelijkse dosering gecontinueerd 
(in plaats van drie maal per week zoals standaard gebeurde) opdat een meer 
constantere hoeveelheid geneesmiddel zou worden verkregen ter bevordering van 
de onderdrukking van het virus en om breakthrough te voorkomen. Bovendien werd 
alle patiënten geadviseerd om de behandeling gedurende in totaal 76 weken voort te 
zetten. Dit schema bewees effectief: de “intention to treat” * SVR bedroeg 67%. 
 
*“intention to treat” wil zeggen dat uitvallers, om wat voor reden dan ook, in de analyse zijn 
meegenomen als een niet succesvolle behandel uitkomst. 
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Om te bepalen of “moeilijk te behandelen” patiënten nogmaals baat zouden hebben 
bij een aangepast behandel schema werd later de individuele data van alle patiënten 
(n=54) in ons ziekenhuis behandeld met hooggedoseerde inductie, dagelijks en 
langdurige interferon-ribavirine combinatie therapie geanalyseerd. (hoofdstuk 4). 
De SVR van de totale groep was iets lager dan die van de pilot studie maar toch nog 
aanzienlijk beter dan die van de standaard behandeling: 57% (95%-
betrouwbaarheids interval 43-71%). 
Blijvende virale response (SVR) varieerde tussen 75-83% bij patiënten met 1 
ongunstig kenmerk zoals lever cirrose, voorafgaande non-response op eerdere 
therapie of genotype 1 infectie. De SVR was echter aanzienlijk lager bij patiënten met 
combinaties van ongunstige kenmerken: tussen 25-60% in patiënten met 2 
ongunstige factoren en slechts 17% bij hen met 3 ongunstige kenmerken. 
 
Op het moment dat we bovenstaande data analyseerden (voorjaar 2003) werden de 
eerste resultaten van de destijds juist geïntroduceerde peginterferon-α ribavirin 
therapie gepubliceerd (6,7). Onze resultaten met hooggedoseerde inductie, dagelijks 
en langdurige interferon-ribavirine combinatie therapie, waren vergelijkbaar terwijl de 
de a-priori kans op response in de door ons geselecteerde patiënten veel lager was.  
 
Van de intensieve en langdurige behandel schema’s werd verwacht dat ze gepaard 
zouden gaan met een toename van bijwerkingen en intolerantie ten opzichte van de 
standaard behandeling en de mate van non-compliantie kon alleen maar laag 
gehouden worden door intensieve begeleiding en sturing. 
 
Door de vergrote effectiviteit van peginterferon-α waren onze resultaten niet langer 
interessant voor een groot publiek. De resultaten hebben ons echter gestimuleerd tot 
verder onderzoek naar initiële hoog gedoseerde peginterferon-α ter behandeling van 
“moeilijk te behandelen” hepatitis C patiënten. 
 
De vroege resultaten van de eerste Nederlandse gerandomiseerde multicenter studie 
betreffende de herbehandeling van hepatitis C patiënten met hoog- of standaard 
gedoseerde peginterferon-α zijn beschreven in hoofdstuk 5.  
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De interesse voor de herbehandeling met peginterferon-α van patiënten die geen 
SVR behaalden bij voorafgaande interferon-α therapie ontstond door de sterk 
verbeterde resultaten bij patiënten die nog nooit eerder waren behandeld. Echter, 
hoewel er op dat moment geen definitieve resultaten voorhanden waren, bedroegen 
vroege schattingen van de te verwachten SVR voor herbehandelden slechts 
ongeveer 7-15%.  
 
Geïnspireerd door het eerder geobserveerde toegenomen effect van 
hooggedoseerde interferon wilden wij het effect van hooggedoseerde peginterferon 
bestuderen. Hiertoe werd gedurende een periode van 1 maand de afname van de 
hoeveelheid virus deeltjes bij patiënten behandeld met hooggedoseerde 
Peginterferon-α2b (3.0 µg/kg lichaamsgewicht 1x per week; 2x de standaard 
dosering) vergeleken met die bij standaard gedoseerde Peginterferon-α2b (1.5 µg/kg 
1x per week). Bovendien werd het effect van hoog doseren op de kwaliteit van leven 
bestudeerd. 
 
Patiënten behandeld met de hooggedoseerde Peginterferon-α2b toonden een 
sterkere response blijkend uit een grotere afname van het HCV RNA op alle 
tijdstippen tijdens de 29 dagen durende studie periode. Significantie kon echter niet 
bereikt worden doordat de studie groep klein (n=40) was en door het grootte succes 
behaald in patiënten met genotypen anders dan 1 of 4 onafhankelijk van het 
behandel schema. 
 
Hooggedoseerde Peginterferon-α2b bleek vooral gunstig voor patiënten geïnfecteerd 
met HCV genotype 1 of 4. De meeste genotype 1/4 geïnfecteerde patiënten met een 
snelle response werden behandeld met hooggedoseerde peginterferon en binnen 
alle genotype 1/4 geïnfecteerde patiënten had hooggedoseerde peginterferon een 
significant sterkere daling van de HCV RNA replicatie tot gevolg op t=2, 7 (en 
borderline significant op t=29) dagen. Hooggedoseerde Peginterferon-α2b 
behandeling had echter geen verslechterend effect op de kwaliteit van leven ten 
opzichte van standaard gedoseerde Peginterferon-α2b. 
 
De resultaten van deze studie laten zien dat in de meerderheid van de patiënten die 
eerder geen SVR behaalden een initiële response kan worden verkregen door 
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behandeling met Peginterferon-ribavirine combinatie therapie. De afname van HCV 
RNA was sterker in patiënten behandeld met hooggedoseerde peginterferon dan in 
vergelijkbare patiënten behandeld met de standaard dosering. Vooral patiënten 
besmet met genotype 1 en 4 kunnen baat hebben bij hooggedoseerde peginterferon. 
Echter, gezien het kleine aantal bestudeerde patiënten en de korte studie periode 
moeten deze bevindingen met voorzichtigheid worden benaderd. De definitieve 
resultaten zullen naar verwachting in december 2005 ter beschikking komen. 
 
10.8 Immunologische factoren samenhangend met (non-) response  
 
In het grootste gedeelte van de patiënten waarbij interferon therapie faalt, is dat ten 
gevolge van virologische non-response. (Bij de overige patiënten waarbij therapie 
faalt, daalt de hoeveelheid virus tot onmeetbaar kleine getallen waarna het weer 
terug lijkt te komen: virologische relapse en rebound.) Bij deze non-responder 
patiënten is HCV RNA gedurende de gehele behandel periode meetbaar (2,3) ten 
gevolge van een gebrek aan in-vivo interferon in combinatie met gebrek aan een 
adequate gastheer antivirale immuun response (figure 10.3).zie pagina 176). 
 
Het mechanisme verantwoordelijk voor de immuun gemedieerde eradicatie van HCV 
wordt (nog) niet goed begrepen. De heersende opvatting is dat HCV specifieke T-
cellen gelokaliseerd in de lever een rol spelen in de onderdrukking van de virale 
replicatie. Bovendien zouden zij het opruimen van geïnfecteerde levercellen tijdens 
de behandeling bevorderen (Introduction to part II) (8,9).  
 
Wij onderzochten de lokalisatie van diverse immuun cellen in de lever door middel 
van kwantitatieve immunohistochemie (CD4+, CD8+, en CD68+ cellen) op lever 
biopten genomen voorafgaand aan en direct na een behandeling en een eventueel 
verband met behandel uitkomst. Ter vergelijking werden bovendien niveau’s van 
perifere immunologische parameters (plasma interleukine (IL)-10, IL-12, IFN-γ) en 
circulerende HCV-specifieke T-cellen bepaald (hoofdstuk 7). 
 
Het aantal CD8+ cellen in de portale velden van de lever bleek significant hoger te 
zijn bij patiënten die vervolgens respondeerden op de behandeling dan bij non-
responders. 
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De relatie tussen het aantal portale CD8+ cellen en de kans op response kon 
beschreven worden met een S-vormige logistische curve (univariate logistische 
regressie analyse); zijn voorspellende waarde bleek groter dan die van genotype of 
andere factoren (multivariate analyse). Dit in tegenstelling tot perifere cytokine 
niveau’s of HCV specifieke T-cel reactiviteit van perifere mononucleaire cellen 
waarbij geen relatie met behandel uitkomst kon worden gevonden. Deze resultaten 
suggereren dat significant prognostische immunologische factoren zich in de lever 
bevinden. 
 
Het nemen van lever biopten is voor patiënten echter een onprettige procedure 
gepaard gaande met pijn, stress en het risico op complicaties. Wij hebben daarom de 
bruikbaarheid getest van een minder invasieve en traumatische dunne naald 
aspiratie biopsie (FNAB van het Engelse “fine-needle aspiration biopsy”) techniek als 
instrument voor het meten van de cellulaire immuun status in de lever van patiënten 
met chronische HCV infectie (hoofdstuk 8). 
 
Het relatieve aantal CD8+ T-cellen in de FNAB bleek niet samen te hangen met dat in 
perifeer bloed maar wel significant gecorreleerd te zijn met de aantallen CD8+ T-
cellen in lever biopten. Bovendien was het relatieve aantal CD8+ T-cellen in de FNAB 
significant hoger bij patiënten die vervolgens bij de ingestelde Peginterferon-
ribavirine therapie een snelle initiële response lieten zien dan bij langzame 
responders. Wij denken dat dit bewijst dat de FNAB techniek gebruikt kan worden als 
een instrument om met regelmaat de cellulaire immune status in de lever te 
bestuderen tijdens chronische HCV infectie. Of met de FNAB techniek een 
voorspelling gedaan kan worden van de lange termijn resultaten van een 
behandeling moet nog worden bezien. Dit dient bij voorkeur te worden onderzocht in 
een grotere populatie. 
 
10.9 Peginterferon farmacokinetiek en -dynamiek en (non-) response  
 
Het derde deel van dit proefschrift beslaat de studies naar plasma (peg-) interferon 
farmacokinetiek en haar relatie tot (non-)response. 
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Waarom HCV RNA in vergelijkbare patiënten behandeld met gelijke doses (peg-) 
interferon bij de één snel en bij de ander langzaam of zelfs niet daalt blijft onduidelijk. 
Het bleek dat op groeps niveau, de snelheid van afname samenhing met de 
toegediende dosis Peginterferon-α (12). Wij onderzochten daarom de hypothese dat 
variatie in farmacokinetiek, variatie in behandel uitkomst tot gevolg kan hebben en 
dat dit effect heeft op de kans tot het bereiken van een blijvende response. 
 
Om concentraties van biologisch actief interferon-α in serum te meten ontwikkelden 
wij allereerst een gevoelige test methode (hoofdstuk 8) die niet verstoord zou worden 
door de beperkingen kenmerkend voor een ELISA. We testten of hepatitis C virus 
replicons, die zeer gevoelig zijn voor interferon-α, gebruikt konden worden als een 
gevoelige bioassay voor de bepaling van de hoeveelheid biologisch actieve 
interferon-α IFN-α in een monster.  
 
Met de op het HCV-replicon systeem gebaseerde test bleek het mogelijk te zijn om 
concentraties van biologisch actief interferon-α te meten in serum en gehepariniseerd 
plasma afgenomen tijdens de antivirale behandeling. Voor de daarop volgende studie 
(hoofdstuk 9) werd de test echter alsnog vervangen door een ELISA in verband met 
de kosten en de te verwachten hoge werkbelasting gezien het grootte aantal 
monsters. 
 
In meer dan 5000 bloedmonsters afgenomen bij 255 patiënten op 7 verschillende 
tijdstippen tijdens de eerste maand van een Peginterferon-ribavirine behandeling 
werd de serum interferon-α concentratie gemeten. Vervolgens werden de populatie 
farmacokinetiek en secundaire parameters bepaald en gecorreleerd met response 
karakteristieken.  
 
Met de farmacokinetiek resultaten kon de vroege virologische response (na 4 weken 
behandeling) voorspeld worden. De significantie nam echter af bij toename van de 
behandel duur en was verdwenen op het einde van de behandeling en had derhalve 
geen voorspellende waarde op het behandel resultaat.  
Deels kon dit verklaard worden door verlies aan statische kracht nadat de studie 
populatie gehalveerd werd. Onze studie maakte gebruik van monsters afgenomen 
tijdens een gerandomiseerde studie (DITTO-HCV) waarbij bij de helft van de 
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populatie (n=126) de behandeling werd aangepast aan de hand van de eerste 
virologische resultaten. De variatie in aangepaste behandel schema’s was echter zo 
groot dat deze patiënten niet konden worden meegenomen in onze analyse naar de 
rol van vroege farmacokinetiek in relatie tot het behandel resultaat. 
 
Een andere reden voor het verlies aan significantie zou kunnen zijn dat het 
uiteindelijke resultaat van een behandeling niet zozeer wordt bepaald door uitsluitend 
peginterferon concentraties maar dat intracellulaire ribavirine concentraties ook een 
belangrijke rol spelen. 
 
Onze studie bevestigde de Peginterferon-α kinetiek resultaten van een eerder 
gepubliceerde kleine studie. We waren echter verbaasd over de enorme variatie in 
klaring tussen en binnen patiënten. Slechts een gedeelte van deze variabiliteit kon 
verklaard worden door het verband tussen klaring en gewicht. 
 
10.10  Tot slot 
 
In de afgelopen vijf jaar hebben wij diverse studies opgezet en uitgewerkt ter 
verbetering en lering van response en non-response tijdens de behandeling van 
chronische hepatitis C infectie. Het merendeel van de studies werd uitgevoerd met 
genegenheid voor hen die het meeste baat hebben bij een succesvolle behandeling; 
patiënten met een lever cirrose, genotype 1/4 infectie en anderen met meer en 
minder belangrijke “moeilijk te behandelen” kenmerken. 
 
Een succesvolle behandeling van patiënten met “moeilijk te behandelen” kenmerken 
vindt uitsluitend plaats onder de juiste omstandigheden bij een combinatie van 
factoren zoals afdoende hoge serum interferon spiegels en een adequate 
gastheerantivirale immuun response. 
 
Wij denken dat toekomstige behandelstrategieën van HCV onder andere het 
screenen op en identificeren van “moeilijk te behandelen” patiënten zou moeten 
bevatten. Dergelijke “moeilijk te behandelen” patiënten zouden in onderzoeksverband 
met een intensief schema en onder voortdurende toetsing van virale kinetiek en 
farmacodynamiek behandeld moeten worden. Op dit moment zouden wij willen 
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pleiten voor het toetsen van gedurende de eerste behandel maand dagelijks 
geïnjecteerde interferon-α inductie gecombineerd met standaard gedoseerde 
Peginterferon-ribavirine ten opzichte van huidige standaard Peginterferon-ribavirine 
behandeling.  
 
Hopelijk zal er in de toekomst een behandeling bestaan waarmee alle HCV 
geïnfecteerde patiënten genezen kunnen worden (figuur 10.4; pagina 180). Op dit 
moment worden daartoe totaal nieuwe medicijnen ontwikkeld. Het is echter 
onwaarschijnlijk dat een dergelijke “wonder pil” binnen 5 jaar ter beschikking komt. 
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List of often used abbreviations 
 
ALT     serum alanine aminotransferase 
APC     Antigen-Presenting Cells 
AUC     aria under the curve 
BMI     body mass index 
CD8+ CTL    cytotoxic T cell 
CL/F     clearance 
Cmax     maximal plasma concentration 
cpm     counts per minute 
CV     coefficient of variation 
EFU     end-of-follow 
ELISA     enzyme-linked immunosorbent assay 
EoT     end of therapy 
EVR     early virologic response 
FNAB     fine needle aspiration biopsy 
FPR/NUR     flat partial or null responders 
HCV     hepatitis C virus or hepatitis C virus infection 
HRQoL    health related quality of life 
IFN-α     interferon-α 
IFN-γ     interferon-gamma 
IL     interleukin 
ITT     intention to treat 
Ka     absorption rate constant  
MU     million units 
NONMEM     nonlinear mixed-effect modelling 
NR     non-response 
PBMC     peripheral blood mononuclear cells 
PEG     polyethylene glycol  
PEG-IFN-α     pegylated interferon-α 
PP     per protocol 
QW     once weekly 
RR     response relapse 
RVR     rapid virological responders 
SF-36     Short Form 36 
SPR     slow partial responders 
SVR     sustained virological response 
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TCR      T cell receptor 
Th1     helper T cells with a type 1 cytokine profile 
Th2      helper T cells with a type 2 cytokine profile 
Tiw     thrice in week 
Tmax     time to maximal plasma concentration 
TNF-α     tumor necrosis factor-alpha 
V/F     volume of distribution 
WHO     World health organization 
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Nawoord 
 
…..en toen ineens was het af. Na bijna vijf jaar lezen, discussiëren, dromen, plannen 
maken, documenteren, analyseren, het schrijven van tientallen protocollen en 
honderden conceptmanuscripten kwam het einde toch nog als een verassing. En het 
voelde ook meteen onwennig. Het altijd knagende gevoel dat er nog veel te doen is 
en dat er niet verzaakt mag worden sloeg ineens nergens meer op. “Het boek is 
dicht” of eigenlijk: het manuscript ligt bij de drukker. Er kan niets meer veranderd 
worden. Hoe was het ook al weer begonnen? 
In mei 2000 verrichtte ik voor het verkrijgen van beenmerg een punctie van het borst 
been bij een fors gebouwde maar angstig kijkende Kaap Verdiaan. Na een 
moeizame maar geslaagde introductie van de naald leek het borstbeen, dat eerst 
zoveel weerstand had geboden, de naald niet meer los te willen laten. Met de 
linkerhand tegendruk biedend op de borst van de patiënt trok ik met steeds grotere 
kracht aan de naald. Het resultaat was dat deze ineens omhoog schoot met de hand 
die hem omklemde en daarna in een reflex terugschoot. Op een haar na ontkwam de 
arme man aan een tweede punctie; de naald stond nu direct naast de nagel in mijn 
linker duim. 
Uit de medische status bleek een mogelijke hepatitis C infectie. In ieder geval waren 
de antistoffen positief. Ongeveer een week later bleek (tot ons beider geluk) de 
infectie doorgemaakt en dus niet besmettelijk te zijn. In de periode tussen het prikken 
en de uitslag heb ik mij verdiept in hepatitis C infectie en de behandeling van de 
ziekte die zij veroorzaakt. Daardoor werd mij belangstelling gewekt. Vierhonderd 
miljoen mensen bleken geïnfecteerd te zijn met een virus waarvan ik eerder dacht 
dat het zelden voorkwam. 
Enkele maanden later bezocht ik de “Rotterdamse Leverdag” alwaar ik in contact 
kwam met Prof. dr. Solko Schalm. Hij adviseerde mij een sollicitatie brief te sturen en 
gaf me vervolgens de kans “onderzoek te verrichten dat bij voorkeur resulteert tot 
een promotie”. Het product hiervan ligt voor u. 
Promoveren bij Solko betekent niet dat er een pasklaar plan op je te wachten ligt. 
Aan de ene kant is er de “rijdende trein” met lopende studies die ook weer verlaten 
dient te worden terwijl de rit in volle vaart door gaat. Gezien de looptijd van de 
studies is dit haast onvermijdelijk bij patiënt gebonden onderzoek. Voor de 
promovendus heeft deze werkwijze het voordeel dat zij bijna altijd wel “iets” oplevert. 
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Aan de andere kant is er de wens en mogelijkheid dat de promovendus zijn eigen 
vragen vormt en uitwerkt. Ik ben Solko hier zeer erkentelijk voor. Het gaf mij de kans 
projecten te starten die a-priori een kleine kans van slagen hadden, zoals de 
“depressie studie”. Zoals hij al voorspelde is daarvan in deze thesis niets terug te 
vinden. Andere voorbeelden die beter lukten zijn het laboratorium werk en de 
multicenter studie waarvoor dankzij zijn uitstekende connecties, banden met andere 
afdelingen en ziekenhuizen werden aangeknoopt. Zijn gedrevenheid en neiging tot 
perfectie brachten me soms tot wanhoop maar altijd tot een beter eindproduct. 
Een kant-en-klaar proefschrift is, zoals velen die mij voorgingen weten, een product 
van velen. Ik wil dan ook graag alle co-auteurs bedanken voor hun bijdrage. Dr. 
Frank Bekkering ben ik erkentelijk voor de studies die hij als promovendus opstartte 
en mij liet uitwerken, Bart Veldt voor het verder uitwerken van de studies die in mijn 
tijd begonnen. Dr. Hans Brouwer bewonder ik om zijn gave altijd in korte tijd de 
zwakke punten van een manuscript, protocol of zomaar een droom te identificeren. 
Zijn wijze van omgang met en behandeling van patiënten strekken mij tot voorbeeld. 
Dr. Rob de Knegt nam later het stokje van hem over. Ik ben hem dankbaar voor zijn 
inzet en voor het opschudden van de kussens waarop ingeslapen studies lagen te 
sluimerden. Ik hoop nog veel van hem te kunnen leren tijdens de klinische stages en 
hoop in de komende maanden de nog lopende onderzoeken met hem verder uit te 
werken. 
Ik bewaar goede herinneringen aan de discussies die ik voerde met Dr. Bart 
Haagmans. Door onze verschillende achtergrond hadden we een verschillende wijze 
van redeneren en interpreteren. Bart is in staat om met groot enthousiasme een 
dergelijke mix tot een nieuwe wetenschappelijke hypothese te brengen. Onze 
pogingen mechanismen te ontrafelen leidden tot een aantal publicaties en diverse 
door tijdgebrek niet verder uitgewerkte “gedachten experimenten”. Het is een eer dat 
hij als deskundige zitting neemt in de commissie. Ik hoop dat onze wegen elkaar in 
de toekomst weer zullen kruisen. 
De behandeling van HCV is “teamwork”. Zonder de begeleiding van Heleen van 
Santen, Cokkie van der Ent en eerder Marjan van de Vrie hadden vele patiënten de 
eindstreep (en dus een kans op genezing) nooit gehaald. Graag wil ik hen ook 
bedanken voor de tomeloze inzet tot het uitwerken en uitvoeren van de 
studieprotocollen en de daarbij behorende duizenden bloedmonsters. 
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Verder ben ik dank verschuldigd aan de volgende personen. Aryanna Herscheid en 
dr. Thjon Tang voor hun hulp bij het samen eindeloze cellen-tellen. Dr. Jaap 
Kwekkeboom voor zijn deel in de begeleiding van de studies en zijn nimmer aflatend 
enthousiasme voor de antivirale immuunresponse. Dr. Ron Mathot voor zijn analyses 
en uitleg. Hij introduceerde me in een vreemde wereld waarin ik zonder zijn hulp 
hopeloos zou zijn verdwaald. Simone van der Plas voor haar kwaliteit de begrippen 
“kwaliteit van leven” voor mij tot leven te brengen. 
Bettina Hansen dank ik voor haar aanstekelijke statistisch vernuft. Wat ik heel 
bijzonder vind is haar vermogen tot creatieve weergave: meer dan eens wist zij met 
de gegevens en uitkomsten die ik ter controle bracht een bijzonder figuur of tabel te 
toveren. 
I am grateful to Prof. Dr. Ralf Bartenschlager and his team for their hospitality and for 
the opportunity to work in their labs in Mainz and Heidelberg. They taught me, a 
complete laboratory-novice, the basics of proper work and thinking in an inspiring 
environment. 
Elke Verhey en Wanda Tielemans van het CRB voor de administratieve uitwerking 
van de klinische studies en de bewaking van “good clinical practice”. 
Margriet, Mieke, Sylvia en vooral Marion voor hun secretariële ondersteuning. 
Margriet, dankzij jou gingen de manuscripten keurig de deur uit. Met de geduldige 
hulp van Marion kwam het toch nog goed met de “standaardbrieven” en de finale lay-
out van dit manuscript. 
Mijn lieve echtgenote Ellen Zwijnenburg ben ik dankbaar voor haar voortdurende 
steun en begrip. Hoewel we ons voorhielden dat het “gewoon werk” betrof vrees ik 
toch dat er enige correlatie tussen mijn gemoedstoestand en de voortgang van de 
promotie was. Een volgende fase is 10 dagen geleden begonnen met de geboorte 
van onze zoon Olivier. Ik hoop dat het altijd door gaat…. 
En tot slot de paranimfen: Gert-Jan van Dalen en Gerben te Velthuis. Daar staan we 
straks schouder aan schouder in een outfit die we onder geheel andere condities al 
vaker droegen. Vrienden van een goed leven buiten het ziekenhuis. Sta me bij. 
 
Rotterdam, 6 maart 2005. 
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CURRICULUM VITAE 
 
De auteur van dit proefschrift werd geboren op 17 februari 1972 te Bilthoven. Na het 
behalen van het V.W.O. eindexamen aan het “Het Rotterdams Lyceum” werd in 1991 
gestart met de studie geneeskunde aan de Erasmus Universiteit Rotterdam. Hij 
behaalde het doctoraal examen op 21 november 1996 en het artsexamen op 21 mei 
1999. Van 1 juni 1999 tot 1 juni 2000 werkte hij als arts-assistent interne 
geneeskunde in het IKAZIA ziekenhuis te Rotterdam (opleider dr. R.J.Th. Ouwendijk) 
alwaar hij na een prik accident geïnteresseerd raakte in virale hepatitiden. Van 1 juni 
2000 tot 31 december 2003 was hij werkzaam als arts-onderzoeker op de afdeling 
Maag-, Darm- en Leverziekten (MDL) van het Erasmus MC Rotterdam (hoofd prof. 
dr. E.J. Kuipers). Tijdens deze periode werd onder begeleiding van prof. dr. S.W. 
Schalm het onderzoek verricht zoals beschreven in dit proefschrift. De klinische 
studies vonden plaats op de polikliniek MDL onder supervisie van dr. J.T. Brouwer en 
dr. R.J. de Knegt. De laboratorium studies werden verricht op de laboratoria van de 
afdeling MDL (hoofd dr. J.G. Kusters) onder begeleiding van dr. J. Kwekkeboom, de 
afdeling Moleculaire Virologie Ruprecht-Karls-Universitat Heidelberg onder 
begeleiding van prof. dr. R. Bartenschlager, en de afdeling Virologie Erasmus MC 
(hoofd prof. dr. A.D. Osterhaus) onder begeleiding van dr. B.L. Haagmans. Sinds 
januari 2004 is hij in opleiding tot Maag-, Darm- en Leverarts. Momenteel is hij 
werkzaam in het IKAZIA ziekenhuis te Rotterdam in het kader van de vooropleiding 
interne geneeskunde (opleider dr. A. Dees). Hij is sinds gehuwd met Ellen 
Zwijnenburg; zij hebben een zoon Olivier. 
 
 
